

# Women's Orgasm

Cindy M. Meston  
University of Texas  
at Austin

Roy J. Levin  
University of Sheffield

Marcia L. Sipski  
University of Miami  
School of Medicine

Elaine M. Hull  
Florida State University

Julia R. Heiman  
The Kinsey Institute,  
Indiana University

An orgasm in the human female is a variable, transient peak sensation of intense pleasure, creating an altered state of consciousness, usually with an initiation accompanied by involuntary, rhythmic contractions of the pelvic striated circumvaginal musculature, often with concomitant uterine and anal contractions, and myotonia that resolves the sexually induced vasocongestion and myotonia, generally with an induction of well-being and contentment. Women's orgasms can be induced by erotic stimulation of a variety of genital and nongenital sites. As of yet, no definitive explanations for what triggers orgasm have emerged. Studies of brain imaging indicate increased activation at orgasm, compared to pre-orgasm, in the paraventricular nucleus of the hypothalamus, periaqueductal gray of the midbrain, hippocampus, and the cerebellum. Psychosocial factors commonly discussed in relation to female orgasmic ability include age, education, social class, religion, personality, and relationship issues. Findings from surveys and clinical reports suggest that orgasm problems are the second most frequently reported sexual problems in women. Cognitive-behavioral therapy for anorgasmia focuses on promoting changes in attitudes and sexually relevant thoughts, decreasing anxiety, and increasing orgasmic ability and satisfaction. To date there are no pharmacological agents proven to be beneficial beyond placebo in enhancing orgasmic function in women.

**Key Words:** physiology of orgasm, treatment of anorgasmia, women's orgasm.

## *Definition of Women's Orgasm*

More than one author has commented on the extensive literature that exists about the human female orgasm. It has been discussed from clinical, ethological, philosophical, physiological, psychological, sociological,

---

Cindy M. Meston, PhD, is affiliated with the Department of Psychology, University of Texas at Austin. Roy J. Levin, PhD, is affiliated with the Department of Biomedical Science, University of Sheffield, Sheffield, UK. Marcia L. Sipski, MD, is affiliated with the University of Miami, Miami, FL, and Elaine M. Hull, PhD, is associated with the Department of Psychology, Florida State University, Tallahassee FL. Julia R. Heiman, PhD, is Director of The Kinsey Institute for Research in Sex, Gender and Reproduction, Indiana University, Bloomington, IN. A portion of this article appeared in Meston, C. M., Hull, E., Levin, R., & Sipski, M. (2004). Women's orgasm. In T. F. Lue, R. Basson, R. Rosen, F. Guiliano, S. Khoury, & F. Montorsi (Eds.), *Sexual Medicine: Sexual dysfunctions in men and women* (pp. 783-850). Paris: Health Publications. It is reprinted here by permission. Reprint requests and correspondence regarding this manuscript should be addressed to Cindy M. Meston, PhD, University of Texas at Austin, Department of Psychology, 108 E. Dean Keeton, Austin, TX 78712. (meston@psy.utexas.edu)

and typological perspectives (Levin, 1992). Symons (1979, p. 86) observed that although "the human female orgasm definitely exists [it] inspires interest, debate, polemics, ideology, technical manuals and scientific and popular literature solely because it is so often absent!" It is clear that natural selection has not favored females who could orgasm easily, hence it is not likely an essential feature of the reproductive process. Even its definition is hard to pin down because enigmatically it has both nomothetic (the study or discovery of general laws) and idiographic (individual's performance) aspects. Because the exact neural activity of the cerebral neuronal discharge is so poorly understood, most of those defining orgasm use reported or observed physical changes (usually muscular and cardiovascular), with an emphasis that this is the culmination or most intense moment of sexual arousal. Levin, Wagner, and Ottesen (1981) tabled some 13 definitions by authors from a variety of backgrounds, and 20 years later Mah and Binik (2001) repeated the exercise with a doubling of the author definitions. They divided them into three groups: those with primarily a biological perspective, those with a psychological perspective, and those with an integrated biopsychological perspective. The authors still had to conclude that a satisfactory universal definition of orgasm could not be accomplished. Considering that the human orgasm is regarded as the ultimate state of ecstatic feeling without recourse to drugs, it is remarkable how few of the definitions incorporated the word "pleasurable." The more recent reports that women with complete spinal cord injury (SCI) can experience orgasm further complicate an all-encompassing definition of orgasm (Sipski, Alexander, & Rosen, 1999). A major problem in defining orgasm is the emphasis that is given to the subjective or self-report, as opposed to objective physiological signs. Despite all these difficulties, it is useful to devise at least an operational definition for women's orgasm, thus we provide the following:

An orgasm in the human female is a variable, transient peak sensation of intense pleasure, creating an altered state of consciousness, usually with an initiation accompanied by involuntary, rhythmic contractions of the pelvic striated circumvaginal musculature, often with concomitant uterine and anal contractions, and mytonia that resolves the sexually induced vasocongestion (sometimes only partially) and mytonia, generally with an induction of well-being and contentment.

### *Typologies of Women's Orgasm*

Intriguingly, typologies of orgasm only exist for women; those for men have not been explored, even though some therapists have suggested that they exist (e.g., Zilbergeld, 1979). Most of the typologies (S. Fisher, 1973) are from self-reported perceptions of women distinguishing orgas-



mic sensations induced by clitoral stimulation (warm, ticklish, electrical, sharp) from those obtained by vaginal stimulation (throbbing, deep, soothing, comfortable). A frequently quoted typology is that of I. Singer (1973, pp. 72-73), a philosopher, with no experience conducting laboratory studies, who analyzed the descriptions of orgasms from a limited literature and characterized three: (a) "vulval," rhythmic contractions of the vagina activated by either clitoral or coital stimulation, (b) "uterine," no vaginal contractions but accompanied by apnoea and gasping activated during coitus alone and largely due to penile-cervix contact, and (c) "blended," containing elements of both vulval and uterine orgasms activated by coitus and accompanied by apnoea.

Great play was made about the importance of apnoea and, especially, cervical stimulation. The latter was not so much about stimulation of the cervix, *per se*, as about its displacement by the thrusting penis, causing the uterus to rub against the peritoneum, claimed by J. Singer and Singer (1972) to be a "highly sensitive organ." Unfortunately, the total evidence for this typology rests on limited scientific observations obtained in remarkably few individuals (Levin, 2001). Furthermore, the role of the cervix in a woman's sexual response (*viz.*, uterine orgasm) is unclear. One reviewer declared that, depending on the studies cited, any position can be supported (Johns, 1997), whereas a more recent reviewer concluded that evidence for and against a role of the cervix in orgasm is weak and that observational studies cannot answer the question (Grimes, 1999). Another difficulty with this typology is that, according to Ingelman-Sundberg (1997), the anterior vaginal wall acts like a hammock around the urethra, and during coitus the penis stretches two of its ligaments that insert around the base of the clitoris thus effectively stimulating it during thrusting. If this mechanism operates in all penile-vaginal coital penetrations, it would create both uterine and vulval stimuli or the so-called "blended" stimulus.

Although Masters and Johnson (1966) claimed that all orgasms in females were physiologically identical, regardless of the source of stimulation, they did not have the instrumentation to obtain detailed muscular recordings for possible differences between clitoral and so-called G-spot (anterior vaginal wall) induced orgasms. There is now some limited physiological laboratory evidence that different patterns of uterine (smooth muscle) and striated pelvic muscular activity may occur with vaginal anterior wall stimulation, as opposed to clitoral stimulation. One such set of recordings is shown in Levin (2001). The case for such a dual typology may well be made more credible by this type of evidence.

Bohlen, Held, Sanderson, and Ahlgren (1982) characterized the vaginal muscular contractions at orgasm in their 11 nulliparous women into

three typologies, which varied greatly in terms of orgasm duration. The typologies were (a) those that had regular rhythmic contractions (Mean duration of orgasm 13 seconds), (b) those that had regular contractions with later irregular ones (Mean orgasm duration 50.6 seconds), and (c) those that had no regular rhythmic contractions during their orgasms (Mean duration of orgasm 24.4 seconds). To create a muscular typology of such a range with so few participants is premature, but, unfortunately, no further studies have been reported. There is a need for simultaneous recordings of the uterine and vaginal motility at orgasm in a large sample of women.

#### *Gender Differences in Orgasm*

Written descriptions/accounts of orgasms by men and women, with any obvious gender clues removed, could not be differentiated by sex when read by other men and women (Vance & Wagner, 1976). This suggests that men and women share common mental experiences during orgasm. Four differences in male and female orgasms, however, have been proposed: (a) unlike the male, the female can have repeated (multiple) orgasms separated by very short intervals (Masters & Johnson, 1966, p. 131); (b) the female can have an extended orgasm, lasting for a long time (so-called "status orgasmus," Masters & Johnson, p. 131); (c) there are differences in the recorded pattern of pelvic muscular contractions; specifically, men have a divided rhythmic pattern not seen in women (Bohlen, Held, Sanderson, & Ahlgren, 1982); and (d) once the male orgasm is initiated, its further expression is automatic even if sexual stimulation is stopped; if stimulation is stopped in the middle of either clitoral-induced or vaginal-induced female orgasm, the female orgasm is halted (Sherfey, 1972, p. 121).

#### *Why Do Women Have Orgasms?*

It is generally accepted that female orgasms are not essential for reproduction. Any benefit for various aspects of female biology is, as of yet, unclear. There are a number of explanations from the literature regarding why the human female has orgasms: (a) the reward of intense pleasure for acceptance of the danger of coitus with its possibility of pregnancy (and of possible death in childbirth); (b) to end coitus; (c) for resolving pelvic vasocongestion/arousal; (d) for resolving vaginal tenting (allows the cervix to enter the seminal pool); (e) orgasmic uterine contractions may create a possible sperm "upsuck"; (f) to create arousal in the male by felt vaginal contractions on the penis and cause ejaculation (capturing the semen); (g) for inducing lassitude to keep the female horizontal and thereby reducing seminal "flowback"; (h) because of the dif-



faculty in attaining orgasm (especially coitus), orgasm acts as a "Mr. Right" indicator and aids the creation of a strong pair bond; (i) to create the loss of body boundaries and separateness allowing a merger or fusion with the chosen coital partner; (j) to create psychological resuscitation—like an electric shock redistributing the potentials of the brain; (k) to release oxytocin, which affects motility of the uterus and fallopian tubes and possibly to induce bonding feelings and emotions; (l) to release Antidiuretic Hormone (ADH) for the possible contraction of uterine musculature and to inhibit urination and delay sperm losses from flowback; (m) for manipulation of the uptake or rejection (flowback) of deposited sperm; (n) by its activation of muscular contractions and the concomitant increased blood flow, orgasms maintain the functionality of the genital tract (Levin, 2003a).

The history of the claimed importance of the female orgasm to reproduction is full of speculative functions with little or no scientific data for their support. Orgasmic coitus was said to activate ovulation and close off the womb to air, thus facilitating conception (Laqueur, 1990). When it was later shown that the human female was a spontaneous ovulator at mid-cycle, unconnected with coitus, the discourse was refocused on the role of uterine orgasmic contractions in the movement of ejaculated spermatozoa through the cervix, into the uterus, and then into the fallopian tubes. I. Singer (1973), in the light of his protagonism for his dual typology of female orgasm (so-called uterine and vulval), published an extensive discussion about fertility and the female orgasm in which he explored issues of (a) uterine suction, (b) extrauterine factors affecting the mechanics of uterine suction (*viz.*, vaginal tenting), and (c) the ejaculatory timing in coitus (*i.e.*, ejaculation must occur before orgasm to assist sperm transport, but see the discussion that follows regarding the proposals of Baker & Bellis, 1995).

It has often been suggested that uterine suction created by the contractions of the uterus at orgasm would facilitate the transport of spermatozoa into the uterus and then to the fallopian tubes. Evidence now shows the fastest transport of spermatozoa into the human uterus is actually in the sexually unstimulated condition (Levin, 2002, 2003a). One essential feature of sexual arousal of the female genitalia is to create the expansion of the vagina (vaginal tenting) and elevation of the uterocervix from the posterior vaginal wall to reduce the possibility of the rapid entry of ejaculated spermatozoa into the uterus. This gives time for the initiation of the decoagulation of the semen and the capacitation of the spermatozoa to begin, and it reduces the chance of incompetent sperm being too rapidly transported into the fallopian tubes. The female orgasm, by dissipating arousal and initiating the resolution of

the tenting, will, in fact, allow the earlier entry of the spermatozoa into the cervical canal and their subsequent rapid transport to the fallopian tubes, although there is some evidence that the motility of the uterus is reduced after sexual arousal and orgasm (see Levin, 2002). Not experiencing orgasm during coitus may thus have a reproductive utility unrealized by previous authors.

Another suggested reproductive function of female orgasms, initiated either from coitus or masturbation, is their use by women to manipulate the ejaculate in the vagina (Baker & Bellis, 1993, 1995). This highly contentious claim is based on the amount of flowback of seminal fluid lost from the vagina. According to these authors, the amount of flowback containing spermatozoa varies exquisitely with the precise timing of the female orgasm in relation to the time of deposition of the ejaculate into the vagina. Low sperm retention was said to be associated with female orgasms earlier than 1 minute before vaginal deposition, whereas maximum retention was claimed with orgasms from greater than 0 to 1 minute after deposition. If orgasm occurred earlier than 1 minute before the ejaculate, deposition sperm retention was the same as when there was no orgasm. According to Baker and Bellis (1995), the effect of orgasm on sperm retention lasts only for the period of 1 minute before semen deposition and up to 45 minutes later. During the period when the seminal fluid was coagulated (15 minutes), orgasms have a significantly reduced effect on sperm retention. These complicated scenarios for the effects of female orgasm on sperm retention still depend on a contractile uterine upsuck sperm mechanism. During orgasm, the cervix "searches and dips" into the seminal pool, and the orgasm-induced movements either facilitate the dipping, and/or the mixing of the cervical mucus with the pool, and/or increase the time that the cervix is in the pool.

The coital scenario previously described (Levin, 2002, 2003a) in which vaginal tenting removes the cervix from the seminal pool, thus delaying the uptake of sperm in order to allow the initiation of its liquefaction and the capacitation of the sperm, contrasts dramatically with the hypothesis of Baker and Bellis (1995). The crucial factor is the presence or absence of vaginal tenting. Masters and Johnson (1966, p. 113-114) reported it is only absent in women with retroverted or retroflexed positioned uteri, but I. Singer (1973) speculated that it may not occur in either his uterine or blended orgasm. The only evidence for this speculation is a preliminary report by Perry and Whipple (1982) who claimed that tenting never occurred in response to Grafenberg (G-spot) stimulation and that G-spot stimulation led to a direct descent of the uterus, placing the cervix immediately and directly into the seminal pool, where it could facilitate conception. So-called uterine orgasms in Perry and



Whipple's preliminary analysis would facilitate conception, whereas vulval ones would not. The cervical disposition created by the former orgasm would allow rapid sperm entry before capacitation had been initiated and, thus, facilitate the uterine/tubal entry of sperm incompetent to fertilize. Ultrasound imaging of face-to-face coitus did not show penile cervical contact (Riley, Lee, & Riley, 1992) as would be expected if Singer's uterine orgasm were to be induced, but the recent imaging by MRI of the relationships between the penis, cervix, and the uterus during coitus and masturbation has confirmed the concept of vaginal tenting in a relatively small number of couples (Faix, Lapray, Calde, Maubon, & Lanfrey, 2002; Faix, Lapray, Courtieu, Maubon, & Lanfrey, 2001; Schultz, van Aniel, Sabelis, & Mooyaart, 1999). It is, thus, likely that tenting occurs in face-to-face coitus and that its effect on fertilization is positive (Levin, 2002, 2003a). It is clear that more MRI scans of human coital activity are needed to confirm this definitively.

A less controversial claim of one of the functions of orgasm to aid in the reproductive process is that if the female allows the expression of orgasm during coitus, its contractions of the vagina can excite the male ejaculate thus allowing the female to capture the sperm of her chosen inseminator. Orgasm increases the secretion of prolactin (Kruger, Haake, Hartman, Schedlowski, & Exton, 2002). If this increased secreted prolactin in plasma is able to enter into the vaginal, cervical, or uterine fluids, it might be a factor in influencing the entry of calcium into the sperm as it acts as a physiological ionophore. This action could play a role in the activation of spermatozoa in the female tract (Reyes, Para, Chavarria, Goicoechea, & Rosado, 1979). Finally, one area of the putative involvement of orgasm in reproduction that is generally not discussed is its use to induce and encourage the first stage of or to relieve the pain of childbirth (Pranzarone, 1991). Some women have spontaneous orgasms during the passage of the fetal head through the vaginal canal, probably through the stretching activation of the cluster of erotic sites along the anterior vaginal wall.

### **Objective Signs of Orgasm**

Orgasm is a subjective experience accompanied by a number of physiological body changes. The degree to which these changes vary among individuals is not known. Males have little difficulty in identifying orgasm because, although orgasm and ejaculation are created by distinct mechanisms, (see Levin, 2003b for references), it is rare for the former not to accompany the latter. In women, the achievement of orgasm appears to be less facile than for males, and recognizing that it has occurred can be difficult for some. Thus, just asking previously anorgas-

mic women whether they experienced an orgasm after a treatment or therapeutic session is somewhat unreliable. An objective indicator(s) that an orgasm has occurred to confirm or to inform any subjective report would be of real clinical and therapeutic value.

Objective indicators of orgasm have been sought for many years, often with little regard for their utility in the clinical context. Kinsey, Pomeroy, Martin, and Gebhard (1953) proposed "the abrupt cessation of the oft-times strenuous movements and extreme tensions of the previous sexual activity and the peace of the resulting state" (p. 628) as the most obvious evidence that orgasm had occurred in the human female. Masters and Johnson (1966) described the onset of orgasm as a "sensation of suspension or stoppage" (p. 135). Clearly, however, the indicator must involve a body change that is unique to orgasm, which rules out simple measures, such as peaks of blood pressure, heart and respiratory rates, or even a naïve subject's own vocalizations indicating it is impending or is occurring because such peaks can arise even if no orgasm occurs. Remarkably, most of the so-called objective indicators of female orgasm rely on the original, nearly 40-year-old observations and descriptions of Masters and Johnson (1966). They are of three types: prospective—those indicating an impending orgasm, current—those occurring during the actual orgasm, and retrospective—those indicating that an orgasm has occurred. They are listed in Table 1 and described in detail in the following section. Surprisingly, even such a simple classification system has its problems, as it is possible to place some of the indicators in either the current or retrospective category, depending on the chosen definition of the initiation of the orgasm. It is unclear whether orgasm should be defined as starting when the woman first mentally perceives it, or whether it starts when the first physical manifestation occurs. Kinsey et al. (1953) tried to limit the definition of orgasm to the sudden and abrupt reduction of sexual tension. The "spasms" into which individuals are thrown were argued to be the "after effects" of the orgasm, and the "vaginal spasms" were regarded simply as "extensions of the spasms that may involve the whole body after orgasms" (p. 632). Hite (1976) also regarded orgasm as a brief intense feeling followed by contractions.

#### *Prospective Changes*

The paired labia minora on either side of the vaginal introitus are continuous ventrally with the prepuce and frenulum of the clitoris and join the labia majora posteriorly. They are composed of adipose tissue, connective tissue rich in elastic fibers with smooth muscle fibers and numerous wide veins. The amount of cavernous tissue present is variable: In some it is extensive, and in others it is hardly present. The tis-



Table 1  
*Characteristic Changes Occurring During Orgasm<sup>a</sup>*

<b>Extragenital</b>	
Respiration	- usually peaks to a maximum at initiation of orgasm (> 40/min)
Blood pressure	- usually peaks at initiation of orgasm and then decreases (systolic +30-80 mmHg, diastolic + 20-40 mmHg)
Heart rate	- usually peaks at initiation of orgasm then decreases (110-180 beats/min)
Sex flush	- superficial maculo-papular (vasocongestive) over epigastrium, anterior chest wall spreading to neck and face has greatest intensity at orgasm
Perspiration	- approximately 33% women in back, thighs, and chest
Breasts	- no specific change
Nipples	- no specific change
Areolae	- rapid detumescence of congestion leading to transient corrugation
Myotonia (generalized)	- contractions in neck, face, arms, and legs may become spastic, carpopedal spasm
<b>Genital/Pelvic</b>	
Clitoris	- no specific change
Labia (majora and minora)	- no specific change
Vagina	- rhythmic contractions (throbbing) of outer third (orgasmic platform) due to pelvic striated muscle contractions
Uterus	- expulsive contractions of smooth muscle
Rectal sphincter	- contractions mirroring vaginal contractions
Cervix	- dilation of os immediately after orgasm lasting 20-30 minutes
<b>Hormonal</b>	
Anterior pituitary	- increased secretion of prolactin
Posterior pituitary	- increased secretion of ADH (Vasopressin) and Oxytocin
VIP	- increase in plasma VIP

<sup>a</sup>Derived primarily from Masters and Johnson (1966).

sue is a spongy mass like that of the clitoris except that it does not have a capsule around it and has fewer nerves in the trabeculae. Merkel tactile discs and genital corpuscle (Dogiel/Krause) are found in the prepuce and ventral part with a rich network of nerves. Free nerve endings lie just beneath the germinative stratum and Pacinian corpuscles and are frequently noted along the courses of nerves (Erickson & Montagna, 1972; Krantz, 1958). Numerous eccrine sweat glands and a few apocrine glands are present.

During sexual arousal, the labia become engorged with blood and increase in size, adding on about 1 cm to the length of the vagina. According to Masters and Johnson (1966, pp. 41-42), once their initial engorgement has been induced, vivid color changes occur with further sexual arousal. The color changes were said to be "clinically pathognomic" of impending orgasm as the claim was made that "no pre-

menopausal woman has been observed to reach plateau-phase levels of sexual tension, develop the 'sex skin' color changes and then not experience an orgasm." After the orgasm occurs, the color changes rapidly within 10-15 seconds, from deep red to light pink. If the color change takes place and then the sexual stimulus is removed, it rapidly fades, well ahead of the slower loss of the engorgement. No other researchers have confirmed these findings despite this highly specific claim of impending orgasm on the minora labia color change. In fact, there has been little detailed study of the minora labia apart from the suggested mechanism by which they become lubricated (Levin, 1999b) and that their increased temperature during sexual arousal has been used as an objective indicator of arousal (Henson, Rubin, Henson, & Williams, 1977) prior to and after orgasm (Henson, Rubin, & Henson, 1982). The color changes of the labia are presumably due to the changing hemodynamics of the tissue in relation to increased blood flow, tissue congestion, and tissue metabolism (oxygen consumption) indicating the balance between oxygenated (red/pink) and deoxygenated or reduced hemoglobin (blue). The blue color of cyanosed mucous membranes occurs when the absolute amount of reduced hemoglobin is greater than 5 gms/100mls blood. The percentage saturation oxygenation of the blood ( $sO_2$ ) is usually measured by light absorbancy, but no quantitative studies have been made on the labia minora during sexual arousal. In the basal state the vaginal surface, which has a very low  $pO_2$ , practically hypoxic (Wagner & Levin, 1978), rapidly increases during sexual arousal up to a maximum at orgasm. Repetition of this study (Sommers, Caspers, Esders, Klotz, & Engelman, 2001) confirmed the vaginal findings and showed that the labia minora followed a similar pattern.

### *Current Indicators of Orgasm*

#### *Vaginal Rhythmic Contractions*

The resting vagina is a collapsed tube lined with a stratified squamous epithelium, approximating an elongated S-shape in longitudinal section and an H-shape in cross-section, invested with an outer longitudinal and inner circular layer of smooth muscle. It is anchored amid a bed of powerful, voluntary, striated muscles (pelvic diaphragm, consisting of the pubococcygeus and iliococcygeus muscle) of which the pubococcygeus has fibers that insert into the smooth muscle (Kegel, 1952; Levin, 2003b). Balloon recordings of the pressure inside the vagina show that just before orgasm is initiated there is a slow increase, probably due to an increase in tone of these circumvaginal muscles (see Figure 1), although the tone of the vaginal smooth muscle per se may also



be involved. According to Masters and Johnson (1966, p. 118), the contractions recorded in the vagina begin some 2-4 seconds after the subjective appreciation of the start of the orgasm. They occur in many pre- and postmenopausal women and are due to the activation of the circumvaginal striated muscles (especially the pelvic diaphragm, bulbospongiosus, ischiocavernosus), which involuntarily contract in 0.8 second repetitions. This squeezes the outer third of the vagina (designated the "orgasmic platform" by Masters & Johnson, 1966) with some force that gradually becomes weaker as the interval between contractions increases.

Contractions were not thought to be the primary initiator of the orgasmic experience because they began a few seconds after the woman perceived that orgasm had started (but see the later section on "What triggers female orgasm?"). Their number (and power) varies enormously and is obviously dependent on the duration of the orgasm and the strength of the pelvic musculature. Masters and Johnson (1966) reported that the stronger the orgasm, the greater the number of contractions and, thus, indirectly the longer the duration of orgasm (as each contraction was approximately 0.8 seconds apart). However, if the number of contractions and their approximate duration are multiplied together, this gives an approximate duration of each grade of orgasm; "mild orgasms" had an average of 3-5 contractions (2.4 to 4 seconds long), "normal" ones 5-8 (4 to 6.4 seconds long), and "intense" orgasms had 8-12 contractions (4 to 9.6 seconds long). This claim and quantification was given without any supporting data. Using physiological (pressure) recordings, there has been difficulty establishing any link between the contractions and the per-




Figure 1. Recording of changes in vaginal luminal pressure measured by a water-filled balloon (diameter 1.5 cm, length 3.5 cm) during self-induced orgasm by clitoral stimulation. The rise in muscular tone followed by 10-11 individual clonic contractions is clearly seen. The upper trace is the electrocardiogram recorded by telemetry. The start and finish of the orgasm (from the women's reports) is shown by the two arrows, and the subjective grading of the orgasm (on a scale of 1 = poor to 5 = excellent) is given as 4-5.

ceived intensity of the orgasm (Bohlen, Held, & Sanderson, 1982; Carmichael, Warburton, Dixen, & Davidson, 1994). The durations of the orgasms recorded were  $M = 35.6$  seconds ( $SD = 24.5$ ,  $N = 11$ ) (Bohlen, Held, & Sanderson, 1982);  $M = 19.9$  seconds ( $SD = 12$ ,  $N = 26$ ) (Levin & Wagner, 1985);  $M = 21.9$  seconds ( $SD = 6.4$ ,  $N = 9$ ) (Carmichael, et al., 1994). Bohlen, Held, and Sanderson (1982) reported, in their small group of women participants, a precise correspondence between the start of orgasm and the onset of regular vaginal contractions, but the end of orgasms and the end of regular contractions were not observed. For some women, the perceived start of orgasm preceded regular contractions by some 2-4 seconds (see report of Masters & Johnson, 1966, described earlier), for others it coincided with the contractions, and for an additional group orgasm followed the onset of contractions. Some of this variation could depend on how accurate and quickly different respondents can report on their internal states. Contractions of the pelvic muscles at orgasm can also be monitored by recording their electromyogram, as was undertaken by Gillan and Brindley (1979) using suction or fine wire electrodes in the circumvaginal muscles.

Masters and Johnson (1966) confidently proposed that the vaginal contractions would "remove any doubt as to whether a woman is pretending or experiencing orgasm" (p. 134), but other authors have noted that not all women who claim to experience orgasms show these contractions (Bohlen, Held, & Sanderson, 1982; Bohlen, Held, Sanderson, & Ahlgren, 1982; Kratochvil, 1994; Ladas, Whipple, & Perry, 1982; Levin et al., 1981; Levine, 1948; Malleon, 1948). It is especially interesting to note in this context that Bohlen, Held, and Sanderson (1982) stated that, although 2 of their 11 participants did not show distinct muscular evidence of orgasm, they were not prepared to conclude that physiological characteristics were more valid than self-reported perceptions for identifying orgasm. They concluded that, until more data were collected, they would continue their analyses of physiological changes based on subjects' self-defined orgasms.

Unfortunately, there has been no further detailed analysis of female orgasms so there is no large body of data from women who have had their vaginal muscular activity recorded during orgasm in order to assess the usefulness of the original contractile pattern classification. There has been little or no advance in the area since these studies in the 1980s. The vaginal contractions have been used to objectively track the attainment of orgasmic capacity by a single initially anorgasmic subject (Bohlen, Held, Sanderson, & Boyer, 1982).

It should also be noted that, in the account of the muscular activity at orgasm, there is no mention of the pattern of activity of the involuntary,



longitudinal, and circular vaginal smooth muscle during sexual arousal and at orgasm. Indeed, it is not even known whether they are relaxed, contracted, or have a high tonus. One author has interpreted intravaginal balloon recordings from one subject as evidence for an enhanced tonus of the vaginal smooth muscle at arousal (Campbell, 1976). The slow rise in pressure in the vaginal lumen shown in Figure 1 may be due to such an increase in smooth muscle tone rather than that of the circumvaginal striated muscles; nevertheless, no routine, simultaneous recordings have been published with any instrumentation that has definitively separated their contractile activity in a series of women.

### *Uterine Contractions*

In their review on the "after-effects of orgasm," Kinsey et al. (1953) commented that studies had shown that the "upper end of the uterus goes into rhythmic contractions of considerable frequency whenever there is sexual arousal" (p. 633). Masters and Johnson (1966), however, claimed, "specific uterine patterns do not develop unless the individual study subject undergoes an orgasmic experience that is recognizable both by trained observers and by the individual involved" (p. 116). Uterine motility was one of the physiological measurements that Masters and Johnson attempted, monitored by "intrauterine and abdominal electrode placement" (p. 116). Unfortunately, apart from this phrase, no details of the technique were ever published, so we have no idea of the exact placement of the electrodes, their type, or the equipment to which they were attached. The one published orgasmic record from the "intrauterine electrodes" (p. 117, Fig. 8-2) is difficult to interpret, as it looks more like an increase in tone of the uterus than a series of contractions. Masters and Johnson claimed that the degree of contraction of the uterus paralleled "the study subject's subjective and the observer's objective evaluations of the physical and emotional intensity of the orgasmic experience" (p. 116). Few other investigators have examined uterine contractile function at orgasm. Fox, Wolff, and Baker (1970) used an intrauterine pressure transducer in a single subject who had sequentially a nonterminative and then terminative orgasm in the same sexual scenario, and uterine (and vaginal) contractions were recorded during the final orgasm. Caution is warranted in interpreting these conclusions because of the idiosyncratic orgasmic behavior of the subject and the possible artifacts created by the large size and malfunctioning of the intrauterine transducer (Levin, 1992). It has been proposed that orgasmic uterine contractions are the terminative signal for sexual arousal in multiorgasmic women (J. M. Davidson, 1980), but, again, caution has been expressed (Levin, 2001). Too few

investigators have assessed orgasmic uterine contractions to make such a definitive statement.

#### *Contractions of the Anal Sphincter*

Although voluntary contractions of the anal sphincter can occur during sexual arousal and are sometimes used by women to facilitate or enhance arousal, involuntary contractions of the anus occur only during orgasm (Masters & Johnson, 1966, p. 34). However, few investigations have been published in which measurements of anal contractions have been taken, aside from those of Bohlen and colleagues, who created a special anal pressure-measuring device (1979) that could record the tone and contractions of the anal sphincter in both sexes during orgasm (Bohlen, Held, Sanderson, & Ahlbren, 1982). They reported that the anal contractions were synchronized with the vaginal contractions, yet the waveforms differed (vaginal = square wave, anal = sinusoidal), and those of the anus showed greater variability. Despite the obvious utility of recording the same muscular activity in both men and women at orgasm, little or no use has been made of the device since its creation in the 1980s (Bohlen & Held, 1979). The genital and extragenital changes that occur at or immediately after orgasm are listed in Table 2.

#### *Retrospective Changes*

##### *Areolae Congestion and Decongestion*

The primary areolae, the usually large pigmented skin area around the nipple of the breasts, contain the follicles of Montgomery (small sebaceous glandular structures), occasional hair follicles, an underlying network of smooth muscle of interlacing bundles some 2 mm thick, blood vessels, elastic tissue, melanoblasts, Pacinian corpuscles, nerve fibers, and a nerve plexus (Cathcart, Gairns, & Garven, 1947-1948; Dickinson, 1949; Winkleman, 1959). The neural basis for areolar sensation was reported by Jones and Turner (1931) to be "typically protopathic or thalamic in its character. The appreciation of the stimulus of cotton wool or testing hairs ceases abruptly at the margin of the specialised pigmented areola area" (p. 778). In a later study, Tairyck et al. (1989) tested the cutaneous sensitivity of the breasts using Semmes-Weinstein monofilaments to obtain normal values and found that the skin of the superior quadrant was the most sensitive, the areola less sensitive, and the nipple the least sensitive. All areas were less sensitive, the larger the breasts.

Swelling of areolae when the woman is sexually aroused is likely due to both vasocongestion and smooth muscle contraction. The volume



Table 2

*Extragenital and Genital/Pelvic Changes During Female Sexual Arousal<sup>a</sup>*

<b>Extragenital</b>	
Hyperventilation	- from a basal of 14 breaths/min to a max of 40
Tachycardia	- from a basal of 80 beats/min to a max of 180
Hypertension	- diastolic blood pressure elevated by 20-80 mmHg, systolic blood pressure elevated by 80-100 mmHg
Sex flush	- superficial maculo-papular (vasocongestive) rash initially over epigastrium and anterior chest wall then on neck, face, and forehead
Breast engorgement	
Areolae engorgement	
Nipple erection	- elongation + 0.5-1cm, base diameter + 0.25-0.5 cm
Myotonia	- elevated tension in muscles (legs, arms, neck, face (grimacing), abdomen)
Emission sounds	- sighs, moans, groans, grunts
Pupil dilation	
<b>Genital/Pelvic</b>	
Labia majora	- thins out and flattens against perineum
Labia minora	- expands in diameter, color changes, lubrication
Clitoris	- tumescence of glans (50% subjects) and shaft, retraction under clitoral hood
Vagina	- increases in blood flow, surface pO <sub>2</sub> , lubrication, Na <sup>+</sup> and Cl <sup>-</sup> , length (+2.5 cm), tenting concomitant with utero-cervical elevation (width +3.75 to 4.25 cm)
Uterus	- elevation into false pelvis
Cervix	- no specific response

<sup>a</sup> Derived primarily from Masters and Johnson (1966).

expansion can become so marked that the swollen/contracted areolae hide a large part of the base of the erect nipples, making it look like they lose their erection. At orgasm, the loss of volume is so rapid that the areolae become corrugated before becoming flatter. This provides a "visual identification of the female orgasmic experience" (Masters & Johnson, 1966, p. 130). In the absence of an orgasm, the areolar detumescence is much slower, and the corrugation does not develop. There has been minimal study of areolar changes as an indicator that orgasm has taken place. Detailed descriptions of pre- and postorgasmic changes of the areolae have not been fully explored, most likely because they are difficult to monitor, either quantitatively or qualitatively.

#### *Enhanced Postorgasmic Vaginal Pulse Amplitude*

Recordings of changes in the blood supply to the human vagina during sexual arousal to orgasm were made using the photoplethysmographic technique of Palti and Bercovici (1967), with a superior vaginal photoplethysmograph created by Sintchak and Geer (1975). Geer and Quarataro (1976) were the first to publish actual records of the vaginal pulse

amplitudes (VPA) of the alternating current (AC) trace of each individual heart beat from their luminal, free-dwelling, vaginal photoplethysmograph before, at, and after orgasm in seven young women. Sexual arousal by masturbation caused an increase in the VPA signal compared to the basal values in all participants, but immediately after the end of orgasm VPA was actually significantly greater than before orgasm in five of the seven women (71%) and was not significantly less in the other two. The postorgasmic period of maximum amplitude lasts for approximately 10-30 seconds, and then VPA slowly returns to its basal value (see Figure 2). This behavior has been observed in VPA signals recorded in other photoplethysmographic studies of orgasm (Gillan & Brindley, 1979; Henson, Rubin, & Henson, 1982; Levin, 1997; Levin & Wagner, 1980). There have been over 50 papers published using photoplethysmographic recording in the vagina but, unfortunately, these studies never took the induced sexual arousal to orgasm and beyond. Because there are so few photoplethysmographic recordings of the actual pre- and postorgasmic VPA traces published (less than a dozen), its utility as an indicator of orgasm in women is unclear. One basic disadvantage in photoplethysmographic recording during orgasm using luminal free-dwelling instruments is that in many women the vaginal motility and orgasmic contractions can create severe movement artifacts in the records and make interpretation of the VPA signals extremely difficult. However, the development and exploitation of a suction photoplethysmograph (Levin et al., 1981) that is attached to the vaginal wall and, thus, moves with the wall would overcome such difficulties and allow interpretable recordings to be taken throughout orgasm. Contemporary collection and computerized processing of the VPA data also uses relatively long time periods (1-3 minutes) during an experiment. Given that the effect is transient and usually only lasts for up to 30 seconds, the response can get lost when calculating overall mean amplitudes. Visual inspection of the data is essential.

#### *Raised Prolactin Plasma Levels After Orgasm*

Prolactin is a hormone secreted by the lactotrophic cells of the anterior pituitary gland. Its sequence of 199 amino acids was identified in 1969 (Li, Dixon, Schmidt, Pankov, & Lo, 1969), and it was thought to regulate lactation as early as the 1920s. Since its sequencing, prolactin has been shown to be involved in a huge variety of actions involving over 300 functions and is known to be produced or stored in a variety of cells. Its release from the pituitary lactotrophs is unusual in that it is under tonic inhibitory control by the hypothalamus primarily via the neurotransmitter dopamine, although other substances and hormones can inhibit (e.g., Somatostatin, Endothelin, Acetylcholine) or facilitate






Figure 2. Recordings of vaginal pulse amplitude (VPA) and vaginal blood volume (BV) obtained by a free dwelling luminal photoplethysmograph for (a) basal, nonsexually stimulated trace, (b) BV (10 secs) during clitoral stimulation, (c) VPA during clitoral stimulation to orgasm and after, (d) BV (10 secs) postorgasm, (e) VPA postorgasm. The start and finish of the orgasm as reported by the woman is shown by the two arrows and is self-graded 2-3 on a scale of 1 = poor to 5 = excellent. The transient, enhanced, immediate postorgasmic VPA signal is clearly seen.

(e.g., VIP, Oxytocin, TRH) its release (Kruger et al., 2002). Prolactin acts on the hypothalamic dopamine neurons to create a negative feedback loop to control its own release, similar to the other anterior pituitary hormones. The receptors for prolactin action are distributed in a variety of tissues (e.g., skin, bone, liver, male and female reproductive organs), but those of essential relevance are in the central nervous system (hippocampus, cortex, amygdala, hypothalamus) in areas known to regulate sexual behavior. A central role for prolactin in modulating sexual behavior and function in animals and in humans is now accepted.

Kruger and colleagues have reported that prolactin secretion is not activated by sexual arousal per se but is specifically activated and doubled in plasma concentration by orgasm, whether generated by masturbation or coitus. This elevation occurs directly after orgasm and is maintained for approximately 60 minutes. Apart from its claimed indicator function for orgasm, the authors proposed that it also acts as a feedback control of sexual drive probably inducing its inhibition (refractory period), especially noted in the male after ejaculation and orgasm (Kruger et al., 2002). Females, of course, do not appear to have this refractory period after only one orgasm and can often undergo a whole series before satiation occurs (Masters & Johnson, 1966). If prolactin is the orgasmic-linked "off" switch for sexual arousal in men, why does it not act similarly in women? Less well known, prolactin can also be released by tactile stimulation of the nipples in both women and in men especially when they are sexually aroused (Jacobs & Daughaday, 1974; Kolodney, Jacobs, & Daughaday, 1972). Thus, increase in prolactin

secretion may be a retrospective signal that orgasm has indeed taken place. Its great disadvantage is the intrusiveness of its measure—it needs the pre-insertion of a butterfly cannula into a vein so that repeated venous samples can be withdrawn. Additional studies need to be undertaken to determine whether prolactin concentrations in other, more easily accessible body fluids, such as saliva, vaginal or cervical fluid, or urine could be used. (See Table 3 for a summary of the prospective, current, and retrospective indicators of female orgasm.)

### *The Female Prostate, Female Ejaculation, and the G-Spot*

In all the areas related to female sexuality, perhaps none have been surrounded with more aura than the concept of the G-spot (named after Grafenberg who reportedly first anecdotally described the phenomenon in Grafenberg, 1950; Ladas et al., 1982). Unfortunately, the popularization of this concept appears to have clouded our ability to make an accurate determination of its existence. To follow is a critical discussion of the scientific evidence for the female prostate, female ejaculation, and the G-spot.

Anatomic evidence from multiple autopsy studies has demonstrated the presence of paraurethral glands (Huffman, 1948; Pollen & Dreilinger, 1984; Tepper, Jagirdar, Heath, & Geller, 1984; Zaviacic, Brozman, Zajickova, Blazekova, & Oberuscova, 1985). In addition to the presence of these glands, histochemical evidence of prostatic acid phosphatase has been documented. (Pollen & Dreilinger, 1984; Tepper et al., 1984). These reports provide strong evidence for the existence of periurethral glands in the female and for the presence of prostatic acid phosphatase. They also lead to the question of female ejaculation, and whether women expel fluid from their urethra concomitant with orgasm from G-spot stimulation, and what the components of this fluid are.

After the popularization of the term *G-spot*, the investigators of a number of questionnaire studies reported that a significant number of

Table 3  
*Objective Indicators of Female Orgasm*

---

**Prospective** (indicating impending orgasm)

Labia minora color changes

---

**Current** (occurring during actual orgasm)

Vaginal rhythmic contractions

Uterine contractions

Contractions of anal sphincter

---

**Retrospective** (indicating an orgasm has occurred)

Areolae congestion and decongestion

Enhanced postorgasmic photoplethysmographic VPA<sup>a</sup>

Raised prolactin plasma levels

---

<sup>a</sup> VPA = Vaginal pulse amplitude.



women acknowledged that they expelled fluid through their urethra at the time of orgasm (Belzer, 1981; Bullough et al., 1984; J. K. Davidson, Darling, & Conway-Welch, 1989), but these reports were anecdotal and did not provide any evidence of the source of fluid. Additionally, the reports were often preceded by the women hearing or being educated about the topic before they gave report of their own situations. This may have provided a suggestion to women that the correct answer was to say that they did ejaculate. There is essentially no scientific evidence to support the belief that women ejaculate with a fluid distinguishable from urine at the time of orgasm (Goldberg, Whipple, Fishkin, Waxman, Fink, & Weisber, 1983). Laboratory studies (Goldberg et al., 1983; Grafenberg, 1950; Hoch, 1986) have not revealed consistent evidence for any anatomical structure on the anterior vaginal wall, apart from the known paraurethral glands and spongiosal tissue around the urethra, that could create sexually pleasurable sensations when stimulated.

#### *What Triggers Women's Orgasm?*

Women's orgasms can be induced by erotic stimulation of a variety of genital and nongenital sites. The clitoris and vagina (especially the anterior wall including Halban's fascia and urethra) are the most usual sites of stimulation, but stimulation of the periurethral glans (Levin, 2001), breast/nipple, or mons (Kolodney et al., 1974; Masters & Johnson, 1966, p. 54), mental imagery or fantasy (Masters & Johnson, 1966; Whipple, Ogden, & Komisaruk, 1992), and hypnosis (Levin, 1992) have also been reported to induce orgasm. Orgasms have been noted to occur during sleep in the able-bodied (C. Fisher et al., 1983; Kinsey et al., 1953; Wells, 1983), hence consciousness is not an absolute requirement. In the psychiatric literature, rare cases of so-called true "spontaneous orgasm," in which no obvious sexual stimulus can be ascertained (Polatin & Douglas, 1953), and which are different from the not uncommon "hyperesthesia sexualis" (orgasm following an extremely variable group of tactile, visual, and auditory stimuli) have been described.

Exactly what initiates the orgasm has been a topic of discourse and speculation for many years. Four pseudoneurophysiological models have been proposed. Sherfey's (1966) model was based on the firing of stretch receptors in the pelvic striated muscles activated by the pelvic engorgement, which initiated a spinal reflex. In H. S. Kaplan's model (1974), the clitoris was the source for the sensory impulses activating the reflex. Mould's contribution (1980, 1982) was to combine the Sherfey and Kaplan models and incorporate the gamma biasing of the muscle spindle of the striated musculature, which would then allow the generation of their clonic reflex contractions. Mould's hypothesized trigger was

the dynamic stretch of the intrafusal fibers of the pelvic striated muscles via the alpha-fusimotor systems. Davidson's model, based on male ejaculation/orgasm (J. M. Davidson, 1980), was grandly called the "bipolar hypothesis," but it was, in fact, a "dual bipolar hypothesis." In brief, he proposed that when sexual arousal reached a critical level, a hypothetical central "orgasm centre," with upward links to the cortex and downward links to activate the smooth and the striated genito-pelvic musculature, was triggered. The neural elements involved in seminal emission and in female uterine contractions fired to contract the smooth muscles and to inhibit arousal, whereas those involved in the contractions of the striated muscles caused the sensation of orgasm and its altered state of consciousness.

A more detailed exposition of the J. M. Davidson (1980) male model was attempted by Tuckwell (1989), who explained the well-known refractory period for men after ejaculation/orgasm by a central build-up of neuronal extracellular  $K^+$ . Women do not experience this inhibited arousability after orgasm, presumably because they do not have the male emission/ejaculation mechanisms. Alternatively, the strong contractions of the uterus at orgasm are thought to be the comparable terminal event in females (J. M. Davidson, 1980). A more recent explanation is that the "switch off" is due to prolactin release. None of the models of orgasm initiation appear satisfactory (Graber, 1982). Although no new definitive mechanism(s) supported by laboratory-backed data has yet emerged, comparing brain imaging during female sexual arousal without orgasm (Karama et al., 2002; Park, Kang, Seo, Ryu, & Jeong, 2001) to brain imaging at orgasm offers at least the possibility of seeing whether there are any areas of the brain specifically involved in generating the orgasm.

## **Physiological Aspects of Women's Orgasm**

### *Central Nervous System Control of Women's Orgasm*

#### *Overview*

Studies of animals have provided some insights into the central nervous system (CNS) control of sexual climax and are often the only avenue of information about the neural functions that coordinate the complex events leading up to and following orgasm. In this section, we will first review the animal models of sexual climax and the brain areas that control genital reflexes. Because there has been very little research on genital function in female animals, studies in males are briefly described and comparisons with females are made. Then, studies of brain imaging during sexual arousal and orgasm are described and comparisons with the animal literature drawn. Next, information about brain disorders in



humans is reviewed to provide insight into the function of relevant brain areas. Finally, brain areas that may mediate the inhibitory effects of antidepressant and antipsychotic medication are discussed, as well as the beneficial effects of drug and hormonal treatments.

### *Animal Models of Orgasm*

There are a number of physiological markers that suggest the presence of orgasm in female animals, including increases in blood pressure and heart rate, and uterine contractions during copulation in female rats, rabbits, cattle, and monkeys (McKenna, 1999). Much of the information about the physiological control of orgasm has come from studies of the urethro-genital (UG) reflex in male and female rats. This reflex, elicited by mechanical stimulation of the urethra or by electrical stimulation of certain brain areas, is characterized by a series of muscle contractions similar to those of orgasm in humans (Chung, McVary, & McKenna, 1988; Gerstenburg, Levin, & Wagner, 1990). These contractions result from the coordinated firing of the pelvic, hypogastric, and pudendal motor nerves (Chung, McVary, & McKenna, 1988; McKenna, Chung, & McVary, 1991). In female rats, this reflex includes rhythmic contractions of vaginal and uterine musculature, as well as anal sphincter contractions (McKenna et al., 1991).

Both the UG reflex in rats and orgasm in humans are thought to be controlled in part by a spinal pattern generator (Bors & Comar, 1960; McKenna, 1999; Sipski, 2001; Sipski & Behnegar, 2001). Input to the pattern generator comes primarily from the sensory branch of the pudendal nerve; output is sent via pudendal motor neurons to the ischiocavernosus and bulbocavernosus muscles, the urethral and anal sphincters, and striated muscles of the pelvis (McKenna & Nadelhaft, 1986, 1989; Truitt & Coolen, 2002) and via hypogastric and pelvic nerves to sympathetic and parasympathetic preganglionic neurons.

### *Brain Areas Controlling Orgasm*

*Tonic inhibition of the UG reflex.* Genital reflexes in animal studies are under tonic inhibitory control by the nucleus paragigantocellularis (nPGi) in the ventrolateral medulla. A majority (78%) of nPGi axons that project to the lumbosacral spinal cord contain serotonin (5-HT) (Marson & McKenna, 1992), suggesting that the lumbosacral cord may be one site where antidepressants of the selective serotonin reuptake inhibitor (SSRI) class act to inhibit orgasm in humans.

*Excitatory influences on the UG reflex.* The medial preoptic area (MPOA) is a major integrative site for the control of both male and female sexual behavior (reviewed in Hull & Dominguez, 2003). Electri-

cal or chemical stimulation of the MPOA of anesthetized male or female rats elicited the UG reflex in the absence of genital stimulation and without spinal transection or lesions of the nPGi (Marson & McKenna, 1994; McKenna, 1999). Electrical stimulation also significantly decreased vaginal vascular resistance (increased engorgement) in anesthetized female rats and increased their blood pressure (Giuliano et al., 2001). Thus, both sympathetic and parasympathetic influences were produced by MPOA stimulation, in accord with the integrated nature of the arousal and orgasmic response. In addition, one group of MPOA neurons fired during proceptive behavior of female rats and a different subset was active during lordosis (Kato & Sakuma, 2000). Therefore, different neurons within the preoptic area appear to promote the female's sexual motivation and her receptive posture.

The MPOA does not send axons directly to the spinal cord but connects with the nPGi (Murphy, Rizvi, Ennis, & Shipley, 1999), which it presumably inhibits. In addition, the MPOA has reciprocal connections with the paraventricular nucleus (PVN) of the hypothalamus and the periaqueductal gray (PAG) of the midbrain (Murphy et al., 1999; Simerly & Swanson, 1988). The PVN is an integrative site for the sympathetic nervous system (Swanson & Sawchenko, 1980). It also contains neurons that release oxytocin into the general circulation via the posterior pituitary and project to the lumbosacral spinal cord of male and female rats (Wagner & Clemens, 1991) and to the hippocampus (Melis, Stancampiano, & Argiolas, 1992). Systemic oxytocin stimulates smooth muscle contractions, including those of orgasm.

The PAG consists of columns that subserve autonomic functions, pain perception, and female rat sexual behavior (Ogawa, Kow, McCarthy, Pfaff, & Schwartz-Giblin, 1991). It receives input from the MPOA and from the area of the spinal cord in which the pudendal and pelvic nerves terminate (van der Horst & Holstege, 1998), and it sends output that ultimately reaches the clitoris and penis (Marson, 1995; Marson, Platt, & McKenna, 1993). The PAG also sends presumably inhibitory input to the nPGi (Holstege, 1991). Thus, the MPOA can inhibit the nPGi both directly and via its outputs to the PAG.

### *An Orgasm-Related Circuit*

The first study of brain activation in women during sexual arousal used blood-level-dependent functional magnetic resonance imaging (BOLD fMRI) during erotic or neutral visual stimuli (Karama et al., 2002). All six women reported moderate sexual arousal in response to the erotic film but not to the neutral film. Areas of greatest activation included the inferior temporal lobe, anterior cingulate gyrus, insular



cortex, corpus callosum, thalamus, caudate nucleus, globus pallidus, and inferior frontal lobe. These areas are similar to those previously reported to be activated in men, although the men showed primarily unilateral activation (Stoleru et al., 1999).

In a second study using BOLD fMRI Karama et al., (2002) compared activation in 20 female and 20 male undergraduates who were presented visual erotic or neutral stimuli. Male students reported greater sexual arousal in response to the erotic film than did female students. Both male and female subjects showed increased bilateral activation in five cortical areas: the medial prefrontal cortex, the orbitofrontal cortex, the anterior cingulate cortex, the insular cortex, and the occipitotemporal cortex. In addition, both sexes showed bilateral activation of the amygdala and the ventral striatum. However, only males showed significant activation of the hypothalamus and the thalamus, although there was a nonsignificant trend toward activation of the hypothalamus in women. The only significant sex difference in activation was in the hypothalamus. However, when perceived sexual arousal was used as a covariate, the sex difference in hypothalamic activation was not significant. Thus, the lower level of perceived arousal in women was associated with lower hypothalamic activity. Several of the cortical and subcortical areas that were activated during sexual arousal have been associated with perception of emotional stimuli. These include the occipitotemporal (or inferior temporal) area, medial prefrontal cortex, and amygdala (Lane, Reiman, Ahern, Schwartz, & Davidson, 1997; Morris et al., 1996; Whalen et al., 1998). Activity in both the orbitofrontal cortex and ventral striatum have been associated with the presentation of rewards (Francis et al., 1999). The anterior cingulate gyrus has been associated with autonomic and emotional processing (Stoleru et al., 1999) and goal-directed behavior (Devinsky, Morrell, & Vogt, 1995).

The first studies of brain imaging (positron emission tomography, PET, coupled with MRI) during orgasm in women have recently been reported (Komisaruk et al., 2002; Whipple & Komisaruk, 2002). Two women with spinal cord injury (SCI) above the 10<sup>th</sup> thoracic segment (T10; i.e., at or above the level at which the hypogastric, pelvic, and pudendal nerves enter the spinal cord), as well as one noninjured woman, showed increased activation at orgasm, compared to pre-orgasm, of the paraventricular nucleus (PVN) of the hypothalamus, the central (or periaqueductal, PAG) gray of the midbrain, the amygdala, the hippocampus, anterior basal ganglia (striatum), cerebellum, and several regions of cortex, including the anterior cingulate, frontal, parietal, temporal, and insular cortices (Komisaruk et al., 2002). During self-stimulation preceding orgasm, there was significant activation of the nucleus of

the solitary tract (NTS, in the medulla), which receives sensory input from the vagus nerve, as well as of somatosensory and motor cortices, thalamus, and sensory areas of the spinal cord and medulla. Several of the areas activated in women with SCI have previously been associated with orgasm, epileptogenic orgasmic auras, or sexual arousal in humans, including the prefrontal cortex (especially the right side: see Tiihonen et al., 1994), anterior cingulate cortex (Childress et al., 1999), amygdala (Bancaud et al., 1970; Childress et al., 1999; Heath, 1972; Janszky et al., 2002), and temporal and insular cortex (Janszky et al., 2002).

A comparison of the areas activated by orgasm (Komisaruk et al., 2002) with those activated during sexual arousal without orgasm (Karama et al., 2002; Komisaruk et al., 2002; Park et al., 2001) reveals several differences. The most important appear to be the activation of the PVN, the PAG, the hippocampus, and the cerebellum with orgasm but not with visual erotic stimuli. The PVN, as noted previously, is an important integrative site for the sympathetic nervous system and supplies oxytocin to the peripheral circulation, via the posterior pituitary, and to the lumbosacral spinal cord. The central gray (PAG) receives and integrates autonomic input from the MPOA and PVN and appears to inhibit the nPGi in rats, thereby disinhibiting sexual reflexes. The roles of the hippocampus and cerebellum in elicitation of orgasm are unknown.

### *Central Effects of Drugs on Women's Orgasm*

*Serotonin.* Selective Serotonin Reuptake Inhibitors (SSRIs) are noted for their inhibitory effects on orgasm/ejaculation and libido (reviewed in Rosen, Lane, & Menza, 1999). However, fewer inhibitory side effects have been reported with some antidepressants than with others. For example, bupropion produced fewer adverse sexual effects in both men and women than did SSRIs (Coleman, et al., 2001; Kavoussi, Segraves, Hughes, Ascher, & Johnston, 1997; Modell, Katholi, Modell, & DePalma, 1997; Shen & Hsu, 1995). (See Table 4 for a summary of effects on orgasm of centrally acting drugs.) Bupropion is a weak inhibitor of serotonin and norepinephrine transport and a more potent inhibitor of dopamine transport, as well as an agonist at 5-HT<sub>1A</sub> receptors; both the increase in extracellular dopamine and the stimulation of 5-HT<sub>1A</sub> receptors may explain its lower incidence of sexual side effects (Ascher et al., 1995). Furthermore, this profile of effects suggests a similarity with the facilitation of ejaculation in male rats and monkeys by 5-HT<sub>1A</sub> receptors, rather than the inhibition of the lordosis posture in female rats by that receptor subtype. Nefazodone also has a lower incidence of sexual side effects, perhaps because it is a 5-HT<sub>2</sub> antagonist, as well as an SSRI (Bobes et al., 2002; Feiger, Kiev, Shrivastava, Wisselink, & Wilcox, 1996;



Montejo, Llorca, Izquierdo, & Rico-Villademoros, 2001). Stimulation of 5-HT<sub>2</sub> receptors has been reported to inhibit the release of both norepinephrine and dopamine from several brain areas (reviewed in Alcantara, 1999). Because dopamine and norepinephrine facilitate sexual behavior (see below), the increase in serotonergic activity at 5-HT<sub>2</sub> receptors could explain some of the inhibitory effects of SSRIs on orgasm (Alcantara, 1999; Segraves, 1995). Moclobemide (a monoamine oxidase A inhibitor, which would increase levels of both 5-HT and norepinephrine) and amineptine (a dopamine transport inhibitor) are also antidepressants with a lower incidence of anorgasmia than the SSRIs (Kennedy, Eisfeld, Dickens, Bacchiochi, & Bagby, 2000; Montejo-Gonzalez et al., 1997; 2001). Indeed, there is a single case report of hyperorgasmia in a woman taking moclobemide (Lauerma, 1995). Therefore, the coordinated increases in either norepinephrine or dopamine appear to offset the inhibitory effects of serotonin on orgasmic ability.

Noradrenergic activity may also improve the profile of effects of the antidepressant mirtazapine. It inhibits  $\alpha_2$  autoreceptors on norepinephrine terminals and also  $\alpha_2$  heteroreceptors on 5-HT terminals (Stimmel et al., 1997). As a result both norepinephrine and 5-HT levels are increased. It is also an antagonist at postsynaptic 5-HT<sub>2</sub> and 5-HT<sub>3</sub> receptors (Stimmel, Dopheide, & Stahl, 1997). A prospective, 12-week, open-label trial with 18 women reported a 48% improvement of ease and satisfaction with orgasm (Boyarsky, Haque, Rouleau, & Hirschfeld, 1999). However, 50% of the participants dropped out of the study, suggesting that other side effects outweighed the improved orgasmic ability in some women.

Among the typical SSRIs, there may also be differences in inhibition of orgasm. Paroxetine delayed orgasm more than fluvoxetine, fluoxetine, and sertraline (Montejo-Gonzalez et al., 1997) and more than nefazadone, fluoxetine, and venlafaxine (Bobes et al., 2002). One explanation for this greater impairment may be that paroxetine is a more potent inhibitor of the serotonin transporter than are fluoxetine and fluvoxetine, and does not inhibit the dopamine transporter, as does sertraline and, to a lesser degree, fluoxetine and fluvoxetine (reviewed in Rosen, Lane, et al., 1999). As discussed subsequently, dopamine antagonists impair several aspects of sexual function, whereas the dopamine precursor, L-Dopa, is facilitative. Both women and men treated with fluoxetine, paroxetine, and sertraline for anxiety disorders reported delays in reaching orgasm and decreased quality of orgasm at 1- and 2-month follow-ups (Labbate, Grimes, Hines, Oleshansky, & Arana, 1998). However, the impairments in the fluoxetine group (but not the other two groups) had abated by the end of the third month. There have been

some reports of little or no effect of SSRIs on orgasm. Indeed, in one multicenter open-label study of fluoxetine, conducted by the manufacturer, an improvement in women's orgasmic ability, associated with improvement in depressive symptoms was reported (Michelson, Schmidt, Lee, & Tepner, 2001). Similarly, in a small pilot study, Piazza et al. (1997) found no effect of fluoxetine on orgasm, and in two industry sponsored trials, either no effects of fluoxetine or clomipramine on orgasm was found, or there were too few complaints to analyze statistically (reviewed in Ackerman, Greenland, & Bystriksky, 1999).

Several factors may account for the variability of response to a given drug. First, there are individual differences in the numbers and anatomical distributions of the relevant receptor subtypes. Thus, increases in extracellular serotonin, resulting from inhibition of uptake, may activate different ratios of 5-HT<sub>2</sub> and 5-HT<sub>1A</sub> receptors in different people. There may also be individual differences in the inhibition of dopamine and norepinephrine release by 5-HT<sub>2</sub> receptors. In addition, improvements in general and interpersonal functioning may tend to offset perceptions of sexual impairment in some women. A major factor in assessing the effects of drugs on orgasm is the method of questioning. Retrospective reports are less reliable than are daily logs.

*Dopamine.* The effects of dopaminergic drugs in humans parallel those reported in animals (Ahlenius, Engel, Eriksson, Modigh, & Sodersten, 1972; Caggiula et al., 1979; Hamburger-Bar & Rigter, 1975; Mani, Allen, Clark, Blaustein, & O'Malley, 1994; Matuszewich, Lorrain, & Hull, 2000; Melis, Succu, & Argiolas, 1996). Although most researchers on the effects of antipsychotic drugs have studied male patients, women patients also reported inhibited orgasm from the antipsychotic drugs trifluoperazine, fluphenazine, and thioridazine (Ghadirian, Chouinard, & Annable, 1982; reviewed in Shen & Sata, 1990). Antipsychotic-induced sexual dysfunction may result directly from blockade of dopamine receptors in areas critical for sexual function, such as the MPOA and PVN, or indirectly from increased prolactin levels, extrapyramidal side effects, or sedation. In one open-label ongoing-treatment study no effect of either haloperidol or clozapine on orgasmic ability was found; however, the authors noted that the women may have underreported sexual side effects (Hummer et al., 1999).

*Gamma Amino Butyric Acid (GABA).* In a retrospective clinical study of women taking antiepilepsy drugs (primarily benzodiazepines) it was reported that women with epilepsy who were taking antiepileptic drugs found orgasm less satisfying than did the healthy, unmedicated controls (S. Duncan, Blacklaw, Beastall, & Brodie, 1997). Untreated women with epilepsy were not significantly different from either of the other two



Table 4  
*Effects of Centrally Active Drugs on Orgasm*

Author(s)	Design	N	Drugs	Conclusion	Level of evidence
<b>Antidepressants</b>					
Bobes et al. (2002)	Prospective, open-label; 6 month tx	58 women, 43 men	Nefazodone, fluoxetine, paroxetine, venlafaxine	Orgasm improvement with nefazodone and orgasm impairment with paroxetine in women	Semistructured interview before and after tx; <sup>a</sup> Bristol Myers Squibb as sponsor
Boyarisky et al. (1999)	Prospective, open-label, flexible dosing; 12 weeks	18 women, 7 men	Mirtazapine	Ease/satisfaction with orgasm improved 48% with mirtazapine compared to baseline; 50% dropout rate	Questionnaires administered bimonthly
Coleman et al. (2001)	Multicenter, randomized double-blind; 8 weeks	288 women, 168 men	Bupropion SR; fluoxetine	~30% of fluoxetine-treated patients had orgasm dysfunction; bupropion SR- and placebo-treated patients had ~10%	Weekly questioning by physician
Feiger et al. (1996)	Prospective, randomized; 6 weeks	143 men and women	Sertraline, nefazodone	Sertraline impaired orgasm in both men and women equally; nefazodone had no negative effects	Sexual function questionnaire
Kavoussi et al. (1997)	Prospective, randomized, double-blind, parallel group; 16 weeks	119 women, 129 men	Bupropion, sertraline	Orgasm dysfunction more common with sertraline compared to bupropion	Investigator-conducted interview at each office visit
Kennedy et al. (2000)	Prospective, 8 or 14 weeks	65 women, 42 men	Paroxetine, sertraline, moclobemide, venlafaxine	No difference between women and men in orgasm impairment; paroxetine and sertraline produced more dysfunction than moclobemide and venlafaxine in women	Sexual functioning questionnaire before and after antidepressant

Table 4 continued on following page.

Table 4  
*Effects of Centrally Active Drugs on Orgasm (continued)*

Author(s)	Design	N	Drugs	Conclusion	Level of evidence
Labbate et al. (1998)	Prospective; 3 months	19 women, 12 men with anxiety disorder; 18 women, 12 men with depression	Fluoxetine, sertraline, paroxetine	Decreased quality and longer delay in orgasm compared to baseline; anorgasmia more common in women than in men; similar effects of all 3 drugs	Descriptive, monthly rating on visual analog scales
Lauerma (1995)	Retrospective reports	1 woman	Moclobemide	Hyperorgasmia with this MAO-A inhibitor (increased 5-HT and norepinephrine)	Single case, patient report
Michelson et al. (2001)	Multicenter, prospective; Acute phase: open-label 13 weeks; Continuation phase: randomized, double-blind, 25 additional weeks	342 women, 159 men	Fluoxetine	Acute phase: 44% of women reported improvement in orgasmic ability, 38% reported no change, 18% reported orgasmic impairment proportional to depressive symptoms	Self-rated, 4-question before, at end of acute phase, and weekly in continuation phase; Eli Lilly as sponsor
Modell et al. (1997)	Retrospective; open-label; patient population	57 women, 49 men	Bupropion, fluoxetine, paroxetine, sertraline	Greater duration and intensity of orgasm with bupropion; ns <sup>b</sup> trend toward increased time to orgasm; fluoxetine and paroxetine decreased orgasm, increased time to orgasm, and produced a ns trend to decreased duration of orgasm; sertraline decreased duration of orgasm, increased time to orgasm, and produced a trend to decreased intensity of orgasm	Descriptive; anonymous questionnaires mailed to patients in practices taking antidepressants; variable return rate

Table 4 continued on following page.



Table 4  
*Effects of Centrally Active Drugs on Orgasm (continued)*

Author(s)	Design	N	Drugs	Conclusion	Level of evidence
Montejo et al. (2001)	Multicenter, prospective open-label; total period 5 years (variable time per subject, from < 3 months to > 1 year)	610 women, 412 men; normal sexual function before tx	Fluoxetine, sertraline, fluoxetine, paroxetine, citalopram, venlafaxine, mirtazepine, nefazodone, amineptine, moclobemide	All SSRIs and venlafaxine produced more delayed orgasm or anorgasmia than mirtazepine, nefazodone, amineptine, or moclobemide; women had fewer but more severe dysfunctions than men	Psychotropic-related sexual questionnaire at each office visit; before and during tx
Montejo-Gonzalez et al. (1997)	Prospective, multicenter, open-label; 17 month	192 women, 152 men	Paroxetine, fluoxetine, fluoxetine, sertraline, moclobemide, amineptine	Paroxetine delayed orgasm more than fluoxetine, fluoxetine & sertraline; few adverse effects with moclobemide or amineptine; women more severely affected; men more frequently affected	Descriptive, physician questioning
Piazza et al. (1997)	Prospective; open-label; 6 weeks; no placebo	14 women, 11 men	Sertraline, paroxetine	No change in orgasm in women; other aspects of sexual function improved; impaired orgasm in men	5-item self-report scale, administered before and after 6-week tx
Shen & Hsu (1995)	Retrospective reports	110 women	Fluoxetine, paroxetine, sertraline, bupropion	Few adverse effects with bupropion; similar inhibition of orgasm with the other 3	Clinic records
<b>Antipsychotics</b>					
Ghadirian et al. (1982)	Retrospective, open-label, ongoing tx	29 women, 26 men; random sample of outpatients	Fluphenazine	33% reported decreased quality of orgasm; 22% reported decreased ability to achieve orgasm; impairment in men, but not women, association with elevated prolactin	Authors' questionnaire

Table 4 continued on following page.

Table 4  
*Effects of Centrally Active Drugs on Orgasm (continued)*

Author(s)	Design	N	Drugs	Conclusion	Level of evidence
Hummer et al. (1999)	Prospective open-label, ongoing tx; assessed weekly during first 6 weeks and monthly thereafter	37 women, 116 men	Haloperidol, clozapine	0/12 women taking haloperidol reported orgasmic dysfunction, compared to 8/41 men (19.5%); 1/25 women (4%) taking clozapine reported orgasmic dysfunction, compared to 17/25 men (22.7%); fewer women reported dysfunction; no difference between drugs; authors note women may have underreported effects	Observer-rated side effect rating scale
<b>Phosphodiesterase inhibitors</b>					
J. R. Berman et al. (2001)	Prospective open-label; 6 weeks	48 women; SAD <sup>c</sup>	Sildenafil	67% improved orgasmic ability	Questionnaire at baseline and end of study; psychological measures
L. A. Berman et al. (2001)	Prospective open-label; 6 weeks	7 women with history of sexual abuse; 24 with no such history	Sildenafil	2/7 with history of CSA <sup>d</sup> reported improved orgasmic ability; 19/24 with no such history CSA improved	5-item questionnaire at end
Caruso et al. (2001)	Prospective double-blind, crossover; 12 weeks	51 premenopausal women; arousal disorder	Sildenafil	25 and 50 mg sildenafil increased orgasm frequency, compared to placebo and baseline; placebo increased orgasm relative to baseline	Self-administered questionnaire, once/week
Kaplan et al. (1999)	Open-label non-randomized; 12 weeks	30 postmenopausal women	Sildenafil	Orgasm satisfaction improved 7.4%	Self-administered questionnaire
<b>Antihypertensives</b>					
Bulpitt et al. (1989)	Retrospective questionnaire	1,080 women, 1,285 men	Hydralazine, beta-adrenergic antagonists, methyldopa	Women showed no increased difficulty achieving orgasm with any of the drugs	Self-administered questionnaire

Table 4 continued on following page.



Table 4  
*Effects of Centrally Active Drugs on Orgasm (continued)*

Author(s)	Design	N	Drugs	Conclusion	Level of evidence
Duncan et al. (2000)	Ambulatory medical record-based choice of subjects; case-control	104 mildly hypertensive women, 107 unmedicated healthy controls	ACE inhibitors, beta adrenergic blockers, CA <sup>2+</sup> channel blockers, diuretics, combination drugs	No difference b/w medicated and unmedicated hypertensives; impaired orgasm in hypertensive compared to healthy women; less orgasm frequency in smokers compared to nonsmokers (not associated with age or hypertension)	Self-administered questionnaire and phone interview
Grimm et al. (1997)	Prospective randomized, controlled, double-blind; 48 months	345 women, 557 men	Acebutolol, amlodipine maleate, chlorthalidone, doxazosin maleate, enalapril maleate	Women showed no increased difficulty achieving orgasm with any of the drugs	Questioning by physician at baseline and annually during tx
<b>Anticonvulsants</b>					
Duncan et al. (1997)	Retrospective	243 women	AED <sup>e</sup>	159 epileptic women taking AEDs: less orgasm satisfaction compared to 48 healthy controls	Validated questionnaire & testosterone assay
<b>Anticholinergics</b>					
Wagner & Levin (1980)	Controlled laboratory study	11 women	Atropine, methyldropine	Neither tx affected orgasm or vaginal blood flow; muscarinic cholinergic receptors do not appear important for orgasm or blood flow	Controlled laboratory study
<b>Estrogens</b>					
Eicher & Muck (1996)	Prospective open-label; 4 months	188 women with sexual dysfunction	Estradiol transdermal patch	25% improved orgasmic ability	Uncontrolled clinical study

Table 4 continued on following page.

Table 4  
Effects of Centrally Active Drugs on Orgasm (continued)

Author(s)	Design	N	Drugs	Conclusion	Level of evidence
Kokcu et al. (2000)	Prospective single-blind; 1 year	50 postmenopausal women	HRT <sup>a</sup> , tibolone	No improvement in orgasm frequency (tibolone has estrogenic, androgenic & metabolites)	Questionnaire at baseline and after 1 year
Nathorst-Boos et al. (1993)	Retrospective clinical study	66 oophorectomized, 35 hysterectomized with ovaries	ERT <sup>b</sup>	No improvement in orgasmic ability in 33 oophorectomized women, compared to 33 oophorectomized no-ERT women	Questionnaire and structured interview
Wu et al. (2001)	Prospective open-label, 3 months	48 postmenopausal women	HRT, tibolone	Tibolone improved orgasmic ability compared to HRT	Questionnaire at end of 3 months
<b>Androgens</b>					
Munarriz et al. (2002)	Retrospective open-label, clinical tx; minimum 3 months	113 women w/low T <sup>b</sup> & dehydroepiandrosterone (DHEA)	DHEA (50 mg/d)	Greater orgasm frequency after DHEA tx; both DHEA and T increased to upper range of normal female levels	Questionnaires and blood samples for hormone levels
Sherwin & Gelfand (1987)	Prospective open-label; 1 month (no hormone injections 8 weeks pre-baseline)	44 oophorectomized and hysterectomized women	E <sup>c</sup> (8.5 mg) + T (150 mg), E alone (10 mg), no tx	Orgasm and coitus rates higher in E+T groups during first 3 weeks after monthly injection, compared to E or no tx and compared to baseline	Daily recording & hormone assays at baseline and days 2, 4, 8, 15, 21, and 28 of tx
Shifren et al. (2000)	Prospective double-blind, counter-balanced; 9 months	75 oophorectomized and hysterectomized women	Conjugated E plus either T (150 or 300mg/d transdermal) or placebo	300mg/d of T improved orgasm pleasure and frequency of sexual activity	Questionnaire & sexual function and diary completed by phone

<sup>a</sup> tx = Treatment. <sup>b</sup> ns = Nonsignificant. <sup>c</sup> SAD = Sexual arousal disorder. <sup>d</sup> CSA = Childhood sexual abuse. <sup>e</sup> AED = Anti-epilepsy drugs. <sup>f</sup> HRT = Conjugated estrogens + medroxy-progesterone acetate. <sup>g</sup> ERT = Conjugated estrogens. <sup>h</sup> T = Testosterone. <sup>i</sup> E = Estrogen.



groups. In the treated women, antiepileptic drugs increased both total testosterone and steroid hormone binding globulin but did not affect levels of free testosterone, compared to the other two groups. Thus, alterations in free testosterone cannot explain the impairment in orgasmic enjoyment.

*Nitric oxide.* Sildenafil (Viagra) selectively inhibits phosphodiesterase V and thereby prolongs the vasodilatory effect of nitric oxide. Although sildenafil has been used successfully for treatment of erectile dysfunction in men, there have been mixed reports of the effects of sildenafil on women's orgasmic function. Caruso, Intelisano, Lupo, and Agnello (2001) found improved sexual arousal and orgasm with sildenafil. However, a minority of women responded positively in three other studies (J. R. Berman et al., 2001; L. A. Berman, Berman, Bruck, Pawar, & Goldstein, 2001; S. A. Kaplan et al., 1999).

*Norepinephrine/Epinephrine.* In a retrospective of 1,080 women, who responded via a self-administered questionnaire, no significant increase in difficulty achieving orgasm while taking hydralazine, beta-adrenergic antagonists, or methyldopa was reported (Bulpitt et al., 1989). Similar results were obtained in a prospective randomized double-blind study of 345 women over a period of 24 months (Grimm et al., 1997) and in unmedicated healthy controls (L. E. Duncan, Lewis, Jenkins, & Pearson, 2000). Therefore, drugs that inhibit beta-adrenergic receptors appear not to affect women's orgasmic ability. However, SSRI-induced inhibition of norepinephrine release onto  $\alpha_1$  receptors could explain some of the impairment of orgasm, as noted previously.

*Acetylcholine.* As in female rats (Giuliano, Rampin, & Allard, 2002), atropine failed to affect blood flow in women during sexual arousal and also did not affect subjective sexual arousal or orgasm (Wagner & Levin, 1980). Therefore, acetylcholine appears to play a minor role in the control of vaginal blood flow, sexual arousal, and orgasm.

*Estrogens.* There is little evidence of estrogenic facilitation of orgasmic function in women. In an uncontrolled, open-label trial, 25% of 188 premenopausal women reported an improvement in orgasmic ability (Eicher & Muck, 1996). However, in a retrospective study of 66 women who were oophorectomized and hysterectomized no difference was found in orgasmic ability between the 33 who received conjugated estrogens and the 33 who did not (Nathorst-Boos, von Schoultz, & Carlstrom, 1993). Similarly, in two prospective studies of postmenopausal women little effect of estrogen plus progestin hormone replacement therapy (HRT) was found (Kokcu, Cetinkaya, Yanik, Alper, & Malatyalioglu, 2000; Wu et al., 2001). Each compared HRT to tibolone, which can be metabolized into estrogenic, androgenic, and progestogenic compounds.

The former, single-blind study of 50 women found no effect of either treatment, based on a questionnaire at baseline and after 1 year. In the latter, open-label study of 48 women a significant improvement after 3 months of tibolone treatment, but not HRT, was found.

*Androgens.* Sherwin and Gelfand (1987), in a prospective, 3-month, open-label study of 44 oophorectomized and hysterectomized women, found that a monthly injection of estrogen and testosterone (E+T) increased the rates of orgasm during the first 3 weeks after the injection compared to these women's own baseline and compared to E-alone or no treatment. The E+T-treated women had been receiving monthly hormone injections for up to 2 years but had not received an injection for 8 weeks prior to the baseline measure. At the time of the baseline interview and hormone sample, these women reported relatively low rates of coitus and orgasm, although their T levels were at least four times the normal levels of gonadally intact premenopausal women (based on normal ranges from Endocrine Sciences reported in Shifren et al., 2000). Therefore, the T from the previous injection 8 weeks before baseline measures had been metabolized rather slowly. These data suggest that, although extremely high levels of T can improve sexual interest and orgasmic ability, more moderate levels have little effect.

In a more extensive and well-controlled study of 75 oophorectomized and hysterectomized women, Shifren et al., (2000) obtained similar results. Conjugated estrogens were administered either alone or with 150 or 300 mg T per day in transdermal patches. The higher dose of T improved orgasm pleasure. However, again, the effective T levels were two to six times the normal range in intact women. Finally, 113 women with low levels of both T and dehydroepiandrosterone (DHEA) and complaints of orgasmic difficulty were treated for at least 3 months with DHEA (50 mg/day orally; Munarriz et al., 2002). These women reported a greater frequency of orgasm after treatment than before. Their T and DHEA levels were in the upper half of the normal range at the end of the 3-month treatment. Unfortunately, there was no control treatment, and the study was an open-label one.

#### *Spinal Cord Pathways Involved in Women's Orgasm*

Our ability to assess the impact of spinal lesions on orgasm in humans is unique because spinal cord lesions are relatively easily located and described via detailed neurologic exam. Thus, the subject of female orgasm and the impact of spinal cord injuries (SCIs) or damage has received significant attention in recent years, and the level and degree of evidence for this phenomenon has increased greatly. Once flippantly considered "phantom" (Money, 1960), the orgasmic experiences of



women with SCIs have recently been described through multiple controlled studies that have consistently proven the existence of orgasm in women with SCIs. Moreover, the researchers conducting these studies have begun to describe the attributes of orgasms in women with SCIs. In Table 5 the notable studies that have assessed the impact of orgasm in humans with SCIs are summarized. As the studies are numerous, only details regarding those reports that are most significant will be discussed.

In the early 1990s, interest in the impact of SCIs on female sexuality and sexual response re-emerged after previous discussion of "phantom orgasms." During this time, a number of questionnaire studies were published with large sample sizes (Charlifue, Gerhart, Menter, Whiteneck, & Manley, 1992; Harrison, Glass, Owens, & Soni, 1995; Kettl et al., 1991; Kreuter, Sullivan, & Siosteen, 1996; Siosteen, Lundquist, Blomstrand, Sullivan, & Sullivan, 1990; Sipski & Alexander, 1993), and accompanying neurologic data were often included (Charlifue et al., 1992; Kettl et al., 1991; Kreuter et al., 1996; Siosteen et al., 1990; Sipski & Alexander, 1993). Although some studies still suffered from a lack of controls (Charlifue et al., 1992; Siosteen et al., 1990), others included pre- and postinjury data as a form of control (Harrison et al., 1995; Kettl et al., 1991; Sipski & Alexander, 1993). These studies documented that women with SCIs did experience orgasms and that, in general, approximately 50% of the women noted the ability to attain orgasm was present postinjury. Similar findings were also noted in the largest study of females with SCI to date. In a multicenter study, Jackson and Wadley (1999) reported on 478 participants. Of these, 315 were sexually active since their injuries and of this subgroup 54% reported achieving orgasm postinjury.

The next advance in the study of orgasm in women with SCIs was the result of the introduction of the laboratory-based assessment of women's orgasmic capacities. Sipski, Alexander, and Rosen (1995) studied 25 women with SCIs at and above the level of T6 using standardized criteria (American Spinal Injury Association, 1992) and compared them with 10 age-matched, able-bodied control women. They were given 75 minutes to perform self-stimulation to orgasm in any way they chose. All able-bodied women achieved orgasm, compared to only 52% of SCI women. Degree and type of SCI were not found related to the SCI woman's ability to achieve orgasm. Orgasmic SCI women scored higher on the sexual information and sexual drive components of the Derogatis Sexual Functioning Inventory (DSFI; 1978).

Sixteen women with SCIs at and below the level of T6 were studied, along with five able-bodied control women (Whipple, Gerdes, & Komisaruk, 1996). The women used a modified tampon to stimulate their

Table 5  
*Studies of Orgasm in Women With Spinal Cord Injuries*

Author(s)	Design	N	Conclusion	Level of evidence
Berard (1989)	Interview supplemented with access to medical records and information regarding their genital sexual response to intimate washing	15 women with SCI <sup>a</sup> , no controls	Provided anecdotal information on how sexual response might be affected in women with SCIs at various levels and degrees of injuries	Anecdotal information
Bregman & Hadley (1975)	Semistructured interviews, no neurologic data	31 women with SCI, no controls	2 reported orgasm unchanged, 22 reported some sensation of orgasm "very similar to those of able-bodied women"	Uncontrolled questionnaire
Charliffue et al. (1992)	Telephone survey with neurologic data	293 subjects identified, 231 SCI women, no controls	Approximately half of the women reported they had experienced orgasm since their injuries; stimulus generally genital or genital combined with breast	Uncontrolled questionnaire
Comarr & Vigue (1978)	Presented series of case reports on women with SCIs who were neurologically examined and counseled regarding their sexuality	21 women with SCI, no controls	1 cervical incomplete, 2 thoracic, and 3 women with lumbar injuries reported they were orgasmic	Case reports
Fitting et al. (1978)	28-item questionnaire, brief taped interview and self-reported neurologic information	24 women with SCI or disease, no controls	6 subjects orgasmic	Uncontrolled questionnaire
Harrison (1995)	Mailed questionnaire, no neurological data	Sent to 226 women, 85 answered	Pre-injury 46% were orgasmic, postinjury 36% were orgasmic, 7% were not orgasmic pre-injury compared to 23% post, 33% reported this question was NA pre-injury and 12% post, 14% did not pre-injury and	Pre/post questionnaire

Table 5 continued on following page.



Table 5  
*Studies of Orgasm in Women With Spinal Cord Injuries (continued)*

Author(s)	Design	N	Conclusion	Level of evidence
Jackson (1999)	Pre- and postinjury questionnaire with neurologic data	478 subjects; multicenter study; 315 sexually active	28% did not post, frequency 55.6% report greater than once per week pre-injury compared to 38% post	Pre/post questionnaire, multi-center study
Kettl (1991)	Mailed questionnaire, subjects reported neurologic data	74 mailings to women with SCI, 27 responses	54% reported orgasms, of those who were orgasmic 32% of injuries were cervical, 41% thoracic and 52% lumbosacral; 32% had complete injuries and 41% had incomplete injuries	Pre/post questionnaire
Kreuter (1996)	80-item questionnaire; subjects contacted by phone then completed a mail in questionnaire, neurologic data were included	264 subjects, 167 SCI and 97 age- and sex-matched controls	52% orgasmic, 7 reported different orgasm, 3 exactly the same, 2 similar; 25% complete paraplegics and 25% complete quadriplegics orgasmic; women with complete quadriplegia related frequently of sexual activity as much less than others	Controlled questionnaire study
Money (1960)	Interview of hospitalized patients, no neurologic data	7 women with SCI, no controls	67% of SCI seldom or never experienced orgasm compared to 6% of controls	Case report
Siosteen (1990)	Structured questionnaire administered via interview, neurologic examination	13 women with SCI, no controls	Coined the term phantom orgasms in their sleep patients reported orgasms in their sleep 33% unaltered orgasm, 25% orgasm decreased, 42% absent, 50% reported interest was unchanged, 33% interest decreased, and 17% reported no interest	Uncontrolled questionnaire

Table 5 continued on following page.

Table 5  
*Studies of Orgasm in Women With Spinal Cord Injuries (continued)*

Author(s)	Design	N	Conclusion	Level of evidence
Sipski & Alexander (1993)	In person 80-item questionnaire, neurologic data provided	25 women with pre/post results; pre/post controls	44% reported ability to have orgasm; ability was not related to the degree of injury; frequency and satisfaction with sexual activity significantly decreased	Pre/post questionnaire
Sipski et al. (1995)	Laboratory based analysis, ASIA <sup>b</sup> exam, EMG, <sup>c</sup> and SCI questionnaire and DSFI <sup>d</sup> ; subjects self-stimulated (maximum 75 min) to orgasm; HR, BP, RR, rectal contractions, quality of and time to orgasm monitored	25 SCI subjects at T6 and above, 10 age-matched able-bodied controls	52% of SCI subjects achieved orgasm; degree and type of SCI did not affect ability to achieve orgasm; orgasmic subjects higher on the sexual information and sex drive subset of the DSFI	Controlled, laboratory study with physiologic testing
Sipski et al. (2001)	Laboratory-based study coupled with detailed neurologic assessment, SCI questionnaire, DSFI; HR, BP and RR monitored	69 SCI, 21 able-bodied controls; all levels of SCI represented	44% of SCI subjects were orgasmic in the laboratory vs. 100% of controls; subjects with complete lower motor neuron injuries affecting the sacral spinal segments were significantly less likely to achieve orgasm than all other SCI subjects	Controlled, laboratory-based study with physiologic testing
Whipple et al. (1996)	Laboratory based study, ASIA exam; subjects performed vaginal, cervical and hypersensitive area stimulation using fixed methodology; BP, HR, anxiety, sexual arousal, endogenous pain, and spasticity recorded	16 complete SCI at T6 and below, 5 able-bodied controls	Three SCI subjects and 1 able-bodied subject reported orgasms during the study	Controlled, laboratory-based study

<sup>a</sup> SCI = Spinal cord injury. <sup>b</sup> ASIA = American Spinal Injury Association. <sup>c</sup> EMG = Electromyograph. <sup>d</sup> DSFI = Derogatis Sexual Functioning Inventory.



cervix and vagina at monitored and specified levels of pressure. Three women with complete SCIs and one able-bodied woman had orgasms under these conditions; one for the first time. Based upon these data and other animal reports (Komisaruk et al., 1996; Ortega-Villalobos et al., 1990) the authors hypothesized that the vagus nerve conveys a sensory pathway from the cervix to the brain that is responsible for the preservation of the ability to achieve orgasm in women with SCIs.

More recently, Sipski et al. (2001) expanded their study of orgasm to include women with all levels of injuries. The methodology used was identical to that in a previous study (American Spinal Injury Association, 1992). Thus, the data were combined. A total of 66 women with SCIs and 21 able-bodied controls were examined. Women with complete lower motor neuron injuries affecting their S2-S5 reflex arc were significantly less likely than other women to achieve orgasm. Overall, 55% of all SCI women reported orgasmic ability post-SCI, whereas 44% were orgasmic in the laboratory. Women with SCIs took significantly longer (26.37 minutes) than able-bodied women (16.33 minutes) to achieve orgasm. Blood pressure, heart rate, and respiratory rate responses were similar between able-bodied and SCI women throughout the study. Moreover, subjective descriptions of sensations during orgasm were indistinguishable between able-bodied and SCI women. These authors reported the importance of an intact sacral reflex arc in the ability to achieve orgasm. Moreover, the presence of the urethro-genital reflex in spinalized rats (Marson & McKenna, 1994; McKenna, Chung, & McVary, 1991), which mimics orgasm in humans, provides an animal model that is consistent with this hypothesis.

Overall, there is a strong evidence for the occurrence of orgasm in women with SCIs. There is also substantial evidence of the impact of specific injuries on orgasmic potential. Future human and animal studies are warranted to confirm the specific effects of spinal lesions on the ability to achieve orgasm. Women with spinal disorders other than SCIs would also be appropriate to study.

#### *Peripheral Nervous System Involvement in Women's Orgasm*

In brief, the nervous supply of the genitalia is by the sympathetic and parasympathetic branches of the autonomic nervous system pelvic nerves, hypogastric nerve, paravertebral sympathetic chains, and by somatic nerves (pudendal nerve from the pelvic splanchnic branches and sacral plexus). The nerves are either efferents, which convey nervous impulses from the brain and spinal cord to control motor, secretory, and vascular functions, or afferents, which mediate sensation, usually by specialized nerve endings. The autonomic nerves regulate blood flow

and the involuntary smooth muscle, whereas the somatic nerves control the voluntary or striated muscles. Sensory nervous traffic can be mediated by both the somatic and autonomic systems. The nerves release a number of neurotransmitters, classically noradrenaline at the sympathetic nerve endings and acetylcholine at the parasympathetic and somatic. However, the former two systems become mixed in the pelvic plexus and, with the recognition of nonadrenergic, noncholinergic (NANC) nerves, many different transmitters and neuropeptides exist and are co-localized. Much of this knowledge comes from animal studies, usually rodent (rabbit/rat) studies; genital data from women are sparse. Although the studies using immunohistochemical techniques to identify and to localize the various neurotransmitters give some insight as to what structures are innervated and by what chemicals, unfortunately, they do not give any information about the exact functions of the nerves/neurotransmitters, and, therefore, some degree of informed speculation has to be applied. Their proposed actions, together with those of secreted hormones, bring about the peripheral changes observed in sexual arousal and at orgasm.

### *Vagina*

The anterior wall of the vagina, the area with the highest erotic sensitivity, has a denser innervation than the posterior wall, and the distal area has more nerve fibers than the proximal (Hilleges, Falconer, Ekman-Ordeberg, & Johansson, 1995). According to Krantz (1958), aggregated ganglion cells and nerve fibers were present in the adventitia surrounding the vagina. The fibers, filiform in shape, penetrated and supplied the muscularis and larger blood vessels. Hoyle, Stones, Robson, Whitely, and Burnstock (1996) showed that nerves were also closely applied to the papillary capillaries and were possibly "sensorimotor" nerves (sensory nerves stimulated by antidromic impulses, giving them an efferent function).

The unaroused human vagina has a low (acid) surface pH, minimal surface fluid, low blood flow, and low surface  $pO_2$ . A good sympathetic tone is probably maintaining this low flow by its constricting effect on the blood supply. Oral administration of the alpha-adrenoceptor blocker phentolamine to premenopausal women increased their vaginal blood flow indicative of a basal constrictive adrenergic tone, but whether the drug acted centrally or peripherally or both is unclear (Rosen, Phillips, Gendrano, & Ferguson, 1999).

Effective sexual arousal causes a rapid increase in the blood flow activated by the release of Vasoactive Intestinal Peptide (VIP) from NANC-nerve endings, and Neuropeptide Y (NPY) probably constricts



the venous drainage creating engorgement. The increased hydrostatic pressure in the capillaries forces a protein poor, plasma-like fluid into the tissues spaces, which then percolates through the Na<sup>+</sup>-absorbing epithelium onto the surface of the vagina as the increased surface fluid lubrication (Levin, 1999b). This neurogenic transudate (pH~7.4) can partially neutralize the acidity of the basal surface vaginal fluid (pH~4-6) and thus raise the vaginal pH (Wagner & Levin, 1984). The enhanced blood flow increases the vaginal surface pO<sub>2</sub>, facilitating the use of aerobic rather than anaerobic mechanisms to generate energy by any sperm when ejaculated into the vagina (see Levin, 1992, 1999a, 1999b for references). Laan et al. (2002) provided evidence for a facilitatory effect of sildenafil (an inhibitor of phosphodiesterase 5, PDE5 influences male genital blood flow by controlling the level of cyclic GMP and nitric oxide [NO]) on vaginal photoplethysmograph measures of sexual arousal. Meston and Worcel (2002) demonstrated a beneficial influence of the nitric oxide precursor L-arginine in combination with the alpha<sub>2</sub> blocker yohimbine on genital engorgement in postmenopausal women. These findings lend support for a role of NO in the enhancement of vaginal blood flow, although very little nitric oxide synthase (NOS) has been found in the vagina using immunohistochemistry (Hoyle et al., 1996).

Meston and colleagues provided evidence for a facilitatory role of peripheral adrenergic activation on sexual arousal in women. Ephedrine (50 mg), an alpha and beta adrenergic agonist, facilitated vaginal photoplethysmograph measures of sexual arousal (Meston & Heiman, 1998), and clonidine, an alpha<sub>2</sub> adrenergic agonist, which blocks peripheral sympathetic outflow, decreased these responses (Meston, Gorzalka, & Wright, 1997). Increased sympathetic nervous system activity, induced via intense acute exercise, enhanced vaginal engorgement in women (Meston & Gorzalka, 1995, 1996a, 1996b).

The pattern and density of innervation of the vaginal vasculature and microvasculature was described by Hoyle and colleagues (1996) using immunohistochemistry in surgical specimens taken from five pre- and five postmenopausal women. They identified a number of neuropeptides in the papillae, subepithelial plexus, propria arteries and veins, and the deep arteries and veins. These included NPY, VIP, calcitonin gene-related peptide (CGRP), Substance P (SP), and the enzyme NOS. The vasomotor properties of VIP (vasodilatation), NO (from NOS production-vasodilatation), and NPY (vasoconstriction) are well-known, but the neuropeptides CGRP, NPY, and SP (and also NO and VIP) are known to be involved in sensory nerve function and can influence the permeability of the capillaries. Orgasm is presumed to cause the decreased release of all of these and to enhance the release of the adren-

ergic system transmitters, thus effectively decreasing the blood flow and the production of vaginal lubrication. At present, however, it should be said that our knowledge of the exact functions of these active agents lags far behind our knowledge of their locations.

Less attention has been paid to the longitudinal and circular smooth muscle coats of the vagina. They can contract spontaneously even in the nonpregnant woman and especially around menstruation, although the contractions are not perceived in consciousness (Levin, 1980, 1983, 1992). The muscles possess both alpha and beta adrenoreceptors: Blockade of the alpha system inhibits spontaneous contractions of vaginal muscle strips, whereas beta blockade induces greater adrenergic-mediated contractions (Czekanowski, Urban, & Latocha, 1971). The vipergic innervation (neurotransmitter = VIP) decreases both tone and induces relaxation. During arousal, the vipergic innervation is likely to be dominant by facilitating smooth muscle relaxation of the vaginal wall and thus not reducing the caliber of its blood vessels, thereby allowing the VIP-activated lubrication mechanism to operate. Contraction of the vaginal smooth muscle, if it happens, does not occur until the late excitation state just before orgasm.

### *Labia Minora*

Although the neural mechanisms and the neurotransmitters creating the congestion and increased blood flow responses of the labia minora to sexual arousal have not been characterized, they are probably mediated through mechanisms similar or even identical to those described above for the vagina (Levin, 1999b).

### *Clitoris*

The most recent anatomical description from cadaveric dissections (O'Connell, Hutson, Anderson, & Plenter, 1998) is of a triplanar complex of erectile tissue with a midline shaft lying in the media sagittal approximately 2-4 cm long and 1-2 cm wide, which bifurcates internally into paired curved crura 5-9 cm long. Posterior to the shaft, on either side of the urethra, are two separate vestibular bulbs (3-7 cm long of crescentic or triangular shape thought to be spongiosus tissue). The shaft is composed of two chambers, the corpora cavernosa, surrounded by a fibrous sheath (tunica albuginea). It is capped externally by the glans some 2-3mm long and wide consisting of cavernous spongiosus tissue coming from the vestibular bulbs (Van Turnhout, Hage, & Van Diest, 1995) and is normally covered by a protective hood of skin formed from the fusion of the two labia minora. Its parasympathetic innervation comes from the lumbosacral segments L2-S2 while its sympathetic supply is from the



hypogastric superior plexus. The pudendal and hypogastric nerves serve its sensory innervation. Sensory nerve terminations include Merkel tactile discs, Pacinian and genital nerve corpuscles, and free nerve endings (Krantz, 1958; Yamada, 1951). There was wide variation in the quantity, quality, and location of the various nerve endings.

The clitoris also responds with increased blood flow and tumescence on being stimulated or through sexual arousal. Nitric oxide synthase (NOS), together with many neuropeptides, have been identified in the complex network of nerves in the clitoral tissue by immunohistochemical studies over the last few years. The list includes VIP, peptide histidine methionine (PHM), NPY, C-flanking peptide of NPY (CPON), CGRP, and SP (Burnett, Calvin, Silver, Peppas, & Docimo, 1997; Cocchia, Rende, Toesca, Viola, & Stolfi, 1990; Hauser-Kronberger, et al., 1999). The presence of the enzyme NOS in the nerves supplying the clitoral cavernous tissues and in the endothelial cells lining the cavernosus tissue indicates that its vasodilating product NO is involved in the enhanced flow and tumescence, whereas the presence of the vasoconstrictors NPY/CPON suggests that they could throttle venous drainage and facilitate the organ's engorgement. VIP/PHM are known vasodilating neurotransmitters. The exact functions of the other neuropeptides are more problematic. It has been suggested that SP, CGRP, and even NO may have sensory roles or may be involved in influencing capillary permeability (Burnett et al., 1997).

### *Uterus*

The uterus was said to increase significantly in size during sexual arousal (Masters & Johnson, 1966) when monitored by palpation, though limited MRI imaging has not confirmed this (Schultz et al., 1999). It may be that the latter needs better resolution. Odd contractions of the uterus can occur during arousal, but at orgasm a specific pattern of contractions occurs.

## **Psychological/Cultural Aspects of Women's Orgasm**

### *Psychosocial Factors Related to Women's Orgasm*

The psychosocial factors most commonly discussed in relation to female orgasmic ability include age, education, social class, religion, personality, and relationship issues. Although no significant relation between education level and orgasmic ability with a partner has been found, substantial differences between education level and ability to attain orgasm during masturbation have been reported. Approximately 87% of women with an advanced degree reported "always" or "usually" attaining orgasm during

masturbation compared with 42% of women with a high school education (Laumann, Gagnon, Michael, & Michaels, 1994).

A negative relation between orgasmic ability and high religiosity has been reported. Laumann et al. (1994) found a substantially higher proportion (79%) of women with no religious affiliation reported being orgasmic during masturbation, compared with those having an affiliation with religious groups (53%-67%). However, there were substantial differences in education levels between religious categories. A relation between improved orgasmic ability and decreased sexual guilt has also been reported (Sholty et al., 1984). Low orgasmic experience has been consistently related to childhood loss or separation from the father, fathers who had been emotionally unavailable, or fathers with whom the women did not have a positive childhood relationship (S. Fisher, 1973). Reports of an association between early abuse and anorgasmia are inconsistent (e.g., Bartoi & Kinder, 1998; Feinauer, 1989; Meston, Heiman, & Trapnell, 1999).

Orgasm consistency, quality, and satisfaction in women have been related to relationship factors, such as marital satisfaction, marital adjustment, happiness, and stability (for a review, see Mah & Binik, 2001), but rates of orgasm consistency in women are higher during masturbation than with a partner (Laumann et al., 1994). In summary, there are no consistent, empirical findings that psychosocial factors alone differentiate orgasmic from anorgasmic women. Research that systematically examines these factors among women who are more carefully diagnosed as either meeting or not meeting clinical criteria for Female Orgasmic Disorder is needed.

#### *Orgasm as a Goal of Women's Sexual Encounters*

Perceived wisdom, or a sex-role stereotype, is that men are goal-oriented to achieve orgasm; if it does not occur in a sexual encounter, then they are supposedly dissatisfied and frustrated. For women, it is equally often stated that orgasm is not as highly prized as a goal in such encounters (Wallin, 1960). Although some women consider coitus without achieving orgasm unfulfilling and frustrating, especially in relation to the lack of dissipation of their pelvic congestion, others have a high regard for coitus and its pleasures but pay low regard to orgasm per se (Clifford, 1978; S. Fisher, 1973). Women have been noted to appreciate the "afterglow" of sexual arousal and the body intimacy of being cuddled (Hollender, 1970; Schaefer, 1974) as much as the orgasm itself.

In questionnaires administered to a self-selected, rather than a statistically random population, it was reported that women, whether they experienced orgasm or not, gave affection, intimacy, and love as



major reasons for liking sexual intercourse, and their favorite experience was the act of penetration rather than orgasm itself (Hite, 1976). All these studies and their conclusions, however, were conducted over 25-40 years ago in the U.S., and sexual perceptions of societies and their individuals can change. Waterman and Chiauzzi (1982) investigated the relationship between sexual enjoyment and orgasm in couples attending university. They reported "nothing in the present data supports the cultural stereotype that orgasms are more important to men than to women" (pp. 155-156). In a recent, statistically valid, national survey of British sexual behavior, Wellings, Field, Johnson, and Wadsworth (1994) asked both men and women to agree or disagree with the statement "Sex without orgasm cannot be really satisfying." Although nearly half of all men (48.7%) agreed or strongly agreed that orgasm is necessary to male sexual satisfaction, a close 43.3% of all women also concurred.

#### *Cultural Aspects of Women's Orgasm*

Sexual arousal to orgasm through coitus is often thought of as a natural biological act, especially if linked to reproduction. A core concept of social constructionists, however, is that sexual behavior and identity are learned rather than intrinsic, and culture, with its social and historical factors, plays a large role in shaping, or at least trying to shape, an individual's sexuality (Foucault, 1980). A very obvious involvement of culture/society in female sexuality has been the acknowledgement of female orgasms, which, in reality, means the acceptance of female sexual pleasure. Anthropologists have noted that in cultures expecting women to enjoy sex as men do, the women have orgasms, whereas in those cultures that censor such a concept, women have more difficulty attaining orgasm. Instances of societies that foster sexual pleasure for women and expect them to enjoy coitus include the Mundugumor (Mead, 1949) and the Manguaia (Marshall, 1971). Manguaian women are taught to have orgasms, hopefully two or three to her male partner's one, and to try to attain mutual orgasm. Manguaian males who are not able to give their partners multiple orgasms are not held in high esteem. At the other end of the spectrum are societies that assume women will have no pleasure from coitus and that the female orgasm does not exist. The Arapesh (Bateson & Mead, 1942) is such a society, as they do not even have a word in their language for the female orgasm. In a similar vein, the Sambia people of the Highlands of New Guinea (Herdt, 1981) accord the clitoris (lakandiku) no function or importance, and it is never mentioned in public by men. Moreover, men deny that there is a female orgasm (imbimboogu).

## Female Orgasmic Disorder

Findings from the National Social and Health Life Survey conducted in the early 1990s (Laumann et al., 1994) suggest that orgasmic problems are the second most frequently reported sexual problems by women. In this random sample of 1,749 U.S. women, 24% reported a lack of orgasm in the past year for at least several months or more. This percentage is comparable to clinic-based data. Rosen, Taylor, Leiblum, and Bachman (1993) noted 29% of 329 healthy women (ages 18-73) who attended an outpatient gynecological clinic reported orgasmic problems, and Read, King, and Watson (1997) reported 23% of 104 women (18-65+) attending a U.K. general practice clinic reported anorgasmia. The consistent use of structured clinical interviews in nationally representative populations may clarify the prevalence of orgasm difficulties. A precise estimate of the incidence of orgasmic disorder in women is, however, difficult to determine because few well-controlled studies have been conducted, and definitions of orgasmic disorder vary widely between studies depending on the diagnostic criteria used. In the *Diagnostic and Statistical Manual of Mental Disorders* (DSM-IV-TR; American Psychiatric Association, 2000), Female Orgasmic Disorder (302.73) is defined using the following diagnostic criteria:

Persistent or recurrent delay in, or absence of, orgasm following a normal sexual excitement phase. Women exhibit wide variability in the type or intensity of stimulation that triggers orgasm. The diagnosis of Female Orgasmic Disorder should be based on the clinician's judgment that the woman's orgasmic capacity is less than would be reasonable for her age, sexual experience, and the adequacy of sexual stimulation she receives.

The DSM-IV-TR uses the terms *lifelong* versus *acquired* and *generalized* versus *situational*. However, some researchers of orgasm in women use the term *secondary* with little clarity as to whether this is an acquired inability to experience orgasm under any circumstances or is, in fact, a situational disorder possibly acquired rather than lifelong. The *International Statistical Classification of Diseases and Related Health Problems* (ICD-10) defines *orgasmic dysfunction* (F52.3) simply as "orgasm either does not occur or is markedly delayed." Regarding women who can obtain orgasm during intercourse with manual stimulation but not intercourse alone, the clinical consensus is that she would not meet criteria for clinical diagnosis.

### *Orgasm in the Postmenopause*

A critical period in the aging process for women is the premenopausal-postmenopausal change. Compared to young women, the



response to sexual stimulation in the laboratory in postmenopausal women showed delay in achieving full tumescence in the clitoris, marked decrease in breast volume engorgement, no engorgement of the uterus, delayed or absent vaginal lubrication, and decreased vaginal expansion. At orgasm, there were fewer vaginal contractions and rarely any rectal ones. The reduced number of vaginal and anal contractions, possible indicators of the intensity of pleasure according to Masters and Johnson (1966), suggested a "generalized reduction in the intensity of orgasm expression" (p. 135). Unfortunately, their wording is ambiguous and could mean either a real decrease in the intensity of orgasm or a decrease in the physical expression of orgasm at various sites. This decrease in intensity of orgasm was also reported by Basson (1995) in androgen deficient menopausal women. These women also had difficulty in trying to focus during arousal to orgasm.

In some menopausal women, pain can occur during and after the uterine/vaginal contractions of orgasm. Levin (2001) suggested that, in the premenopausal women, contractions of the vagina and uterus are induced by a neurotransmitter that has to overcome the inhibitory action of any released VIP. In the menopausal state, however, VIP is probably ineffective in relaxing smooth muscle (Palle, Bredkjaer, Fahrenkrug, & Ottesen, 1991) so that the contractions of the uterus/vagina induced by the neurotransmitter at orgasm is unopposed, leading to spasmodic type contractions creating anoxia and thus pain. Giving oestrogen and progesterone together causes relief, but neither is adequate separately (Masters & Johnson, 1966).

### *Treatment*

The treatment of anorgasmia has been approached from psychoanalytic, cognitive-behavioral, pharmacological, and systems theory perspectives (Heiman, 2000). Substantial empirical outcome research is available only for cognitive behavioral and, to a lesser degree, pharmacological approaches. Although there may be usefulness in other approaches, in particular psychodynamic and systemic treatments, we have no controlled or comparison research establishing their effectiveness. Hence, in this section, we will provide a review only of cognitive-behavioral techniques and pharmacotherapy used to treat female anorgasmia. To this end, Tables 6, 7, and 8 contain summaries of controlled and uncontrolled studies by treatment techniques. Definitive recommendations for treatment are based solely on controlled outcome research. One of the difficulties in assessing treatment effectiveness for anorgasmia is the nebulous manner in which studies often define orgasmic dysfunction. Although some investigators have used clinician inter-

views to determine whether women meet criteria for primary or secondary anorgasmia, others have relied solely on participant verbal reports of orgasmic difficulty or the results of brief self-report inventories. For this reason, whenever possible, information on the way in which orgasmic dysfunction is defined is included in the tables.

### *Cognitive-Behavioral Approaches*

Cognitive-behavioral therapy for anorgasmia focuses on promoting changes in attitudes and sexually relevant thoughts, decreasing anxiety, and increasing orgasmic ability and satisfaction. Behavioral exercises traditionally prescribed to induce these changes include directed masturbation, sensate focus, and systematic desensitization. Sex education, communication skills training, and Kegel exercises are also often included in cognitive-behavioral treatment programs for anorgasmia.

*Directed masturbation.* Given that masturbation can be performed alone, any anxiety that may be associated with partner evaluation is eliminated. Similarly, the amount and intensity of sexual stimulation is directly under the woman's control, and, therefore, the woman is not reliant upon her partner's knowledge or her ability to communicate her needs to her partner. Research that shows a relation between masturbation and orgasmic ability provides empirical support for this treatment approach (Laumann et al., 1994).

Directed masturbation (DM) has been used to effectively treat anorgasmia in a variety of treatment modalities including, group, individual, couples therapy, and bibliotherapy. As can be seen in Table 6, the results from a number of outcome studies and case series indicate that directed masturbation is highly successful for treating primary anorgasmia. In a controlled comparison of therapist-directed group masturbation training, self-directed masturbation training (bibliotherapy), and wait-list control, Heinrich (1976) reported a 100% success rate for treating primary anorgasmia using therapist DM training at 2-month follow-up. Forty-seven percent of the bibliotherapy women reported becoming orgasmic during masturbation compared with 21% of wait-list controls. The effects of self-directed masturbation training were further investigated in a randomized trial comparing written versus videotaped masturbation assignments (McMullen & Rosen, 1979). After 6 weeks, 65% of the women using a text, and 55% of the women using videotapes had experienced orgasm during masturbation, and 50% and 30%, respectively, were orgasmic during intercourse. None of the control women had attained orgasm. More recently, Hurlbert and Apt (1995) compared the effectiveness of DM with coital alignment technique in 36 women with secondary anorgasmia. Coital alignment is a technique in which



the woman assumes the supine position and the man positions himself up forward on the woman such that clitoral contact is maximized during coitus. Thirty-seven percent of woman receiving instructions on coital alignment technique, versus 18% of those receiving DM, reported substantial improvements (> 50% increase) in orgasmic ability during intercourse after only four 30-minute sessions.

In summary, DM has been shown to be an empirically valid, efficacious treatment for women diagnosed with primary anorgasmia. For the woman with acquired anorgasmia who is averse to touching her genitals, DM may be beneficial. If, however, the woman is able to attain orgasm alone through masturbation but not with her partner, issues relating to communication, anxiety reduction, safety, trust, and ensuring the woman is receiving adequate stimulation, either via direct manual stimulation or engaging in intercourse using positions designed to maximize clitoral stimulation (i.e., coital alignment technique), may prove more helpful.

*Anxiety reduction techniques.* Anxiety can serve as a distraction that disrupts the processing of erotic cues by causing the woman to focus instead on performance related concerns, embarrassment, and/or guilt. It can lead the woman to engage in self-monitoring during sexual activity, an experience Masters and Johnson (1970) referred to as "spectatoring." Some researchers have speculated that the increased sympathetic activation that accompanies an anxiety state may impair genital vasocongestion via inhibition of parasympathetic nervous system activity. Others have argued that sympathetic nervous system (SNS) activation plays more of a facilitatory than inhibitory role in sexual arousal (Meston, 2000).

As originally conceived by Masters and Johnson (1970), sensate focus involves a step-by-step sequence of body touching exercises, moving from nonsexual to increasingly sexual touching of one another's body. Components specific for treating anorgasmic women often include non-demand genital touching by the partner, female guidance of genital manual and penile stimulation, and coital positions designed to maximize pleasurable stimulation. Sensate focus is primarily a couples'-skills learning approach designed to increase communication and awareness of sexually sensitive areas between partners. Conceptually, however, the removal of goal-focused orgasm, which can cause performance concerns, the hierarchical nature of the touching exercises, and the instruction not to advance to the next phase before feeling relaxed about the current one, suggest sensate focus is also largely an anxiety reduction technique and could be considered a modified form of in vivo desensitization.

Table 6  
*Psychological Treatment of Orgasmic Dysfunction*

Author(s)	Subject characteristics	Definition of anorgasmia	Treatment	Outcome
<b>Directed Masturbation</b>				
<b>Controlled Outcome Studies</b>				
Andersen (1981)	<i>M</i> age = 25; 25 married, all with regular partners; some sexual aversion; <i>N</i> = 30	Self-reported primary anorgasmia, also assessed via Sexual Interaction Inventory	SD <sup>a</sup> (G) <sup>b</sup> vs. DM <sup>c</sup> (G) vs. WL <sup>d</sup> ; 10 sessions over 5 weeks	DM > SD, WL on orgasmic response; 6-week follow-up: DM > SD on orgasmic response
Bogat, Hamernik, & Brooks (1987)	<i>N</i> = 11	Self-reported pre-orgasmic (less than 10% of time) with desire to improve ability, also assessed with Women's Orgasmic Efficacy and Comfort Scale	DM vs. no treatment (C) <sup>e</sup> ; 10 sessions	80% improvement in orgasmic success in tx <sup>f</sup> vs. controls
Delehanty (1982)	<i>M</i> age = 30; <i>N</i> = 28	Preorgasmic: no history of orgasm within previous 5 years or primary anorgasmia; assessed via self-report and orgasm checklist	DM and assertiveness training in group cotherapy format for 10 weeks vs. WL	82% orgasmic success with tx
Eichel, Eichel, & Kule (1988)	CAT; <sup>g</sup> <i>M</i> age = 40 ( <i>n</i> = 22); Control: <i>M</i> age = 39 ( <i>N</i> = 43); interest in sexual enhancement	Orgasmic function assessed via Orgasmic Attainment Criteria Scale	CAT (C) vs. no treatment (C)	CAT group: improvement in frequency of orgasm, simultaneous orgasm, and orgasm satisfaction compared to controls; use of CAT by both groups correlated with improved frequency of all orgasm variables
Heiman & LoPiccolo (1983)	<i>M</i> age = 30; 25 primary, 16 secondary; absence of severe marital distress; <i>N</i> = 41	Primary and secondary anorgasmia	CBT <sup>h</sup> communication training, DM, SF, systems conceptualization (C) vs. WL; 15/1-hr sessions	Primary and secondary: increased duration foreplay and si; Primary: increased frequency si, increased orgasmic response during masturbation and si; Secondary: increased orgasmic response during si, increased initiation of sexual activity; 3-month follow-up: Primary and secondary: gains maintained

Table 6 continued on following page.



Table 6  
*Psychological Treatment of Orgasmic Dysfunction (continued)*

Author(s)	Subject characteristics	Definition of anorgasmia	Treatment	Outcome
Heinrich (1976)	M age = 25; 20 married, 24 with regular partner; N = 44	Primary anorgasmia	DM (G) vs. DM bibliotherapy (1) vs. WL; DM: 10 sessions over 5 weeks; DM bibliotherapy: 1 session	2 months: DM: 100% om, 47% co <sup>1</sup> ; DM bibliotherapy: 47% om, 13% co; WL: 21% om, 0% co
Hurlbert & Apt (1995)	M age = 28; 36 sec, M years married = 5; CAT (n = 19), DM (n = 17)	Secondary anorgasmia, assessed via self-report and sex diary	CAT (1) vs. DM (1); 4, 30-min sessions involving assertiveness training, communication skills, and SF plus 4, 10-min telephone contacts	CAT: 37% substantially improved, 58% moderately improved orgasmic ability during si; DM: 18% substantially improved, 35% moderately improved orgasmic ability during si
McMullen & Rosen (1979)	M age = 29; 30 married, 30 single; DM + bibliotherapy (n = 20), DM + instructional (n = 20); WL (n = 20)	Primary anorgasmia, defined as orgasmic inability with sexual stimulation; assessed via clinician interview, self-report, General Information Questionnaire, Sexual Behavior Inventory	DM Bibliotherapy (1) vs. DM Instructional videotape (1) vs. WL; 6 sessions over 6 weeks	Bibliotherapy: 65% orgasm with masturbation (om), 50% coitally orgasmic (co); Instructional: 55% om, 30% co; WL: 0% om, 0% co; 1-year follow-up: gains maintained/improved
Munjack et al. (1976)	12 primary, 10 secondary; N = 22	Primary and secondary anorgasmia	SD, DM, assertiveness training, modeling, sexual education (I/C) vs. WL; 22 weekly sessions	Tx > WL orgasmic ability; no difference between primary and secondary
Reisinger (1979)	M age = 33; married 8-15 yrs; N = 3	Secondary anorgasmia, coitally and through masturbation	DM with erotic video 8-13 sessions; stimulation by partner without training 2-6 sessions; stimulation by partner with training 6-10 sessions; solitary stimulation without erotic aids 2-3 sessions; stimulation with partner 4-7 sessions	DM: 3/3 orgasmic ability through masturbation; limited orgasmic success without partner training; 67% orgasmic ability with partner training; 2-, 6-month follow-ups: 80% orgasmic ability with and without partner stimulation

Table 6 continued on following page.

Table 6  
*Psychological Treatment of Orgasmic Dysfunction (continued)*

Author(s)	Subject characteristics	Definition of anorgasmia	Treatment	Outcome
Riley & Riley (1978)	<i>M</i> age = 26; married; SF ( <i>n</i> = 15), DM + SF ( <i>n</i> = 20)	Primary anorgasmia, defined as orgasmic inability regardless of type of sexual stimulation	DM and SF (C) vs. SF (C); 6 weekly and 6 bimonthly sessions	DM and SF: 18/20 orgasmic; SF: 8/15 orgasmic; 1-year follow-up: gains maintained
<b>No Control Outcome Studies</b>				
Adkins & Jehu, (1985)	<i>M</i> age = 28; <i>M</i> years in relationship = 3.5; <i>N</i> = 6	Self-reported primary orgasmic dysfunction	DM and bibliotherapy; 10 sessions over 10 weeks	3/6 orgasmic success at partner-involvement with no intercourse phase; 6-month follow-up: 3/6 orgasmic success via masturbation or coitus with clitoral stimulation
Barbach (1974)	19-48 years; <i>N</i> = 83	Primary anorgasmia, defined as no orgasmic experience	DM (G); 10 sessions over 5 weeks	92% orgasmic with masturbation
Barbach & Flaherty (1980)	19 to 60 years; <i>N</i> = 26	Secondary anorgasmia	DM, communication training (I); 10, 1½ hr sessions; follow-up on previous study	1-, 2-year follow-up: 60% increased orgasmic frequency with partners
De Annicis et al. (1985)	<i>M</i> age = 34; <i>M</i> years married = 13; 13 primary, 9 secondary; <i>N</i> = 22	Primary and secondary anorgasmia	Sensual awareness, SF, DM, communication training, modification of sexual inter-actions (C); 15-20 sessions	No change in orgasmic ability; increased sexual satisfaction; 3-year follow-up: Primary: increase in orgasmic ability with genital caress; Secondary: increase in orgasmic ability during masturbation
Ersner-Hersfield & Kopel (1979)	<i>M</i> age = 26; 14/22 married; 13 primary, 9 secondary; <i>N</i> = 22	Pre-orgasmic, defined as either no orgasmic experience or less than 10% success achieving orgasm in the past, assessed via Survey of Sexual Activities	DM: spaced vs. massed sessions (G, I) vs. DM: spaced vs. massed sessions (G, C), all fashioned after Barbach (1975) and Heiman, LoPiccolo, & LoPiccolo (1976) formats; 10 sessions over 5 weeks	91% orgasmic with masturbation, 73% orgasmic with partner; no difference G, I vs. G, C or spaced vs. massed sessions; 10-week follow-up: 82% orgasmic with partner

Table 6 continued on following page.



Table 6  
*Psychological Treatment of Orgasmic Dysfunction (continued)*

Author(s)	Subject characteristics	Definition of anorgasmia	Treatment	Outcome
Kaplan (1992)	Sexuality seminar participants; 21/30 attempted CAT; N = 21	N/A	CAT for 1-3 sexual encounters over 2 weeks	1/21 enhanced coital orgasm; 20/21 no enhanced or increased coital orgasm, nor increased simultaneous orgasm
Kirkpatrick et al. (1977)	N = 4	N/A	DM (G)	4/4 orgasmic during masturbation, 75% coitally orgasmic
Leiblum & Ernsner-Hersfield (1977)	23-43 years; 12 married; N = 16	Primary and secondary anorgasmia, assessed by General Information Questionnaire	DM, SF, and sexual education (G); 8-10 sessions/5-8 week	88% orgasm with masturbation
Lobnitz & LoPiccolo (1972)	Married; N = 13	Primary anorgasmia	DM (I with partner participation); 15 sessions	13/13 orgasmic with masturbation, 13/13 coitally orgasmic 50% of time
LoPiccolo & Lobnitz (1972)	Married; N = 8	Primary anorgasmia, assessment method not specified	DM (I) modeled after Masters & Johnson (1970); Kegel exercises; 15 sessions	8/8 orgasmic with masturbation, 6/8 coitally orgasmic; 6-month follow-up: gains maintained
McGovern, Stewart, & LoPiccolo (1975)	6 primary, 6 secondary; N = 12	Primary anorgasmia and secondary anorgasmia	Sexual and communication skills training, anxiety re-education, DM; 15 sessions	Primary: 6/6 increased orgasmic ability; Secondary: no change in orgasmic ability
Schneidman & McGuire (1976)	10 < 35 years, 10 > 35 years; 70% prim; some problems with male ejaculatory control; N = 20	Primary anorgasmia (except nocturnal orgasms while dreaming)	Variation of Masters & Johnson (1970; sexual education, group discussions, DM, couples tx) I; 10 weeks	< 35 years: 70% orgasmic during masturbation, 0/10 coitally orgasmic; > 30 years: 40% orgasmic during masturbation, 0/10 coitally orgasmic; 6 month: < 35 years: 80% orgasmic during masturbation, none orgasmic during si; > 30 years: 60% orgasmic during masturbation, 1/10 orgasmic during si

Table 6 continued on following page.

Table 6  
*Psychological Treatment of Orgasmic Dysfunction (continued)*

Author(s)	Subject characteristics	Definition of anorgasmia	Treatment	Outcome
Sotile, Kilmann, & Follingstad (1977)	3 primary, 3 secondary; 15 previous SD sessions; $N = 6$	Primary and secondary anorgasmia, assessed via Sexual Interaction Inventory	Sexual and communication skill training, sexual education, SF, DM, Kegel exercises, role-play orgasm (C); 6, 1½-hr sessions	No change in orgasm
Wakefield (1987)	Reanalysis of data from Ersner-Hersfield & Kopel (1979); $N = 15$	Self-reported primary anorgasmia, assessed via Survey of Sexual Activities	DM: spaced vs. massed sessions (G, I) vs. DM: spaced vs. massed sessions (G, C); 10 sessions over 5 weeks	80% orgasm via masturbation; 7% orgasm via partner stimulation; no coital orgasm; 10-week follow-up: 93% orgasm via masturbation, 20% orgasm via partner stimulation; no coital orgasm
Wallace & Bach (1974)	$M$ age = 28; 11/17 married; all with partners; $N = 17$	Primary anorgasmia	DM (G); 10 sessions over 5 weeks	100% orgasmic with masturbation 87% orgasmic with partner; 8-month follow-up: gains maintained
<b>Systematic Desensitization</b>				
Andersen (1981)	$M$ age = 25; 25 married, all with regular partners; some sexual aversion; $n = 30$	Self-reported primary anorgasmia, also assessed via Sexual Interaction Inventory	SD (G) vs. DM (G) vs. WL; 10 sessions over 5 weeks	DM > SD, WL on orgasmic response; 6-week follow-up: DM > SD on orgasmic response
Husted (1972, 1975)	Mixed sexual dysfunction; all with partners; sexual anxiety; $N = 30$	N/A	SD: Imaginal (I) vs. (C); vs. in vivo (I) vs. (C) vs. No-treatment control; Imaginal $M = 8$ sessions, in vivo $M = 13$ sessions	SD: decreased anxiety, increased coital frequency and orgasmic ability with masturbation; no difference (I) vs. (C) or imaginal vs. in vivo
Mathews et al. (1976)	$M$ age = 28; 13 primary, 5 secondary; 17/18 low sexual desire/arousal; $N = 18$	Primary and secondary anorgasmia	SD, sexual tx (C) vs. SF, sexual tx (C) vs. SF, bibliotherapy (C); 10 sessions; 3 sessions and 10 week mailing for SF, bibliotherapy	2/18 increased orgasmic ability; no difference between groups; 4-month follow-up: no difference between groups

Table 6 continued on following page.



Table 6  
Psychological Treatment of Orgasmic Dysfunction (continued)

Author(s)	Subject characteristics	Definition of anorgasmia	Treatment	Outcome
Nemetz, Craig, & Reith (1978)	21-39 years; 7 primary, 15 secondary; sexual anxiety; all with regular partners; SD (I) (n = 8), SD (G) (n = 8), Control (n = 6)	Primary and secondary anorgasmia	SD (I) vs. SD (G) vs. Control; 5 sessions over 3 weeks	No difference between groups in orgasm; 3 week, 1-year follow-up: gains maintained
Obler (1973)	Mixed sexual dysfunction; marital status matched across groups; N = 37	N/A	SD with videotapes (I) vs. Psychoanalytic tx with videotapes (G) vs. WL; SD: 15, 45-min sessions; Psychoanalytic: 10, 75-min	SD: 85% orgasmic; Psychoanalytic: 36% orgasmic WL: 23% orgasmic SD > Psychoanalytic, WL on decreased anxiety
Obler (1982)	18-36 years; married or cohabiting for over 2 years; Integrated (n = 8), Couples (n = 8), No tx (n = 10)	N/A	42 weeks of integrated hypnotic/behavioral group vs. 16 week of Cotherapist/Couples vs. No tx; 1 year	Integrated: 7/8 self-reported orgasmic ability over 60% of time; Cotherapist/Couples: 2/8 self-reported orgasmic ability over 60% of time; No tx: no self-reported orgasmic ability
O'Gorman (1978)	M age = 36; low sexual desire/arousal, some dyspareunia/Vaginismus; N = 40	Frigidity, including orgasm dysfunction	SD, sex education (G), partner-only discussion groups vs. SD, intravenous methoxitone sodium to induce relaxation (I with partner participation); SD (G) 20 1-hr sessions; SD (I) 15, 10-min sessions over 10 weeks	SD, sex education (G): 63% successful; SD, methoxitone sodium (I): 37% successful

**Own Control or Wait-List Controlled Outcome Studies**

Sotile & Kilmann (1978) M age = 28; 8 primary, 14 secondary; all with partners; no partner sexual dysfunction; sexual anxiety; N = 22

Primary and secondary anorgasmia, assessed via Sexual Behavior and Attitudes Questionnaire and self-report

Sexual education followed by SD (G) or WL for 16 sessions over 8 weeks

Increased noncoital orgasmic frequency; secondary > primary orgasmic frequency following tx; 6-week follow-up: gains maintained

Table 6 continued on following page.

Table 6  
*Psychological Treatment of Orgasmic Dysfunction (continued)*

Author(s)	Subject characteristics	Definition of anorgasmia	Treatment	Outcome
<b>No Control Outcome Studies</b>				
Cooper (1970)	<i>N</i> = 50	Coitally anorgasmic, assessed by clinical interview	In vivo SD, sex education, psychotherapy (I); 21 sessions over 1 year	24/50 coitally orgasmic; 26/50 unchanged or worse
Jones & Park (1972)	Anxiety; sexual shame; <i>N</i> = 55	Primary anorgasmia	SD with Brevital injections to induce relaxation (1 with partner); <i>M</i> = 14 sessions	82% orgasmic success
<b>Controlled Outcome Studies</b>				
<b>Sensate Focus/Other</b>				
Carney, Bancroft, & Mathews (1978)	<i>M</i> age = 29; no sexual anxiety; Vaginismus or primary orgasm difficulty; <i>T</i> <sub>m</sub> ( <i>n</i> = 16), diazepam ( <i>n</i> = 16)	Secondary anorgasmia assessed via self-report, clinician rating and independent assessor rating	SF weekly: T, 10 mg daily vs. diazepam, 10 mg daily (C) vs. SF monthly: T vs. diazepam (C); SF weekly: 16 sessions, SF monthly: 5 sessions	No difference in orgasm between weekly vs. monthly T > diazepam frequency of orgasm; 6-month follow-up (after drug discontinuation): gains maintained
Chambless et al. (1984)	<i>M</i> age = 27; <i>N</i> = 16 (group <i>n</i> s not specified)	< 30% orgasm with coitus; assessed with Women's Sexuality Questionnaire	Kegel exercises vs. Attn <sup>n</sup> placebo (nonsexual imagery) vs. WL; 6 weeks	No differences in coital orgasmic frequency yet improvement in each group; no change in perceived vaginal stimulation during orgasm
Fichten, Libman, & Brender (1983)	<i>M</i> age = 33; secondary; <i>M</i> years married = 10; Orgasmic < 25% of time; <i>n</i> = 23	Secondary anorgasmia, defined as at least 1 orgasmic experience, dissatisfaction with orgasmic frequency and narrow range of orgasmic stimulation	Sexual information, relaxation, Kegel exercises, DM, SF <sup>o</sup> , sexual communication training; ban on si; (C) vs. (G) vs. minimal contact bibliotherapy; 14 weeks	SF: no change in orgasm; increase in enjoyment of noncoital sexual caressing

Table 6 continued on following page.



Table 6  
*Psychological Treatment of Orgasmic Dysfunction (continued)*

Author(s)	Subject characteristics	Definition of anorgasmia	Treatment	Outcome
Kilmann et al. (1986)	<i>M</i> age = 33; 51 married; all with partners; no Dyspareunia or Vaginismus, no premature ejaculation in partners; <i>N</i> = 55	Secondary anorgasmia for 5 months with si or clitoral stimulation and distress about orgasmic ability; assessed via clinician interview and Sexual Behavior and Attitudes Questionnaire	2, 2-hr sessions of sex education followed by Communication skills (C, G) vs. Sexual skills (C, G) vs. WL vs. Attn-placebo	Communication and sexual skills > controls in coital orgasm ability; no difference between groups; 6-month follow-up: gains decreased, no difference between groups
Kilmann et al. (1987)	<i>M</i> age = 30; 10 married; no premature ejaculation in partners; <i>N</i> = 11	Secondary anorgasmia, defined as 50% coital orgasmic success or less over 5 months and dissatisfaction with orgasmic frequency, assessed via structured interviews, Sexual Interaction Inventory and Sexual Behavior and Attitudes Questionnaire	2, 2-hr sessions of sex education followed by communication and sexual skills vs. WL vs. Attn-placebo	Tx > WL, Attn-placebo: increase in orgasmic ability with tx
LoPiccolo et al. (1985)	<i>M</i> age = 35; 12 primary, 19 secondary; <i>M</i> years married = 13; <i>N</i> = 31	Primary and secondary anorgasmia	CBT sexual therapy (LoPiccolo & Hagan, 1979) vs. WL (C), both for 15, 1-hr sessions	Primary and secondary: Increase in orgasm with masturbation; 3-month follow-up: gains maintained/improved
Mathews et al. (1976)	<i>M</i> age = 28; 13 primary, 5 secondary; 17/18 low sexual desire/arousal; <i>N</i> = 18	Orgasmic dysfunction, defined as failure to experience orgasm and assessed via clinician interview	SD, sexual tx (C) vs. SF, sexual tx (C) vs. SF, bibliotherapy (C); 10 sessions; 3 sessions and 10 week mailing for SF, bibliotherapy	2/18 increased orgasmic ability; no difference between groups; 4-month follow-up: no difference between groups
Milan, Kilmann, & Boland (1988)	<i>M</i> age = 33; secondary, <i>M</i> years relationship = 10; regular sexual partners with no sexual dysfunction; 9% orgasmic frequency pre-treatment; <i>N</i> = 38	Secondary anorgasmia, assessed via scale adapted from the Sexual Behavior and Attitudes Questionnaire	10, 2-hr sessions over 5 weeks of sex education plus either: communication skills vs. sexual skills vs. condensed sex and communication skills vs. didactic lecture vs. WL	2-6 years: no difference between tx groups, WL on sexual or relationship functioning

Table 6 continued on following page.

Table 6  
*Psychological Treatment of Orgasmic Dysfunction (continued)*

Author(s)	Subject characteristics	Definition of anorgasmia	Treatment	Outcome
Morokoff & LoPiccolo (1986)	<i>M</i> age = 30; primary, <i>M</i> years married = 9; no male sexual dysfunction, no psychosis or depression; <i>N</i> = 34	Primary anorgasmia, assessed via Sexual History Form	DM and Bibliotherapy in either Minimal therapist contact for 4 sessions (MTC; <i>n</i> = 14) vs. Full therapist contact for 15 sessions (FTC; <i>n</i> = 29)	Increased orgasmic ability with masturbation and si; MTC > FTC on increased frequency orgasm with masturbation
Roughan & Kunst (1981)	<i>M</i> age = 32; PC group ( <i>n</i> = 14), Relaxation ( <i>n</i> = 12), Control ( <i>n</i> = 14)	Primary anorgasmia or secondary anorgasmia lasting over 2 years	PC (G): PC muscle exercises for 50 contractions, 5 times daily for 12 weeks vs. Relaxation (G): physical relaxation for 12 weeks vs. no tx	No relationship between PC muscle tone and orgasmic ability in any group
Van Lankveld, Everaerd, & Grotjohann (2001)	<i>M</i> age = 37; <i>M</i> sexual dysfunction duration = 8 years; Hyposexual Desire Disorder; Vaginismus; Dyspareunia; Bibliotherapy ( <i>n</i> = 9), WL control ( <i>n</i> = 9)	DSM-IV diagnosis of orgasmic dysfunction via structured interview, with no distinction between primary and secondary anorgasmia; assessed via self-report and Golombok Rust Inventory of Sexual Satisfaction	Bibliotherapy (including communication skills, sexual education, and SF) and CBT with telephone support vs. WL; 10 weeks	No improvement in orgasm in tx vs. controls
<b>No Control Outcome Studies</b>				
Billups et al. (2001)	Pre- and postmenopausal women with and without FSDP; <i>N</i> = 32	Orgasm function assessed with Female Intervention Efficacy Index	6 at-home sessions of clitoral vacuum therapy; 5-15 min with or without partner	FSD: 55% increased orgasm; non-FSD: 42% increased orgasm
Blakeney et al. (1976)	10 primary, 28 secondary; some male sexual problems; <i>N</i> = 38	Primary and secondary anorgasmia	4-hr interview and 2½ day workshops based on Masters & Johnson (1970) (C)	Primary: 70% orgasmic; Secondary: 57% orgasmic

Table 6 continued on following page.



Table 6  
*Psychological Treatment of Orgasmic Dysfunction (continued)*

Author(s)	Subject characteristics	Definition of <i>anorgasmia</i>	Treatment	Outcome
Cotten-Huston & Wheeler (1983)	<i>M</i> age tx group = 34; <i>M</i> age control group = 31; both groups with orgasmic dysfunction; <i>N</i> = 70	Primary or secondary anorgasmia, method of assessment not specified	Combination of group and sex therapy approaches vs. no tx	Increased masturbation and orgasm through masturbation in tx vs. controls
Dodge, Glasgow, & O'Neill (1982)	<i>M</i> age = late 20s; <i>N</i> = 13	Primary or secondary anorgasmia (orgasmic mainly through masturbation), Sexual Interaction Inventory and Sexual Arousal Inventory	Tx of minimal-contact bibliotherapy in 3, ½-hr therapy sessions vs. delayed treatment group given information on human sexuality	Tx increased coital orgasm; 2/3 primary attained orgasm with tx vs. 0/2 orgasm in primary controls; no change orgasm via masturbation for tx or control; 6-week follow-up: increase in coital orgasmic ability with tx
Golden et al. (1978)	<i>M</i> age = 27; 14/17 married; <i>N</i> = 17	Secondary anorgasmia as primary diagnosis, assessed via Goals for Sexual Therapy: Female form	Couples assigned SF, sexual skills, and communication skills in either a tx (G) vs. tx (C) format; 12 weeks	Couple and group tx improved orgasm satisfaction (data suggest group tx slightly more beneficial)
Jankovich & Miller (1978)	19-38 years; <i>N</i> = 17	Primary anorgasmia assessed via interview	Therapy and audiovisual sexual education over a single week (G)	7/17 experienced orgasm in a week: 4 via masturbation, 2 via partner manual stimulation, 1 via manual stimulation, si
Kilmann et al. (1983)	<i>M</i> age = 33; <i>M</i> years married = 10; 8.4% coital orgasm frequency, <i>M</i> dysfunction persistence of 9.6 years; <i>N</i> = 48	Secondary anorgasmia, with orgasm frequency less than 50% for 5 month, assessed in interview; orgasmic ability also assessed via Sexual Behavior and Attitudes Questionnaire	Sex education during 2, 2-hr sessions within a single week	Increases in orgasmic frequency subscale; increases in coital, noncoital, and masturbatory orgasm frequency

Table 6 continued on following page.

Table 6  
*Psychological Treatment of Orgasmic Dysfunction (continued)*

Author(s)	Subject characteristics	Definition of anorgasmia	Treatment	Outcome
Lazarus (1963)	<i>M</i> age = 25; married; some decreased desire/arousal; <i>N</i> = 16	Persistent orgasmic dysfunction, method of assessment not specified	SD (I), <i>M</i> = 29 sessions over 6 months	9/16 "nearly always achieve orgasm"; 15-mo follow-up (4 patients): gains maintained or improved
Libman et al. (1984)	<i>M</i> age = 33; <i>M</i> years married = 10; 25% orgasmic frequency; Couple ( <i>n</i> = 7), Group ( <i>n</i> = 8), Bibliotherapy ( <i>n</i> = 9)	Secondary anorgasmia assessed via interview and Jewish General Hospital Sexual Behavior Questionnaire	15, 1-hr sessions over 14 weeks (G) vs. all-female groups for 15, 1½-hr sessions over 14 week (G) vs. Minimal Contact Bibliotherapy: 2 sessions at beginning and end of 14-week period	Therapy (C) and bibliotherapy > therapy (G) in orgasm with manual stimulation; therapy (C) > other groups in orgasm via giving and receiving manual stimulation; all improved orgasm via masturbation, giving and receiving manual stimulation, receiving oral stimulation
Masters & Johnson (1970)	193 primary; 11 masturbatory dysfunction; 106 coital dysfunction; 32 random; <i>N</i> = 342 (1959-1964)	Primary and secondary anorgasmia	Sex education, SF, communication training, in vivo SD (C); 14 sessions over 2 weeks	Primary: 83% orgasmic; masturbatory; 91% orgasmic; coital; 80% orgasmic; random: 63% orgasmic; 5-year follow-up: Primary 1% relapse; Secondary 2% relapse
McCabe (2001)	<i>M</i> age = 36; low sexual interest, arousal disorder, or Vaginismus; <i>N</i> = 36	Orgasm dysfunction, assessed via Sexual Dysfunction Scale	CBT, SF, interpersonal communication; sexual skills; alleviating sexual anxiety	Anorgasmia decreased from 66.7% to 11.1% post-tx; increase in positive sexual attitudes
Sarwer & Durlak (1997)	Couples ages 20-60 years; married; <i>N</i> = 34	DSM-III diagnosis of inhibited orgasm	Behavioral treatment involved SF for 30 min per video, lecture, and sex education material over 7 weekly sessions of 4 hrs	65% resolved orgasm dysfunction by end of tx
Sotile, Kilmann, & Follingstad (1977)	3 primary, 3 secondary; <i>N</i> = 6	Primary and secondary anorgasmia	Sexual and communication skill training, sexual education, SF, DM, Kegel ex, role-play orgasm (C); 6/1½-hr sessions	Decreased sexual anxiety, increased sexual communication

Table 6 continued on following page.



Table 6  
*Psychological Treatment of Orgasmic Dysfunction (continued)*

Author(s)	Subject characteristics	Definition of anorgasmia	Treatment	Outcome
Trudel & Saint-Laurent (1983)	PC Group ( $n = 6$ ), Relaxation Group ( $n = 6$ )	Orgasmic ability via clitoral stimulation, not coitus (assessed through interview)	PC group: 20 min daily PC exercises for 8 weeks; Relaxation group: 20 min daily exercises in sexual awareness, relaxation, and breathing for 8 weeks	No differences between groups in coital orgasm ability; in the relaxation group, 1 orgasmic woman during tx, 1 woman orgasmic post-tx (not attributed to tx effects)
Zajecka et al. (2002)	$M$ age = 43; 65% of sample female; depression; 48% women reported baseline sexual dysfunction; CBASP <sup>a</sup> ( $n = 140$ ), nefazodone ( $n = 144$ ), combined ( $n = 155$ )	Difficult, less intense, or lack of orgasm	CBASP 2 times weekly, nefazodone (200-600 mg/d), or combination for 12-week period	ns improvement in orgasm with CBASP, nefazodone and combination tx groups at 12 weeks compared to baseline

<sup>a</sup> SD = Systematic desensitization. <sup>b</sup> (G) = Group therapy. <sup>c</sup> DM = Directed masturbation. <sup>d</sup> WL = Wait list. <sup>e</sup> C = Couples therapy. <sup>f</sup> tx = Treatment. <sup>g</sup> CAT = Coital alignment technique. <sup>h</sup> CBT = Cognitive behavioral therapy. <sup>i</sup> si = Sexual intercourse. <sup>j</sup> (I) = Individual therapy. <sup>k</sup> om = Orgasmic with masturbation. <sup>l</sup> co = Coitally orgasmic. <sup>m</sup> T = Testosterone. <sup>n</sup> Attn = Attention. <sup>o</sup> SF = Sensate focus. <sup>p</sup> FSD = Female sexual dysfunction <sup>q</sup>CBASP = Cognitive Behavioral Analysis System of Psychotherapy.

Table 7  
Pharmacological Treatments for Nonantidepressant-Induced Orgasmic Dysfunction

Author(s)	Subject characteristics	Definition of anorgasmia	Treatment	Outcome
<b>ArginMax</b>				
Ito, Trant, & Polan (2001)	M age = 43; 6 subjects with previous sexual dysfunction; N = 77	Orgasm function assessed with Female Sexual Functioning Index	ArginMax herbal supplement for 4 weeks vs. placebo	47.1% of ArginMax tx <sup>a</sup> improvement in orgasm function at 4 weeks vs. 30.2% in placebo group
<b>Bupropion</b>				
Modell, May, & Katholi (2000)	21-54 years; healthy; N = 20	Self-reported secondary anorgasmia as inhibited or delayed orgasm in appropriate time frame	3-week placebo dose, 3-week bupropion-SR (150 mg) 1 per day plus placebo dose, 3-week bupropion-SR (150 mg) 2 times per day	No improvement in orgasm, satisfaction, or intensity beyond placebo with either 150 or 300 mg doses
<b>Nefazodone, Psychotherapy</b>				
Zajacka et al. (2002)	M age = 43; 65% of sample female; depression; 48% women reported baseline sexual dysfunction; Nefazodone (n = 144), CBASP <sup>b</sup> (n = 140), Combined (n = 155)	Difficult, less intense, or lack of orgasm	Nefazodone (200-600 mg/d), CBASP 2 times weekly, or combination for 12-week period	Improvement in orgasm in nefazodone, CBASP, and combination tx groups at 12 week vs. baseline
<b>Sildenafil</b>				
J. R. Berman et al. (2001)	M age = 46; all women with Female Sexual Arousal Disorder; hypoactive sexual desire disorder; N = 44	Difficulty or inability to achieve orgasm, assessed via Brief Index of Sexual Functioning (BISF-W) and Female Intervention Efficacy Index (FIEI)	Sildenafil (100 mg) at second visit and 6-week home supply	BISF-W: Increase in orgasm; FIEI: 67% increased orgasmic ability

Table 7 continued on following page.



Table 7  
Pharmacological Treatments for Nonantidepressant-Induced Orgasmic Dysfunction (continued)

Author(s)	Subject characteristics	Definition of anorgasmia	Treatment	Outcome
Caruso et al. (2003)	M age = 27; no sexual dysfunction for < 6 months; healthy relationships	No anorgasmia was assessed; interviews and self-report with the Personal Experiences Questionnaire monitored orgasm function	Randomly assigned to either receive sildenafil 50 mg, then placebo or placebo, then sildenafil 50 mg; sildenafil taken 1 hr before sexual activity	Sildenafil significantly improved orgasm function compared to baseline and placebo; sildenafil use also associated with higher arousal and enjoyment; results maintained at 30-day and 1-year follow-ups
Kaplan et al. (1999)	M age = 52; postmenopausal; N = 12	Self-reported orgasmic difficulty or inability via Index of Female Sexual Function	Sildenafil (50 mg) 1 hr before sexual activity	At 12 weeks, 7.4% improvement in orgasm function
<b>Testosterone</b>				
Carney, Bancroft, & Mathews (1978)	M age = 29; T <sup>c</sup> (n = 16), Diazepam (n = 16)	Secondary anorgasmia assessed via self-report, clinician rating and independent assessor rating	SF <sup>d</sup> weekly; 10 mg/d T vs. diazepam, 10 mg/d vs. SF monthly; T vs. diazepam; SF weekly and monthly	No difference in orgasmic ability between weekly vs. monthly T > diazepam frequency of orgasm; 6-month follow-up (after drug discontinuation); gains maintained
Davis et al., (1995)	E <sup>c</sup> and T: M age = 57; E: M age = 51; postmenopausal; 13/32 hysterectomy; 2/32 oophorectomy; E, T (n = 16), E (n = 17)	Self-reported orgasmic dysfunction, assessed via Sabatberg self-rating scale	E (50 mg) plus testosterone (50 mg) (E&T) vs. E (50 mg), administered 3 times monthly for 2 years; checkups every 6 months	Both E&T and E tx increased orgasmic function; E&T > E greater orgasmic response

<sup>a</sup> tx = Treatment. <sup>b</sup> CBSAP = Cognitive Behavioral Analysis System of Psychotherapy. <sup>c</sup> T = Testosterone. <sup>d</sup> SF = Sensate Focus. <sup>e</sup> E = Estradiol.

Table 8  
Pharmacological Treatments for Antidepressant-Induced Orgasmic Dysfunction

Author(s)	Subject Characteristics	Antidepressant	Definition of Anorgasmia	Treatment	Outcome
<b>Placebo Controlled Outcome Studies</b>					
Kang et al. (2002)	Ginkgo group: <i>M</i> age = 47; placebo group: <i>M</i> age = 46; depressive or anxiety disorders; Ginkgo ( <i>n</i> = 4), Placebo ( <i>n</i> = 6)	Fluoxetine (20 mg/d), paroxetine (20-40 mg/d), or nortriptyline (30 mg/d)	DSM-IV diagnosis of sexual dysfunction; orgasm satisfaction and frequency via self-report and clinical interview	Ginkgo biloba at 120 mg/d for 2 weeks, 160 mg/d for following 2 weeks, 240 mg/d for final 4 weeks vs. placebo doses on same schedule	No improvement in orgasm frequency or satisfaction in ginkgo vs. placebo
Landen et al. (1999)	MDD <sup>a</sup> , decreased libido; orgasmic dysfunction ( <i>n</i> = 19); Buspirone ( <i>n</i> = 16), Placebo ( <i>n</i> = 11)	Citalopram (minimum 40 mg/d) or paroxetine (minimum 30 mg/d)	Orgasm dysfunction assessed in interview via Udvalg for Kliniske Undersogelser scale	Buspirone (20-60 mg/d) for 4 week vs. placebo; SSRI <sup>b</sup> continued during tx <sup>c</sup>	Change in orgasm function not specified
Masand et al. (2001)	Impairment of sex drive, arousal and/or vaginal lubrication; Bupropion ( <i>n</i> = 15), Placebo ( <i>n</i> = 15)	N/A	Impairment in orgasm assessed via Arizona Sexual Experiences Scale	Bupropion SR (150 mg) daily for 3 weeks vs. placebo daily for 3 weeks	No change in bupropion tx in orgasm/orgasm satisfaction; no difference in bupropion vs. placebo
Meston (2003)	Female Sexual Arousal Disorder with complaints of decreased orgasm; <i>N</i> = 19	Fluoxetine, sertraline, or paroxetine; minimum 10 week	Orgasmic ability, intensity/pleasure assessed via self-report	2-week baseline, 8-week crossover design placebo vs. 50 mg ephedrine 1 hr prior to sexual activity	Improved orgasm intensity/pleasure in ephedrine tx and placebo; no difference orgasm tx vs. placebo
Michelson et al. (2000)	Depression; anxiety disorder; OCD <sup>d</sup> ; premenstrual syndrome; premenopausal or estrogen replacement; decreased arousal and pleasure; Buspirone ( <i>n</i> = 19), Amantadine ( <i>n</i> = 18), Placebo ( <i>n</i> = 20)	Fluoxetine dosage by group: Buspirone (31.4 mg/d), Amantadine (28.4 mg/d), and Placebo (25.7 mg/d)	Impaired orgasm, assessed by clinician, self-report, daily diary, and Interview Rating of Sexual Function scale	Baseline and 4-week dose, respectively: Amantadine (50, 100 mg/d) Buspirone (20, 30 mg/d) vs. placebo; Fluoxetine during tx	Improved orgasm in tx and placebo; no difference tx vs. placebo

Table 8 continued on following page.



Table 8  
Pharmacological Treatments for Antidepressant-Induced Orgasmic Dysfunction (continued)

Author(s)	Subject Characteristics	Antidepressant	Definition of Anorgasmia	Treatment	Outcome
Michelson et al. (2002)	M age = 36; depression; decreased vaginal lubrication; Mirtazepine ( <i>n</i> = 36), Yohimbine ( <i>n</i> = 35) Olanzapine ( <i>n</i> = 38) Placebo ( <i>n</i> = 39)	Fluoxetine (20 mg/d or greater)	Self-reported orgasmic inhibition, at least moderate in severity	Random assignment to mirtazapine (15-30 mg/d), yohimbine (5.4-10.8 mg/d), olanzapine (2.5-5 mg/d), or placebo	No differences drug vs. placebo in diary or self-report ratings of orgasm function
<b>No Control Outcome Studies</b>					
Aizenberg et al. (1999)	M age = 7; MDD, OCD, panic disorder, bipolar I disorder; <i>N</i> = 16	Fluoxetine (20-40 mg/d), paroxetine (20-40 mg/d), fluvoxamine (200 mg/d), clomipradmine (75-150 mg/d)	Self-reported that orgasm function had "markedly decreased"	Mianserin (15 mg/d) at bedtime; SRI <sup>e</sup> continued during tx	62% improvement in orgasm function; 7/16 restored orgasm function and 3/16 improved orgasm function to a minor disturbance
Ashton & Rosen (1998)	M age = 42; affective or anxiety disorders; desire and arousal complaints; <i>N</i> = 28	Paroxetine, fluoxetine, setraline, venlafaxine, fluvoxamine	Delayed orgasm or anorgasmia, assessed via clinical interview	Bupropion (75-150 mg/d 1-2 hr before sexual activity); if no response, 75 mg three times daily for 3 days, 75 mg twice daily for 3 days, and 75 mg three times daily for 2 weeks (longest tx period, 9 months); SRI during tx	Improvement in 71% of orgasm complaints
Berk et al. (2000)	M age = 37; diagnoses include major depression, OCD, bulimia, social phobia, bipolar II disorder, panic disorder,	Clomipramine ( $\leq 250$ mg/d), paroxetine ( $\leq 40$ mg/d), sertraline ( $\leq 150$ mg/d), fluvoxamine ( $\leq 300$ mg/d), fluoxetine	Self-reported orgasm difficulty, frequency of difficulty, satisfaction, and intensity via Feiger scale	Sequential course of granisetron (1mg) and sumatriptan (100 mg) 1 hr before sexual activity	Improvement in orgasm difficulty and frequency of difficulty with granisetron; ns improvement with sumatriptan

Table 8 continued on following page.

Table 8  
Pharmacological Treatments for Antidepressant-Induced Orgasmic Dysfunction (continued)

Author(s)	Subject Characteristics	Antidepressant	Definition of Anorgasmia	Treatment	Outcome
Clayton et al. (2001)	trichotillomania, and/or borderline personality disorder; $N = 16$  22-52 years; MDD; decreased desire, arousal, and libido; $N = 4$	( $\leq 40$ mg/d), citalopram ( $\leq 60$ mg/d)  Paroxetine ( $M$ dose = 35 mg/d), sertraline ( $M$ dose = 94 mg/d), fluoxetine ( $M$ dose = 12.5 mg/d), and venlafaxine ( $M$ dose = 225 mg/d)	Orgasmic ability via Changes in interview form of Sexual Functioning Questionnaire	Bupropion (150 minimum at start, 345 mg average ending dose) daily or twice daily, for 8 weeks; SSRI discontinuation by 4 weeks	4 week: Improvement in orgasm subscale scores after discontinuation of SSRI
Cohen & Bartlik (1998)	Decreased libido and orgasm dysfunction; $N = 33$	Fluoxetine, nefazodone, bupropion, sertraline, paroxetine, venlafaxine, phenelzine, or vivactil	Delayed or inhibited orgasm through clinical interview or self-report	Ginkgo Biloba (40-60 mg) 2 times daily up to 120 mg twice daily for 4 weeks; antidepressants continued during tx	Improvement in orgasmic functioning assessed via clinical interview and self-report
Gelenberg et al. (2000)	$M$ age = 43; improvement in MDD with SSRIs; 12/19 female in total sample; $N = 12$	Fluoxetine (20-80 mg/d), sertraline (50-150 mg/d), paroxetine (20 mg/d)	Orgasmic dysfunction diagnosed by clinician via DSM-IV interview and self-reported through Arizona Sexual Experiences Scale	1-2 week washout; Mirtazapine (7.5 mg to 45 mg/d) for 3-6 weeks	6 weeks: Improvement in orgasm function but not satisfaction (results of males and females reported together)
Gitlin et al. (2002)	$M$ age = 41; History of MDD, dysthymic disorder, or depressive disorder not otherwise specified; not currently depressed; $M$ doses presented in next column; $N = 15$	Fluoxetine (33 mg/d), sertraline (106 mg/d), paroxetine (31 mg/d), or citalopram (20 mg/d)	Self-reported orgasmic ability and satisfaction via Arizona Sexual Experiences Scale	Bupropion SR (100-50 mg) 2 times daily for 7 weeks	Improvement in ease of reaching orgasm, $ns^f$ improvement in orgasm satisfaction

Table 8 continued on following page.

Table 8  
*Pharmacological Treatments for Antidepressant-Induced Orgasmic Dysfunction (continued)*

Author(s)	Subject Characteristics	Antidepressant	Definition of Anorgasmia	Treatment	Outcome
Nurnberg et al. (1999)	M age = 37; MDD, panic disorder, bipolar disorder; decreased libido and arousal; pain during intercourse; N = 7	Fluoxetine (20-50 mg/d), sertraline (50-200 mg/d), nefazodone (150 mg/d), valproate (1 gm/d), trazodone (100 mg/d)	Anorgasmia or delayed/less intense orgasm, assessed by clinicians	Sildenafil (50-100 mg) 1-2 hr before sexual activity	7/7 orgasm (less delay, more intense)
Salerian et al. (2000)	Dissatisfaction with libido, arousal, orgasm and lubrication; N = 31	64% of sample receiving SSRIs; other combinations of drugs	Satisfaction with orgasm assessed with Salerian Sexual Satisfaction Survey	Sildenafil (12.5-100 mg); duration of tx: 1-36 weeks	Improved orgasm satisfaction; similar response regardless of psychotropic medication

<sup>a</sup> MDD = Major depressive disorder. <sup>b</sup> SSRI = Selective serotonin reuptake inhibitor. <sup>c</sup> tx = Treatment. <sup>d</sup> OCD = Obsessive compulsive disorder. <sup>e</sup> SRI = Serotonin reuptake inhibitor. <sup>f</sup> ns = Nonsignificant



The success of using anxiety reduction techniques for treating anorgasmia is difficult to assess because most investigators have used some combination of anxiety reduction, sexual techniques training, sex education, communication training, bibliotherapy, and Kegel exercises, and have not systematically evaluated the independent contributions to treatment outcome. In the controlled studies in which anxiety reduction techniques have been included, rarely has treatment outcome for life-long versus acquired female orgasmic disorder been differentiated. As can be seen in Table 6, across studies women have reported decreases in sexual anxiety and, occasionally, increases in frequency of sexual intercourse and sexual satisfaction with systematic desensitization, but substantial improvements in orgasmic ability have not been noted. Similarly, in the few controlled studies that have included sensate focus as a treatment component, none have reported notable increases in orgasmic ability. These findings suggest that, in most cases, anxiety does not appear to play a causal role in anorgasmia, and anxiety reduction techniques are best suited for anorgasmic women only when sexual anxiety is coexistent.

*Other behavioral techniques.* Ignorance about female anatomy and/or techniques for maximizing pleasurable sensations can certainly contribute to orgasm difficulties. Kilmann and associates (1986) compared the effectiveness of various sequences of sex education and communication skills versus wait-list control on orgasmic ability in women with secondary anorgasmia. The authors found sex education to be beneficial for enhancing coital ability at posttest but not at 6-month follow-up. In a comparison study of the effectiveness of sex therapy versus communication skills training for secondary anorgasmia, Everaerd and Dekker (1982) found both treatments were equally effective in improving orgasmic ability. As can be seen in Table 6, in treatment comparison studies, it has been generally found that there were no differences in orgasmic ability between women whose therapy included using Kegel exercises versus those whose therapy did not. To the extent that Kegel exercise may enhance arousal and/or help the woman become more aware and comfortable with her genitals, these exercises may enhance orgasm ability (Heiman, 2000). In summary, there is no direct empirical evidence to suggest that sex education, communication skills training, or Kegel exercises alone are effective for treating either primary or secondary anorgasmia. A review of studies suggests they may serve as beneficial adjuncts to therapy.

#### *Pharmacological Approaches*

There have been few placebo-controlled studies in which the effectiveness of pharmacological agents for treating Female Orgasmic Disor-

der has been examined. Of the few published, in most the efficacy of agents for treating antidepressant-induced anorgasmia has been examined. Whether pharmacological agents would have the same treatment outcome effect on nondrug-induced versus drug-induced anorgasmia is not known.

*Nondrug-induced anorgasmia.* Using a single-blind design, Modell and associates (2000) reported no significant effect beyond placebo of either 150 mg/day or 300 mg/day bupropion-SR on orgasm in 20 women with delayed or inhibited orgasm. Ito, Trant, and Polan (2001) conducted a double-blind, placebo-controlled study of ArginMax, a nutritional supplement comprised of ginseng, Ginkgo biloba, Damiana leaf, and various vitamins, on sexual function in 77 women with unspecified sexual function and reported a marginally significant group difference. It cannot be determined from the report how many women would meet a clinical diagnosis for anorgasmia. To date, there have been no published placebo-controlled studies on sildenafil for female anorgasmia. However, data from a recent double-blind, cross-over, placebo-controlled study on 38 sexually healthy women indicated that 50 mg of sildenafil an hour before sexual activity improved self-reported orgasm function (Caruso, Intelisano, Farina, Di Mari, & Agnello, 2003). Specifically, sildenafil significantly improved orgasm beyond baseline and placebo conditions. Future placebo-controlled studies should clarify how sildenafil impacts orgasm among women with diagnosed orgasmic disorder.

*Antidepressant-induced anorgasmia.* As can be seen in Table 8, a there are a number of case reports and open-label studies in which success in alleviating SSRI-induced anorgasmia with various agents has been reported. Findings from the few placebo-controlled studies published are less optimistic. Michelson, Bancroft, Targum, Kim, and Tepner (2000) examined the comparative effects of 8 weeks of treatment with either buspirone (20 mg/day;  $n = 19$ ), amantadine (50 mg/day;  $n = 18$ ), or placebo ( $n = 20$ ) on fluoxetine-induced sexual dysfunction in premenopausal women reporting either impaired orgasm or sexual arousal. The authors reported all groups experienced an improvement in orgasm during treatment, but neither buspirone nor amantadine was more effective than placebo in restoring orgasmic function. At a higher dose level (mean daily dose = 47 mg), buspirone showed a marginally significant alleviation of sexual side effects in women taking either citalopram or paroxetine compared with placebo (Landen, Eriksson, Agren, & Fahlen, 1999). The authors did not distinguish between orgasm and desire disorders in either the classification of patients or treatment outcome. In a randomized, double-blind, parallel, placebo-controlled study of mirtazapine (15 mg/day), yohimbine (5.4 mg/day), olanzapine (.25



mg/day) or placebo for fluoxetine-induced sexual dysfunction, Michelson, Kociban, Tamura, and Morrison (2002) found no significant improvement in orgasmic ability beyond placebo in 107 women with either impaired orgasm or vaginal lubrication. Kang, Lee, Kim, and Cho (2002) reported no significant effect of Ginkgo-biloba beyond placebo in a small group of women with SSRI-induced sexual dysfunction. Meston (2004) reported no significant effect of ephedrine (50 mg 1-hr prior to intercourse) beyond placebo on orgasmic function in 19 women with sexual side effects secondary to either fluoxetine, sertraline, or paroxetine treatment (Level 1 evidence).

In summary, to date there are no pharmacological agents proven to be beneficial beyond placebo in enhancing orgasmic function in women. Placebo-controlled research is needed to examine the effectiveness of agents with demonstrated success in case series or open-label trials (i.e., granisetron, and sildenafil) on orgasmic function in women.

### *Summary on Treatment*

As in other areas of research on complex, multidetermined disorders, we would expect considerable benefit from comparing psychological to pharmacological techniques, and examining women's preferences with regards to treatment. Given that partner variables are under-researched, we lack a full description of the sociopsychological factors that play a role in women's orgasmic response, consistency, and relationship satisfaction and thus in the treatment of orgasmic disorders.

## References

- Ackerman, D. L., Greenland, S., & Bystritsky, A. (1999). Side effects as predictors of drug response in obsessive-compulsive disorder. *Journal of Clinical Psychopharmacology*, *19*, 459-465.
- Adkins, E., & Jehu, D. (1985). Analysis of a treatment program for primary orgasmic dysfunction. *Behaviour Research and Therapy*, *23*, 119-126.
- Ahlenius, S., Engel, J., Eriksson, H., Modigh, K., & Sodersten, P. (1972). Importance of central catecholamines in the mediation of lordosis behavior in ovariectomized rats treated with estrogen and inhibitors of monoamine synthesis. *Journal of Neural Transmission*, *33*, 247-255.
- Aizenberg, D., Naor, S., Zemishlany, Z., & Weizman, A. (1999). The serotonin antagonist mianserin for treatment of serotonin reuptake inhibitor-induced sexual dysfunction in women: An open-label add-on study. *Clinical Neuropharmacology*, *22*, 347-350.
- Alcantara, A. G. (1999). A possible dopaminergic mechanism in the serotonergic antidepressant-induced sexual dysfunctions. *Journal of Sex and Marital Therapy*, *25*, 125-129.
- American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4<sup>th</sup> ed., text rev.). Washington, DC: Author.
- American Spinal Injury Association. (1992). International standards for neurological and functional classification of spinal cord injury-revised 1992. Chicago: Author.
- Andersen, B. L. (1981). A comparison of systematic desensitization and directed mastur-



- bation in the treatment of primary orgasmic dysfunction in females. *Journal of Consulting and Clinical Psychology*, 49, 568-570.
- Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., et al. (1995). Bupropion: A review of its mechanism of antidepressant activity. *Journal of Clinical Psychiatry*, 56, 395-401.
- Ashton, A. K., & Rosen, R. C. (1998). Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction. *Journal of Clinical Psychiatry*, 59, 112-115.
- Baker, R. R., & Bellis, M. A. (1993). Human sperm competition: Ejaculate manipulation by females and a function for the female orgasm. *Animal Behavior*, 6, 887-909.
- Baker, R. R., & Bellis, M. A. (1995). *Human sperm competition: Copulation, masturbation and infidelity*. London: Chapman & Hall.
- Bancaud, J., Favel, P., Bonis, A., Bordas-Ferrer, M., Miravet, J., & Talarach, J. (1970). Manifestations sexuelles paroxytiques et epilepsie temporale [Sexual consequences of temporal epilepsy]. *Revue Neurologique*, 123, 217-230.
- Barbach, L. G. (1974). Group treatment of preorgasmic women. *Journal of Sex and Marital Therapy*, 1, 139-145.
- Barbach, L., & Flaherty, M. (1980). Group treatment of situationally orgasmic women. *Journal of Sex and Marital Therapy*, 6, 19-29.
- Bartoi, M. G., & Kinder, B. N. (1998). Effects of child and adult sexual abuse on adult sexuality. *Journal of Sex and Marital Therapy*, 24, 75-90.
- Basson, R. (1995). Sexuality and the menopause. *Journal of the Society of Obstetricians and Gynaecologists of Canada*, May(Suppl.), 10-15.
- Bateson, G., & Mead, M. (1942). *Balinese character: A photographic analysis*. New York: New York Academy of Sciences.
- Belzer, E. G. (1981). Orgasmic expulsions of women: A review and heuristic inquiry. *The Journal of Sex Research*, 17, 1-12.
- Berk, M., Stein, D. J., Potgieter, A., Maud, C. M., Els, C., Janet, M. L., et al., (2000). Serotonergic targets in the treatment of antidepressant induced sexual dysfunction: A pilot study of granisetron and sumatriptan. *International Clinical Psychopharmacology*, 15, 291-295.
- Berman, J. R., Berman, L. A., Lin, H., Flaherty, E., Lahey, N., Goldstein, I., et al., (2001). Effect of sildenafil on subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder. *Journal of Sex and Marital Therapy*, 27, 411-420.
- Berman, L. A., Berman, J. R., Bruck, D., Pawar, R. V., & Goldstein, I. (2001). Pharmacotherapy or psychotherapy? Effective treatment for FSD related to unresolved childhood sexual abuse. *Journal of Sex and Marital Therapy*, 27, 421-425.
- Billups, K. L., Berman, L., Berman, J., Metz, M. E., Glennon, M. E., & Goldstein, I. (2001). A new non-pharmacological vacuum therapy for female sexual dysfunction. *Journal of Sex and Marital Therapy*, 27, 435-441.
- Blakeney, P., Kinder, B. N., Creson, D., Powell, L. C., & Sutton, C. (1976). A short-term intensive workshop approach for the treatment of human sexual inadequacy. *Journal of Sex and Marital Therapy*, 2, 124-129.
- Bobes, J., Gonzalez, M. P., Bascaran, M. T., Clayton, A., Garcia, M., Rico-Villade Moros, F., et al., (2002). Evaluating changes in sexual functioning in depressed patients: Sensitivity to change of the CSFQ. *Journal of Sex and Marital Therapy*, 28, 93-103.
- Bogat, G. A., Hamernik, K., & Brooks, L. A. (1987). The influence of self-efficacy expectations on the treatment of preorgasmic women. *Journal of Sex and Marital Therapy*, 13, 128-136.
- Bohlen, G., & Held, J. P. (1979). An anal probe for monitoring vascular and muscular events during sexual response. *Psychophysiology*, 16, 381-323.
- Bohlen, G. J., Held, J. P., & Sanderson, M. O. (1982). Response of the circumvaginal musculature during masturbation. In B. Graber (Ed.), *Circumvaginal musculature and sexual function* (pp. 43-60). Basel: Kager.

- Bohlen, G., Held, J. P., Sanderson, M. O., & Ahlgren, A. (1982). The female orgasm: Pelvic contractions. *Archives of Sexual Behavior*, *11*, 367-386.
- Bohlen, G. J., Held, J. P., Sanderson, M. O., & Boyer, C. M. (1982). Development of a woman's multiple orgasm pattern: A research case report. *The Journal of Sex Research*, *18*, 130-145.
- Bors, E., & Comar, A. E. (1960). Neurological disturbances of sexual function with special reference to 529 patients with spinal cord injury. *Urological Survey*, *10*, 191-222.
- Boyersky, B. K., Haque, W., Rouleau, M. R., & Hirschfeld, R. M. (1999). Sexual functioning in depressed outpatients taking mirtazapine. *Depression and Anxiety*, *9*, 175-179.
- Bullough, B., David, M., Whipple, B., Dixon, J., Allgeier, E. R., & Drury, K. C. (1984). Subjective reports of female orgasmic expulsion of fluid. *Nurse Practitioner*, *9*, 55-59.
- Bulpitt, C. J., Beevers, D. G., Butler, A., Coles, E. C., Hunt, D., Munro-Faure, A. D., et al., (1989). The effects of anti-hypertensive drugs on sexual function in men and women: A report from the DHSS Hypertension Care Computing Project (DHCCP). *Journal of Human Hypertension*, *3*, 53-56.
- Burnett, A. L., Calvin, D. C., Silver, R. I., Peppas, D. S., & Docimo, S. G. (1997). Immunohistochemical description of nitric oxide synthetase isoforms in human clitoris. *Journal of Urology*, *158*, 75-78.
- Caggiula, A. R., Herndon, J. G., Scanlon, R., Greenstone, D., Bradshaw, W., & Sharp, D. (1979). Dissociation of active from immobility components of sexual behavior in female rats by central 6-hydroxydopamine: Implications for CA involvement in sexual behavior and sensorimotor responsiveness. *Brain Research*, *172*, 505-520.
- Campbell, B. (1976). Neurophysiology of the clitoris. In T. P. Lowry & T. S. Lowry (Eds.), *The clitoris* (pp. 35-74). St. Louis: Green.
- Carmichael, M. S., Warburton, V. L., Dixen, J., & Davidson, J. M. (1994). Relationship among cardiovascular, muscular, and oxytocin responses during human sexual activity. *Archives of Sexual Behavior*, *23*, 59-79.
- Carney, A., Bancroft, J., & Mathews, A. (1978). Combination of hormonal and psychological treatment for female sexual unresponsiveness: A comparative study. *British Journal of Psychiatry*, *132*, 339-346.
- Caruso, S., Intelisano, G., Farina, M., Di Mari, L., & Agnello, C. (2003). The function of sildenafil on female sexual pathways: A double-blind, cross-over, placebo-controlled study. *European Journal of Obstetrics and Gynecology and Reproductive Biology*, *110*, 201-206.
- Caruso, S., Intelisano, G., Lupo, L., & Agnello, C. (2001). Premenopausal women affected by sexual arousal disorder treated with sildenafil: A double-blind, cross-over, placebo-controlled study. *International Journal of Obstetrics and Gynecology*, *108*, 623-628.
- Cathcart, E. P., Gairns, F. W., & Garven, H. S. D. (1947-1948). XXIV- The innervation of the human quiescent nipple, with notes on pigmentation, erection, and hyperneury. *Transactions of the Royal Society of Edinburgh*, *LXI*, 699-717.
- Chambless, D. L., Sultan, F. E., Stern, T. E., O'Neill, C., Garrison, S., & Jackson, A. (1984). Effect of pubococcygeal exercise on coital orgasm in women. *Journal of Consulting and Clinical Psychology*, *52*, 114-118.
- Charlifue, S. W., Gerhart, K. A., Menter, R. R., Whiteneck, G. G., & Manley, M. S. (1992). Sexual issues of women with spinal cord injuries. *Paraplegia*, *30*, 192-199.
- Childress, A. R., Mozley, P. D., McElgin, W., Fitzgerald, J., Reivich, M., & O'Brien. (1999). Limbic activation during cue-induced cocaine craving. *American Journal of Psychiatry*, *156*, 11-18.
- Chung, S. K., McVary, K., & McKenna, K. E. (1988). Sexual reflexes in male and female rats. *Neuroscience Letters*, *94*, 343-384.
- Clayton, A. H., McGarvey, E. L., Abouesh, A. I., & Pinkerton, R. C. (2001). Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. *Journal of Clinical Psychiatry*, *62*, 185-190.
- Clifford, R. (1978). Subjective sexual experience in college women. *Archives of Sexual*



*Behavior*, 7, 183-197.

- Cocchia, D., Rende, M., Toesca, A., Viola, R., & Stolfi, V. M. (1990). Immunohistochemical study of neuropeptide Y-containing nerve fibers in the human clitoris and penis. *Cell Biology International Reports*, 14, 865-875.
- Cohen, A. J., & Bartlik, B. (1998). Ginkgo biloba for antidepressant-induced sexual dysfunction. *Journal of Sex and Marital Therapy*, 24, 139-143.
- Coleman, C. C., King, B. R., Bolden-Watson, C., Book, M. J., Seagraves, R. T., Richard, N., et al., (2001). A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. *Clinical Therapeutics*, 23, 1040-1058.
- Cooper, A. J. (1970). Frigidity, treatment and shortterm prognosis. *Journal of Psychosomatic Research*, 14, 133-147.
- Cotten-Huston, A. L., & Wheeler, K. A. (1983). Preorgasmic group treatment: Assertiveness, marital adjustment and sexual function in women. *Journal of Sex and Marital Therapy*, 9, 296-302.
- Czekanowski, R., Urban, J., & Latocha, W. (1971). The effect of adrenergic system receptor's blockade upon the contractility of vagina in vitro in women. *Ginekologia Polska*, 42, 843-847.
- Davidson, J. K., Darling, C. A., & Conway-Welch, C. (1989). The role of the Grafenberg spot and female ejaculation in the female orgasmic response: An empirical analysis. *Journal of Sex and Marital Therapy*, 15, 102-118.
- Davidson, J. M. (1980). The psychobiology of sexual experience. In J. M. Davidson & R. J. Davidson (Eds.), *The psychobiology of consciousness* (pp. 271-332). New York: Plenum.
- Davis, S. R., McCloud, P., Strauss, B. J. G., & Burger, H. (1995). Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. *Maturitas*, 21, 227-236.
- De Amicis, L., Goldberg, D. C., LoPiccolo, J., Friedman, J., & Davies, L. (1985). Clinical follow-up of couples treated for sexual dysfunction. *Archives of Sexual Behavior*, 14, 467-489.
- Delehanty, R. (1982). Changes in assertiveness and changes in orgasmic response occurring with sexual therapy for preorgasmic women. *Journal of Sex and Marital Therapy*, 8, 198-208.
- Derogatis, L. R. (1978). *Derogatis Sexual Functioning Inventory* (Rev. ed.). Baltimore, MD: Clinical Psychometrics Research.
- Devinsky, O., Morrell, M. J., & Vogt, B. A. (1995). Contributions of anterior cingulate cortex to behavior. *Brain*, 118, 279-306.
- Dickinson, R. L. (1949). *Human sex anatomy* (2<sup>nd</sup> ed.). Baltimore: Williams and Wilkins.
- Dodge, L. J. T., Glasgow, R. E., & O'Neill, H. K. (1982). Bibliotherapy in the treatment of female orgasmic dysfunction. *Journal of Consulting and Clinical Psychology*, 50, 442-443.
- Duncan, C. H., & Taylor, H. C. (1952). A psychosomatic study of pelvic congestion. *American Journal of Obstetrics and Gynecology*, 63, 1-13.
- Duncan, L. E., Lewis, C., Jenkins, P., & Pearson, T. A. (2000). Does hypertension and its pharmacotherapy affect the quality of sexual function in women? *American Journal of Hypertension*, 13, 640-647.
- Duncan, S., Blacklaw, J., Beastall, G. H., & Brodie, M. J. (1997). Sexual function in women with epilepsy. *Epilepsia*, 38, 1074-1081.
- Eichel, E. W., Eichel, J. D., & Kule, S. (1988). The technique of coital alignment and its relation to female orgasmic response and simultaneous orgasm. *Journal of Sex and Marital Therapy*, 14, 129-141.
- Eicher, W., & Muck, A. O. (1996). Treatment of estrogen deficiency-induced sex disorders. *Gynakologisch-Geburtshilfliche Rundschau*, 36, 83-89.
- Erickson, K. L., & Montagna, W. (1972). New observations on the anatomical features of the female genitalia. *Journal of the American Medical Women's Association*, 27, 573-581.
- Ersner-Hersfield, R., & Kopel, S. (1979). Group treatment of preorgasmic women: Evalu-



- ation of partner involvement and spacing of sessions. *Journal of Consulting and Clinical Psychology*, 47, 750-759.
- Everaerd, W., & Dekker, J. (1982). Treatment of secondary orgasmic dysfunction: A comparison of systematic desensitization and sex therapy. *Behaviour Research and Therapy*, 20, 269-274.
- Faix, A., Lapray, J. F., Callede, O., Maubon, A., & Lanfrey, K. (2002). Magnetic resonance imaging (MRI) of sexual intercourse: Second experience in missionary position and initial experience in posterior position. *Journal of Sex and Marital Therapy*, 28, 63-76.
- Faix, A., Lapray, J. F., Courtieu, C., Maubon, A., & Lanfrey, K. (2001). Magnetic resonance imaging of sexual intercourse: Initial experience. *Journal of Sex and Marital Therapy*, 27, 475-481.
- Feiger, A., Kiev, A., Shrivastava, R. K., Wisselink, P. G., & Wilcox, C. S. (1996). Nefazodone versus sertraline in outpatients with major depression: Focus on efficacy, tolerability, and effects on sexual function and satisfaction. *Journal of Clinical Psychiatry*, 57(Suppl. 2), 53-62.
- Feinauer, L. L. (1989). Sexual dysfunction in women sexually abused as children. *Contemporary Family Therapy*, 11, 299-309.
- Fisher, C., Cohen, H. D., Schiavi, R. C., Davis, D., Furman, B., Ward, K., et al., (1983). Patterns of female sexual arousal during sleep and waking: Vaginal thermo-conductance studies. *Archives of Sexual Behavior*, 12, 97-122.
- Fisher, S. (1973). *The female orgasm*. New York: Basic Books.
- Fitcher, C. S., Libman, E., & Brender, W. (1983). Methodological issues in the study of sex therapy: Effective components in the treatment of secondary orgasmic dysfunction. *Journal of Sex and Marital Therapy*, 9, 191-202.
- Foucault, M. (1980). *The history of sexuality*. New York: Vintage.
- Fox, C. A., Wolff, H. S., & Baker, J. A. (1970). Measurement of intra-vaginal and intra-uterine pressures during human coitus by radiotelemetry. *Journal of Reproduction and Fertility*, 22, 243-251.
- Francis, S., Rolls, E. T., Bowtell, R., McGlone, F., O'Doherty, J., Browning, A., et al., (1999). The representation of pleasant touch in the brain and its relationship with taste and olfactory areas. *NeuroReport*, 10, 453-459.
- Geer, J. H., & Quartararo, J. (1976). Vaginal blood volume responses during masturbation. *Archives of Sexual Behavior*, 5, 403-413.
- Gelenberg, A. J., Laukes, C., McGahuey, C., Okayli, G., Moreno, F., Zentner, L., et al., (2000). Mirtazapine substitution in SSRI-induced sexual dysfunction. *Journal of Clinical Psychiatry*, 61, 356-360.
- Gerstenburg, T. C., Levin, R. J., & Wagner, G. (1990). Erection and ejaculation in man. Assessment of the electromyographic activity of the bulbocavernosus and ischiocavernosus muscles. *British Journal of Urology*, 65, 395-402.
- Ghadirian, A. M., Chouinard, G., & Annable, L. (1982). Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. *Journal of Nervous and Mental Disease*, 170, 463-467.
- Gillan, P., & Brindley, G. S. (1979). Vaginal and pelvic floor responses to sexual stimulation. *Psychophysiology*, 16, 471-481.
- Gitlin, M. J., Suri, R., Altshuler, L., Zuckerbrow-Miller, J., & Fairbanks, L. (2002). Bupropion-sustained release as a treatment for SSRI-induced sexual side effects. *Journal of Sex and Marital Therapy*, 28, 131-138.
- Giuliano, F., Allard, J., Compagnie, S., Alexandre, L., Droupy, S., & Bernabe, J. (2001). Vaginal physiological changes in a model of sexual arousal in anesthetized rats. *American Journal of Physiology—Regulatory Integrative Comparative Physiology*, 281, R140-R149.
- Giuliano, F., Rampin, O., & Allard, J. (2002). Neurophysiology and pharmacology of female genital sexual response. *Journal of Sex and Marital Therapy*, 28(Suppl. 1), 101-121.
- Goldberg, D. C., Whipple, B., Fishkin, R. E., Waxman, H., Fink, P. J., & Weisber, M.

- (1983). The Grafenberg spot and female ejaculation: A review of initial hypotheses. *Journal of Sex and Marital Therapy*, 9, 27-37.
- Golden, J. S., Price, S., Heinrich, A. G., & Lobitz, W. C. (1978). Group vs. couple treatment of sexual dysfunctions. *Archives of Sexual Behavior*, 7, 593-602.
- Graber, B. (Ed.). (1982). *Circumvaginal musculature and vaginal function*. Basel: Karger.
- Grafenberg, E. (1950). The role of urethra in female orgasm. *International Journal of Sexology*, 333, 145-148.
- Grimes, D. A. (1999). Role of the cervix in sexual response: Evidence for and against. *Clinical Obstetrics and Gynecology*, 42, 972-978.
- Grimm, R. H., Grandits, G. A., Prineas, R. J., McDonald, R. H., Lewis, C. E., Flack, J. M., et al., (1997). Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). *Hypertension*, 29, 8-14.
- Hamburger-Bar, R., & Rigter, H. (1975). Apomorphine: Facilitation of sexual behaviour in female rats. *European Journal of Pharmacology*, 32, 357-360.
- Harrison, J., Glass, C. A., Owens, R. G., & Soni, B. M. (1995). Factors associated with sexual function in women following spinal cord injury. *Paraplegia*, 33, 687-692.
- Hauser-Kronberger, C., Cheung, A., Hacker, G. W., Graf, A. H., Dietze, O., & Frick, J. (1999). Peptidergic innervation of the human clitoris. *Peptides*, 20, 539-543.
- Heath, R. G. (1972). Pleasure and brain activity in man. *Journal of Nervous and Mental Disease*, 154, 3-18.
- Heiman, J. R. (2000). Orgasmic disorders in women. In S. R. Leiblum & R. C. Rosen (Eds.), *Principles and practice of sex therapy* (3<sup>rd</sup> ed., pp. 118-153). New York: Guilford.
- Heiman, J. R., & LoPiccolo, J. (1983). Clinical outcome of sex therapy. *Archives of General Psychiatry*, 40, 443-449.
- Heinrich, A. G. (1976). The effect of group and self-directed behavioral-educational treatment of primary orgasmic dysfunction in females treated without their partners. (Doctoral dissertation, University of Colorado at Boulder, 1976). *Dissertation Abstracts International*, 37, 1902.
- Henson, D. E., Rubin, H. B., & Henson, C. (1982). Labial and vaginal blood volume responses to visual and tactile stimuli. *Archives of Sexual Behavior*, 11, 23-31.
- Henson, D. E., Rubin, H. B., Henson, C., & Williams, J. R. (1977). Temperature changes of the labia minora as an objective measure of female eroticism. *Journal of Behavior Therapy and Experimental Psychiatry*, 8, 401-410.
- Herd, G. (1981). *Guardians of the flutes: Idioms of masculinity*. New York: McGraw Hill.
- Hilleges, M., Falconer, C., Ekman-Ordeberg, G., & Johansson, O. (1995). Innervation of the human vaginal mucosa as revealed by PGP 9.5 immunohistochemistry. *Acta Anatomica*, 153, 119-126.
- Hite, S. (1976). *The Hite report: A nationwide study of female sexuality*. New York: MacMillan.
- Hoch, Z. (1986). Vaginal erotic sensitivity by sexological examination. *Acta Obstetrica et Gynecologica Scandinavica*, 65, 767-773.
- Hollender, M. H. (1970). The need or wish to be held. *Archives of General Psychiatry*, 22, 445-453.
- Holstege, G. (1991). Descending pathways from the periaqueductal gray and adjacent areas. In the midbrain periaqueductal gray matter: Functional, anatomical, and neurochemical organization. *NATO ASI Series*, 213, 239-265.
- Hoyle, C. H., Stones, R. W., Robson, T., Whitley, K., & Burnstock, G. (1996). Innervation of the vasculature and microvasculature of the human vagina by NOS and neuropeptide-containing nerves. *Journal of Anatomy*, 188, 633-644.
- Huffman, J. W. (1948). The detailed anatomy of the pararethral ducts in the adult human female. *American Journal of Obstetrics and Gynecology*, 55, 86-101.
- Hull, E. M., & Dominguez, J. M. (2003). Sex behavior. In R. J. Nelson & M. Gallagher (Eds.), *Comprehensive handbook of psychology: Biological psychology* (Vol. 3, pp. 321-



- 353). New York: Wiley.
- Hummer, M., Kemmler, G., Kurz, M., Kurzthaler, I., Oberbauer, H., & Fleischhacker, W. W. (1999). Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. *American Journal of Psychiatry*, *156*, 631-633.
- Hurlbert, D. F., & Apt, C. (1995). The Coital Alignment Technique and directed masturbation: A comparative study on female orgasm. *Journal of Sex and Marital Therapy*, *21*, 21-29.
- Husted, J. R. (1972). The effect of method of systematic desensitization and presence of sexual communication in the treatment of female sexual anxiety by counterconditioning. (Doctoral dissertation, University of California at Los Angeles, 1972). *Dissertation Abstracts International*, *33*, 441.
- Husted, J. R. (1975). Desensitization procedures in dealing with female sexual dysfunction. *Counseling Psychology*, *5*, 3037.
- Ingelman-Sundberg, A. (1997). The anterior vaginal wall as an organ for the transmission of active forces to the urethra and clitoris. *International Urogynecology Journal and Pelvic Floor Dysfunction*, *8*, 50-51.
- Ito, T. Y., Trant, A. S., & Polan, M. L. (2001). A double-blind placebo-controlled study of ArginMax, a nutritional supplement for enhancement of female sexual function. *Journal of Sex and Marital Therapy*, *27*, 541-549.
- Jackson, A. B., & Wadley, V. (1999). A multicenter study of women's self-reported reproductive health after spinal cord injury. *Archives of Physical Medicine and Rehabilitation*, *80*, 1420-1428.
- Jacobs, L. S., & Daughaday, W. (1974). Physiologic regulation of prolactin secretion in man. In J. B. Josimovich, M. Reynolds, & E. Cobo (Eds.), *Lactogenic hormones, fetal nutrition and lactation* (pp. 351-378). New York: Wiley.
- Jankovich, R., & Miller, P. R. (1978). Response of women with primary orgasmic dysfunction to audiovisual education. *Journal of Sex and Marital Therapy*, *4*, 16-19.
- Janszky, J., Szucs, A., Halasz, P., Borbely, C., Hollo, A., Barsi, P., et al. (2002). Orgasmic aura originates from the right hemisphere. *Neurology*, *58*, 302-304.
- Johns, A. (1997). Supracervical versus hysterectomy. *Clinical Obstetrics and Gynecology*, *40*, 903-913.
- Jones, F. W., & Turner, J. B. (1931). A note on the sensory characters of the nipple and areola. *Medical Journal of Australia*, *1*, 778.
- Jones, W., & Park, P. (1972). Treatment of single partner sexual dysfunction by systematic desensitization. *Obstetrics and Gynecology*, *39*, 411-417.
- Kang, B., Lee, S., Kim, M., & Cho, M. (2002). A placebo-controlled, double-blind trial of ginkgo biloba for antidepressant-induced sexual dysfunction. *Human Psychopharmacology*, *17*, 279-284.
- Kaplan, H. S. (1974). *The new sex therapy: Active treatment of sexual dysfunction*. New York: Brunner-Mazel.
- Kaplan, H. S. (1992). Does the CAT technique enhance female orgasm? *Journal of Sex and Marital Therapy*, *18*, 285-291.
- Kaplan, S. A., Reis, R. B., Kohn, I. J., Ikeguchi, E. F., Laor, E., Te, A. E., et al. (1999). Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. *Urology*, *53*, 481-486.
- Karama, S., Lecours, A. R., Leroux, J. M., Bourgoign, P., Beaudoin, G., Joubert, S., et al. (2002). Areas of brain activation in males and females during viewing of erotic film excerpts. *Human Brain Mapping*, *16*, 1-13.
- Kato, A., & Sakuma, Y. (2000). Neuronal activity in female rat preoptic area associated with sexually motivated behavior. *Brain Research*, *862*, 90-102.
- Kavoussi, R. J., Segraves, R. T., Hughes, A. R., Ascher, J. A., & Johnston, J. A. (1997). Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. *Journal of Clinical Psychiatry*, *58*, 532-537.
- Kegel, A. H. (1952). Sexual functions of the pubococcygeus muscle. *Western Journal of*

- Surgical Obstetrics and Gynecology*, 60, 521-524.
- Kennedy, S. H., Eisfeld, B. S., Dickens, S. E., Bacchiochi, J. R., & Bagby, R. M. (2000). Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. *Journal of Clinical Psychiatry*, 61, 276-281.
- Kettl, P., Zarefoss, S., Jacoby, K., Garman, C., Hulse, C., Rowley, F., et al. (1991). Female sexuality after spinal cord injury. *Sexuality and Disability*, 9, 287-295.
- Kilmann, P. R., Milan, R. J., Boland, J. P., Mills, K. H., Caid, C., Davidson, E., et al., (1987). The treatment of secondary orgasmic dysfunction II. *Journal of Sex and Marital Therapy*, 13, 93105.
- Kilmann, P. R., Mills, K. H., Bella, B., Caid, C., Davidson, E., Drose, G., et al., (1983). The effects of sex education on women with secondary orgasmic dysfunction. *Journal of Sex and Marital Therapy*, 9, 79-87.
- Kilmann, P. R., Mills, K. H., Caid, C., Davidson, E., Bella, B., Milan, R., et al., (1986). Treatment of secondary orgasmic dysfunction: An outcome study. *Archives of Sexual Behavior*, 15, 211-229.
- Kinsey, A. C., Pomeroy, W. D., Martin, C. E., & Gebhard, P. H. (1953). *Sexual behaviour in the human female*. Philadelphia: W.B. Saunders.
- Kirkpatrick, C., McGovern, K., & Lo Piccolo, J. (1977). Treatment of sexual dysfunction. In G. G. Harris (Ed.), *The group treatment of human problems*. New York: Grune & Stratton.
- Kokcu, A., Cetinkaya, M. B., Yanik, F., Alper, T., & Malatyalioglu, E. (2000). The comparison of effects of tibolone and conjugated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. *Maturitas*, 36, 75-80.
- Kolodny, R. C., Jacobs, L. S., & Daughaday, W. H. (1972). Mammary stimulation causes prolactin secretion in non-lactating women. *Nature*, 238, 284.
- Komisaruk, B. R., Bianca, R., Sansone, G., Gomez, L. E., Cueva-Rolon, R., Beyer, C., et al., (1996). Brain-mediated responses to vaginocervical stimulation in spinal cord-transected rats: Role of the vagus nerves. *Brain Research*, 708, 128-134.
- Komisaruk, B. R., Whipple, B., Crawford, A., Grimes, S., Kalnin, A. J., Mosier, K., et al., (2002). Brain activity (fMRI and PET) during orgasm in women, in response to vaginocervical self-stimulation. [Abstract]. *Society for Neuroscience*, 841, 17.
- Krantz, K. E. (1958). Innervation of the human vulva and vagina. *Obstetrics and Gynecology*, 12, 382-296.
- Kratochvil, S. (1994). Vaginal contractions in female orgasm. *Ceskoslovenska Psychiatrie*, 90, 28-33.
- Kreuter, M., Sullivan, M., & Siosteen, A. (1996). Sexual adjustment and quality of relationship in spinal paraplegia: A controlled study. *Paraplegia*, 77, 541-548.
- Kruger, T. H. C., Haake, P., Hartman, U., Schedlowski, M., & Exton, M. S. (2002). Orgasm-induced prolactin secretion: Feedback control of sexual drive. *Neuroscience and Biobehavioral Reviews*, 26, 31-44.
- Kuriansky, J. B., Sharpe, L., & O'Connor, D. (1982). The treatment of anorgasmia: Long-term effectiveness of a short-term behavioral group therapy. *Journal of Sex and Marital Therapy*, 8, 29-43.
- Laan, E., & Everaerd, W. (1995). Determinants of female sexual arousal: Psychophysiological theory and data. *Annual Review of Sex Research*, 6, 32-76.
- Laan, E., van Lunsen, R. H. W., Everaerd, W., Riley, A., Scott, E., & Boolell, M. (2002). The enhancement of vaginal vasocongestion by sildenafil in healthy premenopausal women. *Journal of Women's Health and Gender-Based Medicine*, 11, 357-365.
- Labbate, L. A., Grimes, J., Hines, A., Oleshansky, M. A., & Arana, G. W. (1998). Sexual dysfunction induced by serotonin reuptake antidepressants. *Journal of Sex and Marital Therapy*, 24, 3-12.
- Ladas, A. K., Whipple, B., & Perry, J. D. (1982). *The G-spot and other recent discoveries about human sexuality*. New York: Holt, Rinehart & Winston.
- Landen, M., Eriksson, E., Agren, H., & Fahlen, T. (1999). Effect of buspirone on sexual



- dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. *Journal of Clinical Psychopharmacology*, 19, 268-271.
- Lane, R. D., Reiman, E. M., Ahern, G. L., Schwartz, G. E., & Davidson, R. J. (1997). Neuroanatomical correlates of happiness, sadness, and disgust. *American Journal of Psychiatry*, 154, 926-933.
- Laqueur, T. (1990). *Making sex: Body and gender from the Greeks to Freud*. Cambridge, MA: Harvard University Press.
- Lauerma, H. (1995). A case of moclobemide-induced hyperorgasmia. *International Clinical Psychopharmacology*, 10, 123-124.
- Laumann, E. O., Gagnon, J. H., Michael, R. T., & Michaels, S. (1994). *The social organization of sexuality: Sexual practices in the United States*. Chicago: University of Chicago Press.
- Lazarus, A. (1963). The treatment of chronic frigidity by systematic desensitization. *Journal of Nervous and Mental Disease*, 136, 272-278.
- Leiblum, S. R., & Ersner-Hersfield, R. (1977). Sexual enhancement groups for dysfunctional women: An evaluation. *Journal of Sex and Marital Therapy*, 3, 139-152.
- Levin, R. J. (1980). The physiology of sexual function in women. *Clinical Obstetrics and Gynecology*, 7, 213-252.
- Levin, R. J. (1983). Human female sexual arousal: An update. *Nordic Sexology*, 1, 138-151.
- Levin, R. J. (1992). The mechanisms of human female sexual arousal. *Annual Review of Sexual Research*, 3, 1-48.
- Levin, R. J. (1997). Assessing human female sexual arousal by vaginal photoplethysmography: A critical examination. *European Journal of Medical Sexology*, 6, 25-31.
- Levin, R. J. (1999a). The impact of the menopause on the physiology of genital function. *Menopause Review*, IV, 23-31.
- Levin, R. J. (1999b). Measuring the menopause genital changes: A critical account of laboratory procedures past and for the future. *Menopause Review*, IV, 49-57.
- Levin, R. J. (2001). Sexual desire and the deconstruction and reconstruction of the human female sexual response model of Masters and Johnson. In W. Everaerd, E. Laan, & S. Both (Eds.), *Sexual appetite, desire and motivation: Energetics of the sexual system* (pp. 63-93). Amsterdam: Royal Netherlands Academy of Arts and Sciences.
- Levin, R. J. (2002). The physiology of sexual arousal in the human female: A recreational and procreational synthesis. *Archives of Sexual Behavior*, 31, 405-411.
- Levin, R. J. (2003a). Do women gain anything from coitus apart from pregnancy? Changes in the human female genital tract activated by coitus. *Journal of Sex and Marital Therapy*, 29, 59-69.
- Levin, R. J. (2003b). The physiology of male and female sexual arousal. In J. Paynes-James, A. Busuttill, & B. Smock (Eds.), *Forensic Medicine* (pp. 277-389). England: Greenwich Medical Media.
- Levin, R. J., & Wagner, G. (1980). Sexual arousal in women: Which haemodynamic measure gives the best assessment? *Journal of Physiology, London*, 302, 22-23P.
- Levin, R. J., & Wagner, G. (1985). Orgasm in women in the laboratory: Quantitative studies on duration, intensity, latency, and vaginal blood flow. *Archives of Sexual Behavior*, 14, 439-449.
- Levin, R. J., Wagner, G., & Ottesen, B. (1981). Simultaneous monitoring of human vaginal haemodynamics by three independent methods during sexual arousal. In Z. Hoch & H. I. Lief (Eds.), *Sexology* (pp. 114-120). Amsterdam: Elsevier.
- Levine, L. (1948). A criterion for orgasm in the female. *Marriage Hygiene*, 1, 173.
- Li, C. H., Dixon, J. S., Schmidt, K. D., Pankov, Y. A., & Lo, T. B. (1969). Amino and carboxy-terminal sequences of ovine lactogenic hormone. *Nature*, 222, 1268-1269.
- Libman, E., Fichten, C. S., Brender, W., Burstein, R., Cohen, J., & Binik, Y. M. (1984). A comparison of three therapeutic formats in the treatment of secondary orgasmic dysfunction. *Journal of Sex and Marital Therapy*, 10, 147-159.
- Lobitz, W. C., & LoPiccolo, J. (1972). New Methods in the behavioral treatment of orgas-

- mic dysfunction. *Journal of Behavior Therapy and Experimental Psychiatry*, 3, 265-271.
- LoPiccolo, J., & Lobitz, W. C. (1972). The role of masturbation in the treatment of orgasmic dysfunction. *Archives of Sexual Behavior*, 2, 163-171.
- LoPiccolo, J., Heiman, J. R., Hogan, D. R., & Roberts, C. W. (1985). Effectiveness of single therapist versus cotherapy teams in sex therapy. *Journal of Consulting and Clinical Psychology*, 53, 287-294.
- Mah, K., & Binik, Y. M. (2001). The nature of human orgasm: A critical review of major trends. *Clinical Psychology Review*, 21, 823-856.
- Malleson, J. (1948). A criterion for orgasm in the female. II. *Marriage Hygiene*, 1, 174.
- Mani, S. K., Allen, J. M., Clark, J. H., Blaustein, J. D., & O'Malley, B. W. (1994). Convergent pathways for steroid hormone- and neurotransmitter-induced rat sexual behavior. *Science*, 265, 1246-1249.
- Marshall, D. S. (1971). Sexual behavior on Mangaia. In D. S. Marshall & R. C. Suggs (Eds.), *Human sexual behavior: Variations in the ethnographic spectrum* (pp. 103-162). New York: Basic Books.
- Marson, L. (1995). Central nervous system neurons identified after injection of pseudorabies virus into the rat clitoris. *Neuroscience Letters*, 190, 41-44.
- Marson, L., & McKenna, K. E. (1992). A role for 5-hydroxytryptamine in descending inhibition of spinal sexual reflexes. *Experimental Brain Research*, 88, 313-320.
- Marson, L., & McKenna, K. E. (1994). Stimulation of the hypothalamus initiates the urethrogenital reflex in male rats. *Brain Research*, 638, 103-108.
- Marson, L., Platt, K. B., & McKenna, K. E. (1993). Central nervous system innervation of the penis as revealed by the transneuronal transport of pseudorabies virus. *Neuroscience*, 55, 263-280.
- Masand, P. S., Ashton, A. K., Gupta, S., & Frank, B. (2001). Sustained-release bupropion for selective serotonin reuptake inhibitor-induced sexual dysfunction: A randomized, double-blind, placebo-controlled, parallel-group study. *American Journal of Psychiatry*, 158, 805-807.
- Masters, W. H., & Johnson, V. (1966). *Human sexual response*. Boston: Little, Brown.
- Masters, W. H., & Johnson, V. E. (1970). *Human sexual inadequacy*. London: Churchill.
- Mathews, A., Bancroft, J., Whitehead, A., Hackmann, A., Julier, D., Bancroft, J., et al., (1976). The behavioral treatment of sexual inadequacy: A comparative study. *Behaviour Research and Therapy*, 14, 427-436.
- Matuszewich, L., Lorrain, D. S., & Hull, E. M. (2000). Dopamine alterations in the medial preoptic area of female rats in response to hormonal manipulation and sexual activity. *Behavioral Neuroscience*, 114, 772-782.
- McCabe, M. P. (2001). Evaluation of a cognitive behavior therapy program for people with sexual dysfunction. *Journal of Sex and Marital Therapy*, 27, 259-271.
- McGovern, K. B., Stewart, R. C., & LoPiccolo, J. (1975). Secondary orgasmic dysfunction: Analysis and strategies for treatment. *Archives of Sexual Behavior*, 4, 265-275.
- McKenna, K. E. (1999). Orgasm. In E. Knobil & J. D. Neill (Eds.), *Encyclopedia of reproduction* (Vol. 3, pp. 528-531). New York: Academic Press.
- McKenna, K. E., Chung, S. K., & McVary, K. T. (1991). A model for the study of sexual function in anesthetized male and female rats. *American Journal of Physiology*, 30, R1276-R1285.
- McKenna, K. E., & Nadelhaft, I. (1986). The organization of the pudendal nerve in the male and female rat. *Journal of Comparative Neurology*, 248, 532-549.
- McKenna, K. E., & Nadelhaft, I. (1989). The pudendo-pudendal reflex in male and female rats. *Journal of the Autonomic Nervous System*, 27, 67-77.
- McMullen, S., & Rosen, R. C. (1979). Self administered masturbation training in the treatment of primary orgasmic dysfunction. *Journal of Consulting and Clinical Psychology*, 47, 912-918.
- Mead, M. (1949). *Male and female*. New York: William Morrow.



- Melis, M. R., Stancampiano, R., & Argiolas, A. (1992). Hippocampal oxytocin mediates apomorphine-induced penile erection and yawning. *Pharmacology, Biochemistry and Behavior*, *42*, 61-66.
- Melis, M. R., Succu, S., & Argiolas, A. (1996). Dopamine agonists increase nitric oxide production in the paraventricular nucleus of the hypothalamus: Correlation with penile erection and yawning. *European Journal of Neuroscience*, *8*, 2056-2063.
- Meston, C. M. (2000). Sympathetic nervous system activity and female sexual arousal. *American Journal of Cardiology*, *86*(2A), 30-34.
- Meston, C. M. (2004). A randomized, placebo-controlled, crossover study of ephedrine for SSRI-induced female sexual dysfunction. *Journal of Sex and Marital Therapy*, *30*, 57-68.
- Meston, C. M., & Gorzalka, B. B. (1995). The effects of sympathetic activation following acute exercise on physiological and subjective sexual arousal in women. *Behaviour Research and Therapy*, *33*, 651-664.
- Meston, C. M., & Gorzalka, B. B. (1996a). The differential effects of sympathetic activation on sexual arousal in sexually functional and dysfunctional women. *Journal of Abnormal Psychology*, *105*, 582-591.
- Meston, C. M., & Gorzalka, B. B. (1996b). The effects of immediate, delayed, and residual sympathetic activation on physiological and subjective sexual arousal in women. *Behaviour Research and Therapy*, *34*, 143-148.
- Meston, C. M., Gorzalka, B. B., & Wright, J. M. (1997). Inhibition of subjective and physiological sexual arousal in women by clonidine. *Journal of Psychosomatic Medicine*, *59*, 399-407.
- Meston, C. M., & Heiman, J. R. (1998). Ephedrine-activated sexual arousal in women. *Archives of General Psychiatry*, *55*, 652-656.
- Meston, C. M., Heiman, J. R., & Trapnell, P. D. (1999). The relation between early abuse and adult sexuality. *The Journal of Sex Research*, *36*, 385-395.
- Meston, C. M., & Worcel, M. (2002). The effects of yohimbine plus L-arginine glutamate on sexual arousal in postmenopausal women with Sexual Arousal Disorder. *Archives of Sexual Behavior*, *31*, 323-332.
- Michelson, D., Bancroft, J., Targum, S., Kim, Y., & Tepner, R. (2000). Female sexual dysfunction associated with antidepressant administration: A randomized, placebo-controlled study of pharmacologic intervention. *American Journal of Psychiatry*, *157*, 239-243.
- Michelson, D., Kociban, K., Tamura, R., & Morrison, M. F. (2002). Mirtazapine, yohimbine, or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: A randomized, placebo controlled trial. *Journal of Psychiatric Research*, *36*, 147-152.
- Michelson, D., Schmidt, M., Lee, J., & Tepner, R. (2001). Changes in sexual function during acute and six-month fluoxetine therapy: A prospective assessment. *Journal of Sex and Marital Therapy*, *27*, 289-302.
- Milan, R. J., Kilmann, P. R., & Boland, J. P. (1988). Treatment outcome of secondary orgasmic dysfunction: A two- to six-year follow-up. *Archives of Sexual Behavior*, *17*, 463-480.
- Modell, J. G., Katholi, C. R., Modell, J. D., & DePalma, R. L. (1997). Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. *Clinical Pharmacology and Therapeutics*, *61*, 476-487.
- Modell, J. G., May, R. S., & Katholi, C. R. (2000). Effect of bupropion-SR on orgasmic dysfunction in nondepressed subjects: A pilot study. *Journal of Sex and Marital Therapy*, *26*, 231-240.
- Money, J. (1960). Phantom orgasm in the dreams of paraplegic men and women. *Archives of General Psychiatry*, *3*, 372-383.
- Montejo-Gonzalez, A. L., Llorca, G., Izquierdo, J. A., Ledesma, A., Bousono, M., Calcedo, A., et al., (1997). SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344

- patients. *Journal of Sex and Marital Therapy*, 23, 176-194.
- Montejo, A. L., Llorca, G., Izquierdo, J. A., & Rico-Villademoros, F. (2001). Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. *Journal of Clinical Psychiatry*, 62(Suppl. 3), 10-21.
- Morokoff, P. J., & LoPiccolo, J. (1986). A comparative evaluation of minimal therapist contact and 15-session treatment for female orgasmic dysfunction. *Journal of Consulting and Clinical Psychology*, 54, 294-300.
- Morris, J. S., Frith, C. D., Perrett, D. I., Rowland, D., Young, A. W., Calder, A. J., et al., (1996). A differential neural response in the human amygdala to fearful and happy facial expressions. *Nature*, 383, 812-815.
- Mould, D. E. (1980). Neuromuscular aspects of women's orgasms. *The Journal of Sex Research*, 16, 193-201.
- Mould, D. E. (1982). Women's orgasm and the muscle spindle. In B. Graber (Ed.), *Circumvaginal musculature and vaginal function* (pp. 93-100). Basel: Karger.
- Munarriz, R., Talakoub, L., Flaherty, E., Gioia, M., Hoag, L., Kim, N. N., et al., (2002). Androgen replacement therapy with dehydroepiandrosterone for androgen insufficiency and female sexual dysfunction: Androgen and questionnaire results. *Journal of Sex and Marital Therapy*, 28(Suppl. 1), 165-173.
- Munjack, D., Cristol, A., Goldstein, A., Phillips, D., Goldberg, A., Whipple, K., et al., (1976). Behavioral treatment of orgasmic dysfunction: A controlled study. *British Journal of Psychiatry*, 129, 497-502.
- Murphy, A. Z., Rizvi, T. A., Ennis, M., & Shipley, M. T. (1999). The organization of preoptic-medullary circuits in the male rat: Evidence for interconnectivity of neural structures involved in reproductive behavior, antinociception and cardiovascular regulation. *Neuroscience*, 91, 1103-1116.
- Nathorst-Boos, J., von Schoultz, B., & Carlstrom, K. (1993). Elective ovarian removal and estrogen replacement therapy: Effects on sexual life, psychological well-being and androgen status. *Journal of Psychosomatic Obstetrics and Gynecology*, 14, 283-293.
- Nemetz, G. H., Craig, K. D., & Reith, G. (1978). Treatment of female sexual dysfunction through symbolic modeling. *Journal of Consulting and Clinical Psychology*, 46, 62-73.
- Nurnberg, H. G., Hensley, P. L., Lauriello, J., Parker, L. M., & Keith, S. J. (1999). Sildenafil for women patients with antidepressant-induced sexual dysfunction. *Psychiatric Services*, 50, 1076-1078.
- O'Connell, H. E., Hutson, J. M., Anderson, C. R., & Plenter, R. J. (1998). Anatomical relationship between urethra and clitoris. *Journal of Anatomy*, 159, 1892-1897.
- O'Gorman, E. C. (1978). The treatment of frigidity: A comparative study of group and individual desensitization. *British Journal of Psychiatry*, 132, 580-584.
- Obler, M. (1973). Systematic desensitization in sexual disorders. *Journal of Behavior Therapy and Experimental Psychiatry*, 4, 93-101.
- Obler, M. (1982). A comparison of a hypnoanalytic/behavior modification technique and a cotherapist-type treatment with primary orgasmic dysfunctional females: Some preliminary results. *The Journal of Sex Research*, 18, 331-345.
- Ogawa, S., Kow, L. M., McCarthy, M. M., Pfaff, D. W., & Schwartz-Giblin, S. (1991). Mid-brain PAG control of female reproductive behavior: In vitro electrophysiological characterization of actions of lordosis-relevant substances. In A. Depaulis & R. Bandler (Eds.), *The midbrain periaqueductal gray matter: Functional, anatomical and neurochemical organization* (pp. 211-235). New York: Plenum.
- Ortega-Villalobos, M., Garcia-Bazan, M., Solano-Flores, L. P., Ninomiya-Alarcon, J. G., Guvares-Guzman, R., & Wayner, M. J. (1990). Vagus nerve afferent and efferent innervation of the rat uterus: An electrophysiological and HRP study. *Brain Research Bulletin*, 25, 365-371.
- Palle, C., Bredkjaer, H. E., Fahrenkrug, J., & Ottesen, B. (1991). Vasoactive intestinal polypeptide loses its ability to increase vaginal blood flow after menopause. *American Journal of Obstetrics and Gynecology*, 164, 556-558.



- Palti, Y., & Bercovici, B. (1967). Photoplethysmographic study of the vaginal blood pulse. *American Journal of Obstetrics and Gynecology*, *97*, 143-153.
- Park, K., Kang, H. K., Seo, J. J., Ryu, S. B., & Jeong, G. W. (2001). Blood-oxygenation-level-dependent functional magnetic resonance imaging for evaluating cerebral regions of female sexual arousal response. *Urology*, *57*, 1189-1194.
- Perry, J. D., & Whipple, B. (1982). Multiple components of female orgasm. In B. Graber (Ed.), *Circumvaginal musculature and vaginal function* (pp. 100-114). Basel: Karger.
- Piazza, L. A., Markowitz, J. C., Kocsis, J. H., Leon, A. C., Portera, L., Miller, N. L., et al., (1997). Sexual functioning in chronically depressed patients treated with SSRI antidepressants: A pilot study. *American Journal of Psychiatry*, *154*, 1757-1759.
- Polatin, P., & Douglas, D. E. (1953). Spontaneous orgasm in a case of schizophrenia. *Psychoanalytic Review*, *40*, 17-26.
- Pollen, J. J., & Dreilinger, A. (1984). Immunohistochemical identification of prostatic acid phosphatase and prostate specific antigen in female periurethral glands. *Urology*, *23*, 303-304.
- Pranzarone, G. F. (1991). Sexuoerotic stimulation and orgasmic response in the induction and management of parturition—clinical possibilities. In P. Kothari & R. Patel (Eds.), *Proceedings of First International Conference on Orgasm* (pp. 105-119). Bombay: VRP Publishers.
- Read, S., King, M., & Watson, J. (1997). Sexual dysfunction in primary medical care: Prevalence, characteristics and detection by the general practitioner. *Journal of Public Health Medicine*, *19*, 387-391.
- Reisinger, J. J. (1979). Generalization of treatment effects following masturbatory training with erotic stimuli. *Journal of Behavior Therapy and Experimental Psychiatry*, *10*, 247-250.
- Reyes, A., Para, A., Chavarria, M. E., Goicoechea, B., & Rosado, A. (1979). Effect of prolactin on the calcium binding and/or transport of ejaculated and epididymal human spermatozoa. *Fertility and Sterility*, *31*, 669-672.
- Riley, A. J., & Riley, E. J. (1978). A controlled study to evaluate directed masturbation in the management of primary orgasmic failure in women. *British Journal of Psychiatry*, *133*, 404-409.
- Riley, A. J., Lee, W., & Riley, E. J. (1992). An ultrasound study of human coitus. In W. Bezemmer, P. Cohen-Kettenis, K. Slob, & N. Van Son-Schoones (Eds.), *Sex matters* (pp. 29-36). Amsterdam: Elsevier.
- Rosen, R. C., Lane, R. M., & Menza, M. (1999). Effects of SSRIs on sexual function: A critical review. *Journal of Clinical Psychopharmacology*, *19*, 67-85.
- Rosen, R. C., Phillips, N. A., Gendrano, N. C., & Ferguson, D. M. (1999). Oral phentolamine and female sexual arousal disorder: A pilot study. *Journal of Sex and Marital Therapy*, *25*, 137-144.
- Rosen, R. C., Taylor, J. F., Leiblum, S. R., & Bachman, G. A. (1993). Prevalence of sexual dysfunction in women: Results of a survey study of 329 women in an outpatient gynecological clinic. *Journal of Sex and Marital Therapy*, *19*, 171-188.
- Roughan, P. A., & Kunst, L. (1981). Do pelvic floor exercises really improve orgasmic potential? *Journal of Sex and Marital Therapy*, *7*, 223-229.
- Salerian, A. J., Deibler, W. E., Vittone, B. J., Geyer, S. P., Drell, L., Mirmirani, N., et al., (2000). Sildenafil for psychotropic-induced sexual dysfunction in 31 women and 61 men. *Journal of Sex and Marital Therapy*, *26*, 133-140.
- Sarwer, D. B., & Durlak, J. A. (1997). A field trial of the effectiveness of behavioral treatment for sexual dysfunctions. *Journal of Sex and Marital Therapy*, *23*, 87-97.
- Schaefer, L. C. (1974). *Women and sex*. London: Hutchinson.
- Schneidman, B., & McGuire, L. (1976). Group therapy for nonorgasmic women: Two age levels. *Archives of Sexual Behavior*, *5*, 239-247.
- Schultz, W. W., van Andel, P., Sabelis, I., & Mooyaart, E. (1999). Magnetic resonance imaging of male and female genitals during coitus and female sexual arousal. *British*

*Medical Journal*, 319, 1596-1600.

- Segraves, R. T. (1995). Antidepressant-induced orgasm disorder. *Journal of Sex and Marital Therapy*, 21, 192-201.
- Shen, W. W., & Hsu, J. H. (1995). Female sexual side effects associated with selective serotonin reuptake inhibitors: A descriptive clinical study of 33 patients. *International Journal of Psychiatric Medicine*, 25, 239-248.
- Shen, W. W., & Sata, L. S. (1990). Inhibited female orgasm resulting from psychotropic drugs: A five-year, updated, clinical review. *Journal of Reproductive Medicine*, 35, 11-14.
- Sherfey, M. J. (1966). The evolution and nature of female sexuality in relation to psychoanalytic theory. *Journal of the American Psychoanalytic Association*, 14, 28-128.
- Sherfey, M. J. (1972). *The nature and evolution of female sexuality*. New York: Random House.
- Sherwin, B. B., & Gelfand, M. M. (1987). The role of androgen in the maintenance of sexual functioning in oophorectomized women. *Psychosomatic Medicine*, 49, 397-409.
- Shifren, J. L., Braunstein, G. D., Simon, J. A., Casson, P. R., Buster, J. E., Redmond, G. P., et al., (2000). Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. *New England Journal of Medicine*, 343, 682-688.
- Sholty, M. J., Ephross, P. H., Plaut, S. M., Fischman, S. H., Charnas, J. F., & Cody, C. A. (1984). Female orgasmic experience: A subjective study. *Archives of Sexual Behavior*, 13, 155-164.
- Simerly, R. B., & Swanson, L. W. (1988). Projections of the medial preoptic nucleus: A Phaseolis vulgaris leucoagglutinin anterograde tract-tracing study in the rat. *Journal of Comparative Neurology*, 270, 209-242.
- Singer, I. (1973). *The goals of human sexuality*. London: Wildwood House.
- Singer, J., & Singer, I. (1972). Types of female orgasm. *The Journal of Sex Research*, 8, 255-267.
- Sintchak, G., & Geer, J. H. (1975). A vaginal plethysmograph system. *Psychophysiology*, 12, 113-115.
- Siosteen, A., Lundquist, C., Blomstrand, C., Sullivan, L., & Sullivan, M. (1990). Sexual ability, activity, attitudes and satisfaction as part of adjustment in spinal cord-injured subjects. *Paraplegia*, 28, 285-295.
- Sipski, M. L. (2001). Sexual response in women with spinal cord injury: Neurologic pathways and recommendations for the use of electrical stimulation. *Journal of Spinal Cord Medicine*, 24, 155-158.
- Sipski, M. L., & Alexander, C. J. (1993). Sexual activities, response and satisfaction in women pre- and post-spinal cord injury. *Archives of Physical Medicine and Rehabilitation*, 74, 1025-1029.
- Sipski, M. L., Alexander, C. J., & Rosen, R. C. (1995). Orgasm in women with spinal cord injuries: A laboratory-based assessment. *Archives of Physical Medicine and Rehabilitation*, 76, 1097-1102.
- Sipski, M. L., Alexander, C. J., & Rosen, R. C. (1997). Physiological parameters associated with sexual arousal in women with incomplete spinal cord injuries. *Archives of Physical Medicine and Rehabilitation*, 78, 305-313.
- Sipski, M. L., Alexander, C. J., & Rosen, R. C. (1999). Sexual response in women with spinal cord injuries: Implications for our understanding of the able-bodied. *Journal of Sex and Marital Therapy*, 25, 11-22.
- Sipski, M. L., Alexander, C. J., & Rosen, R. (2001). Sexual arousal and orgasm in women: Effects of spinal cord injury. *Annals of Neurology*, 49, 35-44.
- Sipski, M. L., & Behnegar, A. (2001). Neurogenic female sexual dysfunction: A review. *Clinical Autonomic Research*, 11, 279-283.
- Sommers, F., Caspers, H. P., Esders, K., Klotz, T., & Engelmann, U. (2001). Measurements of vaginal and minor labial oxygen tension for the evaluation of female sexual function. *Journal of Urology*, 165, 1181-1184.
- Sotile, W. M., & Kilmann, P. R. (1978). Effects of group systematic desensitization on



- female orgasmic dysfunction. *Archives of Sexual Behavior*, 7, 477-491.
- Sotile, W. M., Kilmann, P. R., & Follingstad, D. R. (1977). A sexual enhancement workshop: Beyond group systematic desensitization for women's sexual anxiety. *Journal of Sex and Marital Therapy*, 3, 249-255.
- Stimmel, G. L., Dopheide, J. A., & Stahl, S. M. (1997). Mirtazapine: An antidepressant with noradrenergic and specific serotonergic effects. *Pharmacotherapy*, 17, 10-21.
- Stoleru, S., Gregoire, M. C., Gerard, D., Decety, J., Lafarge, E., Cinotti, L., et al., (1999). Neuroanatomical correlates of visually evoked sexual arousal in human males. *Archives of Sexual Behavior*, 28, 1-21.
- Swanson, L. W., & Sawchenko, P. E. (1980). Paraventricular nucleus: A site for the integration of neuroendocrine and autonomic mechanisms. *Neuroendocrinology*, 31, 410-417.
- Symons, D. (1979). *The evolution of human sexuality*. New York: Oxford University Press.
- Tairych, G. V., Kuzbari, R., Rigel, S., Todoroff, B. P., Schneider, B., & Deutinger, M. (1989). Normal cutaneous sensitivity of the breast. *Plastic and Reproductive Surgery*, 102, 701-704.
- Taylor, H. C. (1949a). Vascular congestion and hyperemia: Part I. Physiologic basis and history of the concept. *American Journal of Obstetrics and Gynecology*, 57, 211-227.
- Taylor, H. C. (1949b). Vascular congestion and hyperemia: Part II. The clinical aspects of congestion-fibrosis syndrome. *American Journal of Obstetrics and Gynecology*, 57, 637-653.
- Taylor, H. C. (1949c). Vascular congestion and hyperemia: Part III. Etiology and therapy. *American Journal of Obstetrics and Gynecology*, 57, 654-668.
- Tepper, S. L., Jagirdar, J., Heath, D., & Geller, S. A. (1984). Homology between the female paraurethral (Skene's) glands and the prostate. *Archives of Pathology and Laboratory Medicine*, 108, 423-425.
- Tiihonen, J., Kuikka, J., Kupila, J., Partanen, K., Vainio, P., Airaksinen, J., et al., (1994). Increase in cerebral blood flow of right prefrontal cortex in man during orgasm. *Neuroscience Letters*, 170, 241-243.
- Trudel, G., & Saint-Laurent, S. (1983). A comparison between the effects of Kegel's exercises and a combination of sexual awareness relaxation and breathing on situational orgasmic dysfunction in women. *Journal of Sex and Marital Therapy*, 9, 204-209.
- Truitt, W. A., & Coolen, L. M. (2002). Identification of a potential ejaculation generator in the spinal cord. *Science*, 297, 1566-1569.
- Tuckwell, H. C. (1989). A neurophysiological theory of a reproductive process. *International Journal of Neuroscience*, 44, 143-148.
- van der Horst, V. G., & Holstege, G. (1998). Sensory and motor components of reproductive behavior: Pathways and plasticity. *Behavioral Brain Research*, 92, 157-167.
- Van Lankveld, J. J. D. M., Everaerd, W., & Grotjohann, Y. (2001). Cognitive-behavioral bibliotherapy for sexual dysfunctions in heterosexual couples: A randomized waiting-list controlled clinical trial in the Netherlands. *The Journal of Sex Research*, 38, 51-67.
- Van Turnhout, A. A. W. M., Hage, J. J., & Van Diest, P. J. (1995). The female corpus spongiosum revisited. *Acta Obstetrica et Gynecologica Scandinavica*, 74, 767-771.
- Vance, E. B., & Wagner, N. N. (1976). Written descriptions of orgasm: A study of sex differences. *Archives of Sexual Behavior*, 5, 87-98.
- Wagner, C. K., & Clemens, L. G. (1991). Projections of the paraventricular nucleus of the hypothalamus to the sexually dimorphic lumbosacral region of the spinal cord. *Brain Research*, 539, 254-262.
- Wagner, G., & Levin, R. J. (1978). Oxygen tension of the vaginal surface during sexual stimulation in the human. *Fertility and Sterility*, 30, 50-53.
- Wagner, G., & Levin, R. J. (1980). Effect of atropine and methylatropine on human vaginal blood flow, sexual arousal and climax. *Acta Pharmacologica et Toxicologica*, 46, 321-325.
- Wagner, G., & Levin, R. J. (1984). Human vaginal pH and sexual arousal. *Fertility and Sterility*, 41, 389-394.

- Wakefield, J. C. (1987). The semantics of success: Do masturbation exercises lead to partner orgasm? *Journal of Sex and Marital Therapy, 13*, 3-14.
- Walker, P. W., Cole, J. O., Gardner, E. A., Hughes, A. R., Johnston, J. A., Batey, S. R., et al., (1993). Improvement in fluoxetine-associated sexual dysfunction in patients switches to bupropion. *Journal of Clinical Psychiatry, 54*, 459-465.
- Wallace, D. H., & Barbach, L. G. (1974). Preorgasmic group treatment. *Journal of Sex and Marital Therapy, 1*, 146-154
- Wallin, P. (1960). A study of orgasm as a condition of women's enjoyment of intercourse. *Journal of Social Psychology, 51*, 191-198.
- Waterman, C. K., & Chiauzzi, E. J. (1982). The role of orgasm in male and female sexual enjoyment. *The Journal of Sex Research, 18*, 146-159.
- Wellings, K., Field, J., Johnson, A., & Wadsworth, J. (Eds.). (1994). *Sexual behavior in Britain*. London: Penguin Books.
- Wells, B. L. (1983). Nocturnal orgasms: Females' perception of a "normal" sexual experience. *The Journal of Sex Research, 22*, 412-437.
- Whalen, P. J., Rauch, S. L., Etcoff, N. L., McInerney, S. C., Lee, M. B., & Jenike, M. A. (1998). Masked presentations of emotional facial expressions modulate amygdala activity without explicit knowledge. *Journal of Neuroscience, 8*, 411-418.
- Whipple, B., Gerdes, C. A., & Komisaruk, B. R. (1996). Sexual response to self-stimulation in women with complete spinal cord injury. *The Journal of Sex Research, 33*, 231-240.
- Whipple, B., & Komisaruk, B. R. (2002). Brain (PET) responses to vaginal-cervical self-stimulation in women with complete spinal cord injury: Preliminary findings. *Journal of Sex and Marital Therapy, 28*, 79-86.
- Whipple, B., Ogden, G., & Komisaruk, B. R. (1992). Physiological correlates of imagery-induced orgasm in women. *Archives of Sexual Behavior, 21*, 121-133.
- Wincke, J. P., & Caird, W. K. (1976). The effects of systematic desensitization in the treatment of essential sexual dysfunction in women. *Behavior Therapy, 7*, 335-342.
- Winkleman, R. K. (1959). The erogenous zones: Their nerve supply and significance. *Mayo Clinic Proceedings, 34*, 39-47.
- World Health Organization. (1992). *ICD 10: International statistical classification of diseases and related health problems*. Geneva: Author.
- Wu, M. H., Pan, H. A., Wang, S. T., Hsu, C. C., Chang, F. M., & Huang, K. E. (2001). Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. *Climacteric, 4*, 314-319.
- Yamada, K. (1951). On sensory nerve terminations in clitoris in human adult. *Tohoku Journal of Experimental Medicine, 54*, 163-174.
- Zajacka, J., Dunner, D. L., Gelenberg, A. J., Hirschfeld, R. M. A., Kornstein, S. G., Ninan, P. T., et al., (2002). Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. *Journal of Clinical Psychiatry, 63*, 709-716.
- Zaviacic, M., Brozman, M., Zajickova, M., Blazekova, J., & Oberusova, J. (1985). The adult human female urethra: Enzyme-histochemical study. *Acta Histochemica, 77*, 165-175.
- Zilbergeld, B. (1979). *Men and sex* (1<sup>st</sup> British ed. pp. 105-106). Essex: Anchor Press.



Copyright of *Annual Review of Sex Research* is the property of Society for the Scientific Study of Sexuality and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.